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Abstract 
 
Meckel-Gruber syndrome (MKS) is a genetically heterogeneous disease 
characterised by the phenotypic triad of occipital encephalocele, polycystic kidneys, 
and polydactyly. MKS is classified as a ciliopathy as mutations to the MKS proteins 
result in dysfunction to the primary cilium. Recent research has expanded the 
aetiology of MKS, as increasing evidence for non-ciliary roles for the MKS proteins are 
uncovered. Evidence includes their presence at focal adhesions and a role in 
controlling extracellular matrix (ECM) morphology. The relative contributions of ciliary 
and non-ciliary cellular phenotypes to the clinical presentations of MKS are not 
currently known. This thesis identifies ECM-dependent aberrations to the perinuclear 
actin cap in MKS patient cells lacking the MKS type 3 transmembrane protein 
TMEM67, likely contributing to migration defects previously identified in patient cells. 
Furthermore, GFP-Trap analysis identifies a number of myosins as potential binding 
partners of TMEM67; a previously unreported association. Analysis of these binding 
partners reports the top biological processes for TMEM67 as myosin-motor activity 
and actin-based movement, adding to the potential non-ciliary roles of the protein 
already reported. By expanding our understanding of the role of ciliopathy proteins 
outside of the cilium, we better comprehend the aetiology of the diseases, providing 
an opportunity to find new therapeutic interventions.  
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1 Introduction 
 
 
1.1 Ciliopathies: rare disorders of human development 
 
The cilium is a highly conserved, microtubule-based organelle found on almost all cells 
in the human body. There are two types of cilium: motile and primary, the latter on 
which this thesis focuses (Mitchison and Valente, 2017). Reflective of their wide 
distribution throughout the body, defects in motile and primary cilia have a broad 
spectrum of effects. Defects in cilium formation or function cause a recognizable 
cluster of syndromes called ciliopathies (Hildebrandt et al., 2011). 
 
The link between defects in motile cilia at the cellular level and patients’ resulting 
clinical presentation is straightforward: in humans, motile cilia are required for sperm 
motility and for generating fluid flow in a number of tissues, including in the respiratory 
tract, the fallopian tubes, and within the ventricular system (Mitchison and Valente, 
2017). Patients with defects affecting the motility of cilia can therefore present with an 
inability to remove mucus from the lungs due to aberrant movement of cilia in the 
respiratory tract, as well infertility in men and women as a result of immotile sperm and 
aberrant fluid flow in the fallopian tubes, respectively. Situs inversus is also seen in 
about 50% of patients with mutations affecting motile cilia due to the importance of a 
motile cilium directing fluid flow and left-right asymmetry in the node during embryonic 
development (Leigh et al., 2009). Loss of cilium motility is the key factor in the 
pathogenicity of ciliopathies stemming from defects in motile cilia, and thus the cellular 
basis of disease is clear.  
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Conversely, mutations in proteins comprising the primary cilia have a much more 
convoluted link to phenotype of primary ciliopathies for a few reasons. Firstly, there is 
large phenotypic overlap across the primary ciliopathies (Table 1.1).  
 
Table 1.1 The phenotypic overlap of ciliopathies (Gerdes et al., 2009; Norris and Grimes, 
2012; GARD, 2018). ‘ü’ represents that the phenotype is frequently reported. Due to universal 
lethality in MKS syndrome, usually during early embryonic development, ‘?’ denotes 
phenotypes which may be present but cannot be established as they would develop during 
later developmental stages. 
 
 MKS BBS JBTS Jeune NPHP OFD LCA SLS Alström COACH 
Cleft palate ü          
Skeletal 
dysplasia 
ü   ü  ü    ü 
Situs inversus ü ü ü  ü ü  ü   
Retinopathy  ? ü ü ü ü  ü ü ü  
Polydactyly  ü ü ü ü  ü     
Obesity  ? ü ü      ü  
Cognitive 
defects  
? ü ü  ü ü ü   ü 
Renal disease ü ü ü ü ü ü  ü   
Hepatic 
disease 
ü ü ü ü ü ü  ü  ü 
Encephalocele ü          
Cerebellar 
hypoplasia 
 ü ü  ü     ü 
Deafness ?        ü  
 
MKS = Meckel Gruber Syndrome, BBS = Bardet Biedl Syndrome, JBTS = Joubert Syndrome, NPHP = 
Nephronophthisis, OFD = Orofaciodigital Syndrome, LCA = Leber Congenital Amaurosis, SLS = 
Sjögren-Larsson Syndrome. 
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This broad spectrum of phenotypes in primary ciliopathies is reflective of the primary 
cilium’s wide expression throughout the body: virtually every cell type in the human 
body has a primary cilium at some stage of its cell cycle (Malicki and Johnson, 2017). 
The primary cilium also has a number of different functions and thus mutation can 
affect many cellular processes. The cilium is often referred to as the cell’s antenna 
due to its multi-faceted role sensing both mechanical and chemical stimuli (Singla and 
Reiter, 2006). In addition to these sensory roles, the primary cilium also has a vital role 
regulating a number of key signalling pathways in development (reviewed in detail in 
Malicki and Johnson, 2017; Wheway et al., 2018). Thus, dysfunction or malformation 
of the primary cilium has far ranging, and often severe developmental consequences.   
The second difficulty in linking the pathogenic mutation to phenotype in primary 
ciliopathies is the fact that mutations in the same gene can result in clinically distinct 
diseases. It has been suggested that the type and location of mutation in the gene 
could determine the ciliopathy, and that the mutational load across the ciliary proteome 
could contribute to the reduced penetrance and clinical variability of the ciliopathies 
(Iannicelli et al., 2010; Novarino et al., 2011). For example, mutations in TMEM67 have 
been linked to Meckel Gruber Syndrome (MKS; Smith et al., 2006), Joubert Syndrome 
(JBTS; Baala et al., 2007), Nephronophthisis (NPHP; Otto et al., 2009), and COACH 
(Brancati et al., 2009). Studies have linked missense mutations falling between exons 
8 to 15 of TMEM67 with MKS, especially when in conjunction with a truncating 
mutation, whereas mutations in other parts of the gene have been linked more closely 
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to JBTS (Iannicelli et al., 2010). TMEM67 can also act as a modifier to the clinical 
presentation of Bardet-Biedl Syndrome (BBS; Leitch et al., 2008). 
 
The third difficulty in linking genotype to phenotype in primary ciliopathies is the 
increasing evidence of extraciliary roles of primary ciliopathy proteins. This will be 
the primary focus of this thesis and will be discussed in detail later. 
 
1.2 MKS is a lethal ciliopathy 
 
The present study focuses on MKS. One of the most severe ciliopathies, MKS is 
universally lethal, usually during early embryonic development (Salonen, 1984). MKS 
is typically characterised by the phenotypic triad of polycystic kidneys (97.7% of 
cases), occipital encephalocele (83.8%), and polydactyly (typically post-axial; 87.3%), 
however, as summarised in Table 1.1, much wider phenotypic variability is seen 
(Barisic et al., 2015). Additional phenotypes often observed include skeletal defects, 
hepatic fibrosis, cleft palate, abnormalities of the central nervous system, heart 
defects, and abnormal genitalia development (Fraser and Lytwyn, 1981; Salonen, 
1984). The leading cause of death is pulmonary hypoplasia, but liver and kidney failure 
have also been reported (Kheir et al., 2012). 
 
MKS is autosomal recessive, and as such has variable incidence with higher incidence 
in regions were consanguineous marriage is commonplace. In Gujurat Indians the 
carrier rate is reported as 1 in 18, with 1 per 1300 births affected. In Belgians and 
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Bedouins in Kuwait, a carrier rate of 1 in 30 is reported, with 1 in 3,500 births affected 
(Parelkar et al., 2013). Typical global statistics for MKS affected births are estimated 
between 1 in 9,000 and 1 in 140,000 (Salonen, 1984). 
 
MKS is a genetically heterogeneous condition, with 14 causative genes identified at 
the time of writing this thesis; see Table 1.2 for full details.  
 
Table 1.2 MKS causative genes. Gene name in bold refers to the commonly used protein 
name.  
 
MKS locus Gene name(s) Identification of gene as MKS locus 
MKS1 MKS1 
BBS13 
(Kyttälä et al., 2006) 
MKS2 TMEM216 
JBTS2 
CORS2 
(Valente et al., 2010) 
MKS3 TMEM67 
JBTS6 
NPHP11 
(Smith et al., 2006) 
MKS4 CEP290 
KIAA0373 
3H11AG 
JBTS5 
SLSN6 
LGA10 
BBS14 
NPHP6 
(Baala et al., 2007) 
MKS5 RPGRIP1L 
KIAA1005 
JBTS7 
NPHP8 
(Delous et al., 2007) 
MKS6 CC2D2A 
KIAA1345 
(Tallila et al., 2008) 
MKS7 NPHP3 (Bergmann et al., 2008) 
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NPH3 
RHPD 
MKS8 TCTN2 
TECT2 
(Shaheen et al., 2011) 
MKS9 B9D1 
MKSR1 
(Hopp et al., 2011) 
MKS10 B9D2 
MKSR2 
(Dowdle et al., 2011) 
MKS11 TMEM231 
JBTS20 
(Shaheen et al., 2013) 
MKS12 KIF14 (Filges et al., 2014) 
MKS13 TMEM107 (Shaheen et al., 2015) 
n/a CSPP1 (Shaheen et al., 2014) 
 
 
1.2.1 Genotype-phenotype relationships in MKS 
 
There is very limited knowledge of genotype-phenotype correlations in MKS. As 
previously mentioned, the extensive phenotypic variability and genetic heterogeneity 
of MKS makes it difficult to link the underlying genetic mutation in patients to their 
clinical presentation. However, there are some observable patterns in genotype-
phenotype correlation. While occipital encephalocele, polydactyly and polycystic 
kidneys are the most commonly observed malformations associated with MKS, 
forming the classic diagnostic triad, only occipital encephalocele and polycystic 
kidneys are near universally present: the incidence of polydactyly varies with mutation 
(Szymanska et al., 2012). Polydactyly is rarely observed in TMEM67 patients. 
Szymanska et al., (2012) observed polydactyly in only 3/19 TMEM67 patients: this 
was much lower than the incidence of polydactyly in RPGRIP1L and CC2D2A patients 
(n = 4/6). Conversely, polydactyly is a near-obligatory feature of MKS1, being 
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observed in 10/12 patients in a study by Khaddour et al., (2007). Polydactyly stems 
from a disruption to the Hedgehog (Hh) signalling pathway during embryogenesis 
(Ehlen et al., 2006). The variable presence of polydactyly in TMEM67 patients, 
compared to the near obligatory presence in MKS1 and other genotypes suggests that 
loss of TMEM67 is less disruptive to the Hh pathway than other mutations. Central 
nervous system (CNS) malformations are also less frequent in TMEM67 patients than 
in MKS1 patients, with occipital encephalocele, bone dysplasia defects, cleft palate, 
and situs defects frequently associated with MKS1 mutations (Consugar et al., 2007; 
Khaddour et al., 2007). TMEM67 mutations are often associated with hepatic 
involvement (Brancati et al., 2009; Otto et al., 2009). While these patterns might help 
to narrow down the potential mutant genotype, providing a subset of genetic targets 
of interest, the phenotypes are still non-specific and thus genetic screening is required 
to confirm the mutation. 
 
The wide range of phenotypes in MKS patients, and the lack of clear genotype-
phenotype correlations led to the hypothesis that the presence of modifier alleles may 
be influencing disease presentation. Indeed, many modifiers have now been identified 
in MKS contributing to the wide and variable phenotypes observed in not just MKS, 
but all the ciliopathies. For example, it has been shown that MKS1, TMEM67, and 
CEP290 have been shown to have epistatic effects on mutations in BBS (Leitch et al., 
2008).  
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1.3 The ciliary roles of MKS proteins 
 
Most work on the biological function of MKS proteins thus far has focussed on their 
role in assembly and function of cilia. 
 
1.3.1 Ciliogenesis 
 
The primary cilium is a microtubule-based organelle, projecting from the apical cell 
surface. The ‘back-bone’ of the cilium, called the axoneme, consists of a ring of nine 
outer microtubule doublets, and functions as a scaffold for a number of protein 
complexes, in addition to acting as a “rail-road” for microtubule-based transport (in this 
context, known as intraflagellar transport (IFT; Rosenbaum and Witman, 2002). 
 
Cilia are complex organelles, and their assembly is carried out in a series of highly 
regulated steps: a combination of cell cycle regulation, vesicle trafficking and IFT must 
be tightly controlled. Primary cilia are only found on cells in the quiescent state and 
are resorbed before the cells enter the S phase of the cell cycle (Avasthi and Marshall, 
2012). It has been suggested that there is bidirectional crosstalk between the cell cycle 
and ciliogenesis, as cell lines with proliferation abnormalities (such as rapidly dividing 
cancer cells) often lack cilia, and cell lines with ciliary defects often have issues with 
cell division and cystogenesis (hence the presence of cystic kidneys caused by cells 
with IFT defects; Hassounah et al., 2012; Hassounah et al., 2013; Emoto et al., 2014; 
Menzl et al., 2014; Nobutani et al., 2014) 
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The first step of ciliogenesis involves the docking of a centrosome to the membrane 
at the apical cell surface. In unciliated cells, the centrosome is usually attached to the 
nucleus at the centre of the cell. Centrosome migration to the apical cell surface is a 
two-step process. First, the centrosome moves around the nucleus until it is sitting at 
its apical surface. It has not been established whether the centrosome moves 
independently of the nucleus or remains attached and the nucleus itself rotates to 
orientate the centrosome. Once orientated correctly, the centrosome then migrates 
from the nucleus to the apical cell surface (Barker et al., 2015).  
 
In order to dock to the apical cell surface and support ciliogenesis, the mother centriole 
must undergo a maturation process, and acquire a number of distal and sub-distal 
appendages (Vorobjev and Chentsov, 1982). Maturation of the mother centriole 
occurs as a number of sequential protein recruitments and without these appendages, 
the centrosome migrates to the apical surface but cannot dock, as the appendages 
facilitate the association between the mother centriole and the ciliary vesicle (Sorokin, 
1962; Garcia-Gonzalo and Reiter, 2012; Tanos et al., 2013).  
 
After association with the ciliary vesicle, the axoneme begins to extend from the 
mother centriole, bending the vesicle membrane. Through the translocation and fusion 
of secondary vesicles, the ciliary vesicle grows as the axoneme is extended, becoming 
the ‘ciliary sheath’. The sheath then fuses with the plasma membrane, thus 
externalising the primary cilium, and the once internal ciliary sheath becomes the 
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periciliary membrane (Sorokin, 1962). Extension of the axoneme from the mother 
centriole (termed the basal body when involved in ciliogenesis) is supported by IFT 
(Rosenbaum and Witman, 2002; Scholey, 2003). 
 
1.3.2 All MKS proteins localise to the primary cilium 
 
MKS was first reported by Johann Friedrich Meckel in 1822. It was first linked to ciliary 
dysfunction over 180 years later in 2006 when MKS1, encoding a component of the 
flagellar apparatus, and TMEM67 were identified as causative genes (Kyttälä et al., 
2006; Smith et al., 2006). Since this link was made, many further genes have been 
identified that cause MKS, all of which localise to the primary cilium. Mutation or loss 
of these genes results in aberrations to function or formation of the primary cilium. 
 
1.3.3 The transition zone 
 
Organelles are typically enclosed within their own lipid bilayer, creating unique 
compartments that are isolated from the cytosol. This allows functionally specialised 
processes to occur without the risk of affecting other cellular processes. Enclosure by 
membranes allows organelles to maintain a distinct complex of proteins that facilitates 
their unique function (Alberts et al., 2002). The cilium however, as an extension of the 
cell membrane, is not fully enclosed in its own compartment. Thus, to allow the 
specialised function of the cilium, a ciliary gate is present at the bottom of the 
axoneme, which acts as a diffusion barrier, preventing the free migration of cytosolic 
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proteins into the cilium. The ciliary gate was first observed by transmission electron 
microscopy of cross sections of the cilium, and was observed to form during early 
ciliogenesis, before IFT extends the axoneme (Gibbons and Grimstone, 1960; Ringo, 
1967). Two sub-regions comprise the ciliary gate: the transition zone and the transition 
fibres. 
 
Transition fibres are involved in anchoring the basal body to the plasma membrane, 
and correspond to the distal appendages (Anderson, 1972). IFT52’s localization to the 
transition fibres also suggests a role in the docking of IFT proteins and translocation 
of these and their associated motor proteins into the cilium (Deane et al., 2001). It has 
been suggested that these fibres act as a pore complex, functioning as a selective 
barrier to diffusion, similar to the nuclear pore (Rosenbaum and Witman, 2002). The 
complete structure and composition of these fibres is still to be elucidated, as well as 
their complete function, and as such further proteins associated with the fibres, and 
by extension the primary cilium and its associated disorders are likely to be 
discovered. 
 
The transition zone is characterised by Y-links and the ciliary necklace. While these 
fundamental structural components are conserved, the appearance of the transition 
zone can vary between species and even cell type (Fisch and Dupuis-Williams, 2011). 
Y-links, so called because of their shape, form an attachment between the ciliary 
membrane and the microtubule doublets (Gilula and Satir 1972). Until recently, the 
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proteins composing these Y-links, as well as their arrangement into the Y-shaped 
structure was not known. However, recent developments in super resolution 
microscopy have allowed the ultrastructure of this complex to be revealed (Yang et 
al., 2015; Shi et al., 2017). 
 
Transition zone proteins can be split into the MKS/JTBS module and the NPHP 
module (Figure 1.1; Chih et al., 2012; Dowdle et al., 2011; Garcia-Gonzalo et al., 2011; 
Sang et al., 2011; Williams et al., 2011). The MKS/JBTS module consists of the three 
tectonic proteins TCTN1, TCTN2 and TCTN3, the three B9 domain-containing 
proteins B9D1, B9D2, and MKS1, coiled-coil proteins CEP290, CC2D2A and AHI1, 
and the transmembrane proteins TMEM17, TMEM67, TMEM107, TMEM216 and 
TMEM231 (and possibly also TMEM237 and TMEM218; Chih et al., 2012; Garcia-
Gonzalo et al., 2011; Sang et al., 2011; Lambacher et al., 2016; Roberson et al., 2015; 
Garcia-Gonzalo and Reiter, 2017). The NPHP complex consists of the core complex 
NPHP1, NPHP4, and RPGRIP1L, with the remaining network of NPHP5, NPHP8, 
ATXN10, INVS, NEK8 variably associated at different times (Mollet et al., 2005; Arts 
et al., 2007; Sang et al., 2011; Garcia-Gonzalo and Reiter, 2017). The NPHP complex 
is found close to the axoneme, with NPHP4 binding to the microtubule doublets (Mollet 
et al., 2005; Garcia-Gonzalo and Reiter, 2017). The MKS/JBTS complex sits closer to 
the ciliary membrane, consistent with the presence of multiple transmembrane 
proteins in this cluster (Yang et al., 2015; Garcia-Gonzalo and Reiter, 2017). 
 
 
21 
 
Figure 1.1 The transition zone is a complex of proteins, including the MKS/JTBS module (red) 
and the NPHP module (yellow). CM = ciliary membrane, MT = microtubule, CP = ciliary pocket, 
TF = transition fibre, BB = basal body. 
 
CEP290, part of the MKS/JTBS complex, binds to other MKS proteins CC2D2A and 
TCTN1, but also binds NPHP protein NPHP5, forming a point of attachment between 
the two complexes. CEP290 is essential for the formation of the MKS module, and its 
loss results in a breakdown of the ultrastructure of the transition zone, and a leaky 
ciliary gate (Li et al., 2016). CEP290 is localised to the transition zone by RPGRIP1L, 
which appears to be the key modulator of both NPHP and MKS/JTBS modules 
(Jensen et al., 2015). 
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Most MKS proteins localize to the transition zone, however, mutations or loss of 
function in these proteins have varying phenotypic effects, often varying between 
species, and even cell type.  
 
1.3.4 MKS proteins are required for ciliogenesis 
 
A large number of studies have investigated MKS homologues and their effects on 
ciliogenesis, showing that MKS proteins are required for normal ciliogenesis to occur. 
Table 1.3 summarises the known localisation and roles of these proteins at the cilia. 
 
Table 1.3 The ciliary localisation and roles of MKS proteins. TZ = transition zone; BB = basal 
body; AX = axoneme; CS = centriolar satellites  
MKS protein Localisation Ciliary role 
MKS1 BB  
TZ 
Required for basal body docking and ciliogenesis (Dawe 
et al., 2007b); component of the transition zone (Williams 
et al., 2011); mediates Hedgehog and Wnt signalling 
(Wheway et al., 2013; Goetz et al., 2017). 
TMEM216 
 
AX 
BB  
TZ 
Required for ciliogenesis through centrosome docking 
(Valente et al., 2010); component of the transition zone 
(Williams et al., 2011); modulates Wnt signalling through 
phosphorylation of Dishevelled (Valente et al., 2010). 
TMEM67 
 
AX 
TZ 
Regulates ciliary number (Tammachote et al., 2009); 
required for centrosome migration to apical membrane 
and ciliogenesis (Dawe et al., 2007b); component of the 
transition zone (Williams et al., 2011); essential for 
phosphorylation of non-canonical Wnt receptor ROR2 
(Abdelhamed et al., 2015). 
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CEP290 
 
BB 
CS  
TZ 
Centrosomal protein involved in ciliary assembly and 
ciliary trafficking (Coppieters et al., 2010); component of 
the transition zone (Williams et al., 2011); required for 
normal Hedgehog signalling (Hynes et al., 2014). 
RPGRIP1L 
 
AX  
BB 
TZ 
Establishment of left/right asymmetry and patterning of 
neural tube and limbs (Vierkotten et al., 2007); controls 
ciliary length (Gerhardt et al., 2015); component of the 
transition zone (Williams et al., 2011); controls ciliary 
proteasomal activity (Gerhardt et al., 2015). 
CC2D2A 
 
BB  
TZ 
Component of the transition zone (Williams et al., 2011); 
essential for assembly of subdistal appendages (Veleri et 
al., 2014); required for Hedgehog signalling (Chih et al., 
2012). 
NPHP3 TZ Required for normal ciliary development and function 
(Nauli et al., 2003); inhibits disheveled-1-induced 
canonical Wnt signalling activity; may also function in the 
control of non-canonical Wnt signalling (Bergmann et al., 
2008). 
TCTN2 
 
AX 
BB  
TZ 
Part of the tectonic-like complex of the transition zone 
(Garcia-Gonzalo et al., 2011); required for Hedgehog 
signalling (Reiter and Skarnes, 2006). 
B9D1 
 
BB  
TZ 
Part of the tectonic-like complex of the transition zone 
(Dowdle et al., 2011); regulates ciliary length and number, 
but not essential for ciliogenesis (Roberson et al., 2015); 
required for Hedgehog signalling (Chih et al., 2012). 
B9D2 TZ Part of the tectonic-like complex of the transition zone 
(Williams et al., 2011). 
TMEM231 TZ Part of the tectonic-like complex of the transition zone; 
regulates ciliary length and number, but not essential for 
ciliogenesis (Roberson et al., 2015); required for 
Hedgehog signalling (Chih et al., 2012). 
KIF14 AX Microtubule motor protein crucial for ciliogenesis and IFT 
(Scholey, 2008; Filges et al., 2014). 
TMEM107 TZ Component of the transition zone; required for 
ciliogenesis and Hedgehog signalling (Shaheen et al., 
2015). 
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CSPP1 BB Centrosome and spindle-pole associated protein; 
required for cilium formation and Hedgehog signalling; 
required for ciliary localisation of RPGRIP1L (Shaheen et 
al., 2014). 
 
 
In order for ciliogenesis to occur, the basal body must dock with the apical cell 
membrane; a process which requires the transition fibres. IFT must then extend the 
axoneme; a process requiring the effective compartmentalisation of the cilium. Thus, 
mutations in the MKS proteins which form the transition zone, and are essential for 
the compartmentalisation of the cilium, result in abnormal ciliogenesis.  
 
The relationship between MKS proteins and ciliogenesis is not straight forward. Some 
of the published data are conflicting, thus making the elucidation of these proteins’ 
properties complicated. Focusing onTMEM67 as an example (as it is the gene of 
interest in this thesis), in vitro knockdown of the gene in mouse cell lines has been 
shown to result in a failure of the basal body to dock to the apical cell surface, and 
thus prevent ciliogenesis (Dawe et al., 2007b; Valente et al., 2010). However, in 
contrast to these cell culture studies, reduction of TMEM67 in vivo has shown no 
interference with basal body localisation: in the Wpk MKS type 3 rat, longer cilia have 
been observed in some cell types, as well as centriole overduplication and multiple 
cilia (Tammachote et al., 2009). Furthermore, tissue-specific ciliogenesis defects have 
been reported, with fewer cilia in the kidney tubules of TMEM67-null mice and 
ciliogenesis defects in an inner medullary collecting duct (IMCD3) cell line with 
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TMEM67 knocked down. However, replicating this in mouse embryonic fibroblasts 
(MEF) resulted in no ciliogenesis defects, indicating tissue specific roles of TMEM67 
in ciliogenesis (Garcia-Gonzalo et al., 2011). These seemingly contradictory results 
are not singular to TMEM67: knockdown of MKS1 in mouse cell lines has been shown 
to result in the failure of basal body docking (Dawe et al., 2007b; Valente et al., 2010), 
while an in vivo study in the Mks1krc mutant mouse model reported normal apical 
localisation of basal bodies, and tissue-dependent defects to ciliogenesis, indicating 
that the ciliogenesis defect is not due to the failure of basal-body docking, but rather 
for the extension of the cilia (Weatherbee et al., 2009). Tissue-specific roles of the 
MKS proteins provide one explanation for the conflicting reports of ciliogenesis in MKS 
mutants, however the presence of alternate pathways in ciliogenesis which have 
mediating or modifying effects in vivo could also contribute. Further research into these 
potential alternate pathways is required to unravel their contribution to ciliopathy. 
 
In summary, many MKS proteins are required for ciliogenesis, and it is clear that their 
roles are tissue- or organism-specific, but the data are incomplete. In contrast, there 
is broad agreement that MKS proteins play key roles in regulating a major function of 
primary cilia: developmental signalling. 
 
1.3.5 The primary cilium is a signalling hub during embryonic development 
 
The primary cilium was first identified as an important regulator of vertebrate 
development when IFT machinery was linked to Hedgehog (Hh) signalling (Huangfu 
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et al., 2003). Since this discovery, a number of other important developmental 
pathways have been linked to the primary cilium, including the Wnt pathway.  
 
The Hedgehog pathway 
 
The Hh pathway is involved in determining cell fate and regulating tissue patterning 
during early development. There are three mammalian analogs of Hh: Sonic (Shh), 
Indian (Ihh), and Desert (Dhh). Hh signalling relies on the two transmembrane 
receptors, Patched1 (Ptch1) and Smoothened (Smo), and results in the activation of 
Gli transcription factors. In the absence of Hh signalling, Gli transcription factors are 
in their repressor form, and Ptch1 maintains Smo in its inactive state. When one of the 
Hh ligands binds to Ptch1, it translocates along the ciliary membrane, onto the 
membrane of the main body of the cell. Smo moves into the cilium, and this allows 
activation of Gli transcription factors and their translocation to the nucleus (Briscoe 
and Thérond, 2013; Nozawa et al., 2013; Rimkus et al., 2016). 
 
The Hh pathway is one of the key regulators of mammalian development, and 
disruptions to Hh signalling can give rise to severe developmental abnormalities 
(Briscoe and Thérond, 2013). Between the three Hh homologues, Shh plays the most 
critical role, being involved in the patterning of multiple systems during development, 
including the brain midline, limb bud, spinal cord, thalamus, lungs and teeth. During 
the development of the limb bud, the concentration of Shh is responsible for the 
patterning of digits, whereby the amount of Shh and the timing of exposure during 
 
27 
development specifies digit identity (Briscoe and Thérond, 2013). In humans, the 
gradient of Shh decreases from the posterior to anterior side of the limb bud: from the 
little finger down to the thumb (which develops independently of Shh). An absence of 
Shh therefore results in only the digit on the farthest anterior position developing (the 
thumb in humans), as this is the only Shh-independent digit (Ehlen et al., 2006). 
Conversely, the overexpression of Shh results in polydactyly: the presence of extra 
digits.   
 
Hh signalling is dependent on the effective compartmentalisation of the primary cilium 
and the function of the transition zone. It thus follows that mutation to the transition 
zone results in phenotypes indicative of affected Hh signalling, for example the 
polydactyly and CNS malformations observed in MKS. As summarised above in Table 
1.3, many of the MKS proteins are required for Hh signalling due to their role at the 
transition zone. 
 
The Wnt pathway 
 
The Wnt pathway is involved in cell fate determination and body axis patterning during 
development. Wnt proteins activate three different pathways (although there is overlap 
between all): one canonical pathway, and two non-canonical pathways (the planar cell 
polarity (PCP) pathway, and the Wnt/calcium pathway; Nusse and Clevers, 2017). All 
three pathways are instigated by the binding of a Wnt ligand to a Frizzled receptor but 
culminate in different actions: the canonical pathway regulates gene transcription, the 
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PCP pathway regulates the cytoskeleton, while the Wnt/Calcium pathway regulates 
the amount of intracellular calcium (Yu et al., 2012; Dijksterhuis et al., 2015). 
Intracellular calcium levels are important regulators of proteins such as cdc42, 
essential for ventral patterning, and cell morphology and migration. 
 
The Wnt pathway was originally linked with cilia when the PCP proteins Inversin and 
Dishevelled were identified at the basal body, followed by the discovery that the 
knockdown of a number of other ciliary-associated genes resulted in hyperactivated 
canonical Wnt signalling (Otto et al., 2003; Watanabe et al., 2003; Simons et al., 2005). 
However, there have also been several studies disputing the link between cilia and 
the Wnt pathways: normal Wnt signalling has been reported in zebrafish ift88 mutants 
lacking cilia, and loss of primary cilia or defects in retrograde IFT did not have any 
effect on the response of mouse embryos to Wnt ligands (Huang and Schier, 2009; 
Ocbina et al., 2009). 
 
It has been suggested that these seemingly conflicting results could be due to spatio-
temporal differences in Wnt signalling throughout development, but also tissue-
specific function and localisation of proteins (Wallingford and Mitchell, 2011). In 
addition, May-Simera and Kelley, (2012) suggested that the cilia-independent Wnt 
responsiveness reported by Huang and Schier (2009) and Ocbina et al. (2009) could 
be explained if the basal body and transition zone were key modulators of Wnt 
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signalling. While the cilia could be absent, if the basal body and surrounding structures 
remained intact, this could allow a degree of Wnt signalling to continue.  
 
1.3.6 Defects in the transition zone result in aberrant signalling 
 
As covered above, the transition zone consists of a complex of the MKS proteins and 
is required in order to allow the specialisation of the cilium. The transition zone 
functions like a selective sieve at the base of the cilium, preventing the movement of 
unwanted proteins from the cell body into the cilium, as well as having roles in 
recruiting and trafficking proteins destined for the cilium into the organelle. Mutations 
in transition zone proteins can therefore have profound consequences on the cilium-
dependent signalling pathways. For example, the transition zone protein TCTN2 
(mutations in which result in MKS type 8) is required for the targeting of Smo to the 
primary cilium in a tissue-specific manner (Garcia-Gonzalo et al., 2011). Knockdown 
of Tctn2 in mouse studies resulted in a tissue-dependent reduction in Smo and thus a 
reduction in the levels of Hh activity (Garcia-Gonzalo et al., 2011; Sang et al., 2011). 
MKS protein B9D1 is also essential for Smo localisation to the cilia (Dowdle et al., 
2011; Garcia-Gonzalo et al., 2011). It is not known whether an interaction between 
Smo and the transition zone facilitates its entry to the cilium, but it is apparent that the 
transition zone is important for the regulation of Hh signalling. Furthermore, as 
transition zone components are recruited in a series of hierarchical steps, mutation in 
core transition zone-assembling proteins can have knock on effects on signalling 
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pathways (which the individual protein may not have on its own). For example, 
RPGRIP1L has been reported to be the key transition zone protein, which is required 
for the localisation of all other transition zone proteins (Huang et al., 2011; Williams et 
al., 2011). Thus, mutation to RPGRIP1L would result in aberrant Hh signalling due to 
the subsequent loss of TCTN2 and B9D1 at the transition zone. This hierarchical 
recruitment suggests how mutations in different transition zone proteins can result in 
overlapping phenotypes. 
 
1.4 The non-ciliary roles of MKS proteins 
 
The ciliopathies have significant overlap in both clinical presentation (see Table 1.1) 
and cellular basis: mutations in different genes result in different disorders with similar 
phenotypes as all mutations affect the same organelle – the primary cilium. However, 
as the ciliopathies are all clinically distinct conditions, the question arises of how does 
ciliary dysfunction result in so many different diseases? 
 
As touched on earlier, the identity of the mutated gene and the function of the affected 
protein is a leading factor: for example complete loss of cilium formation versus 
impairment of a specific ciliary pathway receptor will have varying degrees of impact 
on development. A second factor is the mutational load of ciliopathy genes and the 
presence of modifying alleles, which both affect clinical presentation (Iannicelli et al., 
2010; Novarino et al., 2011). A third factor, and the factor that this thesis investigates, 
is the extra-ciliary role of ciliopathy proteins, and how these contribute to pathogenicity. 
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Increasingly, non-ciliary roles of ciliopathy proteins are being identified. Cilia are 
known to have a role in cell-cycle control, as they sequester the centrosome apparatus 
needed for cell division (Quarmby and Parker, 2005; Plotnikova et al., 2009). 
Additionally, ciliopathy proteins have been linked to the DNA damage response 
pathway, cell growth and cancer (where disruption to the Hh and Wnt pathways have 
been linked to tumour-promotion), mitochondria, autophagy, and cytoskeleton 
organisation (Dawe et al., 2007b; Böttinger, 2010; O’Toole et al., 2010; Valente et al., 
2010; Adams et al., 2012; Chaki et al., 2012; Polakis, 2012; Hoff et al., 2013; Hanna 
and Shevde, 2016; Pampliega and Cuervo, 2016; Walz, 2017). Many MKS proteins 
have been shown to have non-ciliary localisations. While localisation cannot be used 
to assign a definitive function, there are several lines of functional evidence to indicate 
that at least some MKS proteins have extra-ciliary roles (summarised in Table 1.4).  
 
Table 1.4 Evidence of non-ciliary roles for MKS proteins. 
MKS protein Non-ciliary role or localisation (if reported) 
MKS1 Localises to centrosome in non-ciliated cells (Bialas et al., 2009). 
TMEM216 Required for distribution of Filamin A (Valente et al., 2010). 
TMEM67 Interacts with Filamin A (Adams et al., 2012); interacts with Nesprin 2 
(Dawe et al., 2007b); localises to actin cytoskeleton (Adams et al., 2012), 
the cell surface of polarised cells (Dawe et al., 2007b), and to focal 
adhesions (Meadows, 2017); required for ROR2 phosphorylation 
(Abdelhamed et al., 2015) and ECM organisation (Meadows, 2017); 
localises to endoplasmic reticulum (Wang, Tytell and Ingber, 2009). 
CEP290 Localises to centrosome (Coppieters et al., 2010). 
RPGRIP1L Present throughout the cytoplasm during cell division (Delous et al., 
2007). 
CC2D2A Not reported 
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NPHP3 Not reported 
TCTN2 Not reported 
B9D1 Localises to centrosome in non-ciliated cells (Bialas et al., 2009)  
B9D2 Localises to centrosome in non-ciliated cells (Bialas et al., 2009)  
TMEM231 Not reported 
KIF14 Involved in processes including vesicle transport, chromosome 
segregation, mitotic spindle formation, cytokinesis, apoptosis (Zhu et al., 
2005; Carleton et al., 2006; Singel et al., 2014); regulates cell cycle 
progression, cell growth, cell spreading, focal adhesion dynamics, and 
cell migration (Ahmed et al., 2012; Xu et al., 2014). 
TMEM107 Not reported 
CSPP1 Regulates cell-cycle progression, spindle organisation, microtubule 
organisation, and cytokinesis (Patzke et al., 2005; Patzke, Stokke and 
Aasheim, 2006). 
 
 
A common non-ciliary role of the MKS proteins is involvement in cytoskeletal-related 
processes. Indeed, a number of actin-binding proteins were identified as being 
required for ciliogenesis in two functional genomics screens (Kim et al., 2010; Wheway 
et al., 2015) and the key function of the actin cytoskeleton in ciliogenesis has recently 
been established. Actin remodelling has been identified as a regulator of ciliogenesis,  
and many actin regulatory proteins localise to the cilium.  Actin has been linked to the 
regulation of ciliogenesis in at least three distinct ways (green arrows, Figure 1.2). 
Firstly, actin localises a number of proteins to the cilium that negatively control cilium 
length (arrow 1, Figure 1.2). One such protein is histone deacetylase 6 (HDAC6), 
targeted to the cilium by death inducer obliterator (Dido3). The amount of both proteins 
negatively correlates with cilium length (de Diego et al., 2014). Secondly, actin is 
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thought to play a role in regulating vesicle transport to the cilium (arrow 2, Figure 1.2), 
and thus blocking the rapid vesicle transport that ciliogenesis requires (Kim et al.,  
2015). Thirdly, F-actin polymerisation has been linked to the disassembly of cilia 
through YAP/TAZ activation (arrow 3, Figure 1.2). YAP/TAZ activity is involved in the 
growth of organs, tissue regeneration, and cell proliferation (Piccolo et al., 2014). 
Through the actomyosin cytoskeleton, YAP/TAZ functions as a transcriptional 
regulator that responds to tension changes in a cell’s microenvironment (Dupont et al., 
2011). On a hard substrate, YAP/TAZ localizes to the nucleus, whereas on soft 
substrates, YAP/TAZ re-localises to the cytoplasm, where its transcriptional activity is 
thus inhibited (Dupont et al., 2011). The knockdown of YAP/TAZ facilitates 
ciliogenesis, whereas its hyperactivation prevents ciliogenesis, and meaning that 
rigidity in a cell’s microenvironment, as well as cortical tension from the cytoskeleton 
are important regulators of ciliogenesis.  
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Figure 1.2 Actin affects ciliogenesis in at least three distinct mechanisms.  
 
Defects to the actin cytoskeleton have been observed in MKS cells (Dawe et al., 2009; 
Valente et al., 2010; Adams et al., 2012). In TMEM67 patient cells, actin bundle density 
is markedly increased four days after plating the cells compared to levels observed in 
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non-diseased cells (McIntosh, 2016). In TMEM216 patient cells, dense actin bundles 
have been seen as quickly as 40 minutes after plating (McIntosh, 2016). Actin defects 
have been reported in other ciliopathies, including BBS (Hernandez-Hernandez et al., 
2013), suggesting a general role of ciliopathy proteins in the regulation of the actin 
cytoskeleton. 
 
The cytoskeletal roles of MKS proteins summarised in Table 1.4 could therefore result 
in ciliogenesis defects as a downstream factor of altered cortical or extracellular 
tension, rather than the ciliogenesis defect arising only as a result of a compromised 
transition zone.  
 
1.5 The cytoskeleton and cell migration 
 
This thesis investigates the impact of the loss of MKS type 3 protein TMEM67 on the 
actin cytoskeleton. The cytoskeleton is the network of filaments and tubules extending 
throughout the cytoplasm of the cell. It has multiple functionalities, for example 
providing the structural shape of the cell, protecting the cell from deformation, acting 
as the railroad for intracellular transport, facilitating whole cell migration, and roles in 
mitosis and meiosis (reviewed thoroughly in Fletcher and Mullins, 2010). Cytoskeletal 
components also form specialised structures, such as cilia. A cytoskeleton is 
universally present across eukaryotes and prokaryotes, but the composition of the 
cytoskeleton varies (Löwe and Amos, 2009). The eukaryotic cytoskeleton is comprised 
of three main types of structure: actin filaments, microtubules, and intermediate 
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filaments. This thesis focuses on the actin cytoskeleton, which is discussed in more 
detail below. Microtubules and intermediate filaments will not be discussed in detail, 
but are reviewed thoroughly in Fletcher and Mullins, (2010). 
 
Present in almost all eukaryotic cells (the one reported exception being nematode 
sperm; Roberts and Stewart, 1997), actin has diverse roles, for example muscle 
contraction, apoptosis, adhesion, cytokinesis, whole cell locomotion, vesicle and 
organelle trafficking, maintenance of cell and nuclear shape, and signalling, amongst 
many others (Le Clainche and Carlier, 2008; Khatau et al., 2009; Pollard and Cooper, 
2009). Three main actin isoforms have been identified in vertebrates: α, β, and γ 
(Gunning et al., 1983). α actin, or skeletal actin, is part of the contractile apparatus in 
skeletal muscle, while β and γ are the components of the cytoskeleton (NCBI, 2018). 
β and γ actin assemblies form various structures within the cell, including filamentous 
dendritic actin in the leading edge of a migrating cell, the cortical actin network, the 
circumferential actin belt (or adhesion belt), and stress fibres. Stress fibres form the 
foundation of contractile forces within a cell (Pellegrin and Mellor, 2007). 
 
Actin exists in two principle forms: as a globular monomer (G-actin), and as a 
polymeric filament (F-actin). Filamentous actin is highly dynamic and the formation of 
filaments happens in three phases: nucleation, elongation, and steady state (see 
Pollard and Cooper, 1986; Pollard et al., 2000; Stricker et al., 2010; Wen and Janmey, 
2011 for reviews on actin biochemistry and cytoskeletal mechanics). The first step in 
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formation of F-actin is nucleation, where three G-actin monomers associate into a 
trimer. This trimer is energetically unfavourable, and therefore elongation occurs in 
order to make a more stable structure (Winder and Ayscough, 2005). F-actin is 
asymmetric with a plus end and a minus end, with different dynamic states. The plus 
end of the actin filament has faster dynamics than the minus end, and as such when 
there is an excess of free G-actin, the monomers associate at the plus end of the 
filament and the filament grows in length. When the volume of G-actin reaches a 
‘critical concentration’, F-actin reaches the steady state, where there is no net growth 
of the filament: polymerisation and the plus end, and monomer disassembly at the 
minus end are happening at the same rate. This is also known as actin treadmilling 
(Winder and Ayscough, 2005). 
 
Numerous actin-binding proteins (ABPs) facilitate actin’s various cellular roles. See 
Table 1.5 for an overview of the main classes of ABPs. 
 
Table 1.5 Function of the main classes of ABPs (reviewed in Winder and Ayscough, 2005). 
Function of ABP Protein 
Nucleation of G-actin Arp2/3; formins; WASP 
Nucleotide exchange profilin 
Actin capping/sequestration thymosins  
Depolymerisation and severing ADF/cofilin 
Bundlers and crosslinkers Microvilli: fimbrin; scruin; villin; espin 
Filopodia and stress fibres: fascin; α-actinin 
Crosslinkers filamin; spectrin; transgelin 
Cytoskeletal linkers Actin to intermediate filaments: spectrin 
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Actin to intermediate filaments and 
microtubules: plectin; BPAG; MACF; MAP2 
Actin to microtubules: tau 
Actin-based motility and 
contraction 
myosins 
Rulers and stabilisers  adducin; caldesmon; nebulins; tropomyosin 
Anchors to membranes and 
membrane proteins 
α-actinin; annexin II; α-catenin; BPAG; 
dystrophin; ERM proteins; plectin; spectrin; 
Sla2; talin; tensin; utrophin; vinculin 
Sidebinders and signallers IQGAP; Abp1; cortactin; coronin; drebrin; 
ENA/VASP 
Branch formation Arp2/3; WASP/SCAR/WAVE 
 
 
1.5.1 The cytoskeleton during crawling motility 
 
One of the major roles for the cytoskeleton is cell migration (Fletcher and Mullins, 
2010). Whole cell locomotion is a fundamental process during development and 
maintenance of multicellular organisms: early in embryonic development, tissue 
formation requires the carefully orchestrated migration of precursor cells to specific 
locations, then throughout multicellular life, wound healing and immune response are 
key processes to survival that rely on cell migration (Friedl and Gilmour, 2009). 
 
There are several modes of cell migration. While many unicellular eukaryotes propel 
themselves by cilia and flagella, cell migration in multicellular eukaryotes is more 
complex, although flagella-driven propulsion is present, such as in sperm motility 
(Ridley et al., 2003). Cell motility in eukaryotic cells is largely pushed by cytoskeletal-
driven changes in cell shape, with two main forms: crawling motility and blebbing 
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motility. While blebbing motility occurs independently from the actin cytoskeleton 
(Blaser et al., 2006), crawling motility depends on the protrusion and retraction of actin. 
The present study focuses on crawling motility in MKS cells, and so the mechanics of 
blebbing and other forms of motility will not be covered but are reviewed in (Paluch 
and Raz, 2013). 
 
Crawling motility in a 2-D environment can be broken down into four stages: 
protrusion, adhesion, traction, and de-adhesion/tail retraction (Mitchison and Cramer, 
1996). During the protrusion phase, rapid actin polymerisation at the leading edge of 
the cell drives the lamellipodium forwards. Adhesion of the cell to the external 
environment is required for lamellipodial protrusion to be converted into cell traction 
(Ridley et al., 2003). Adhesion occurs through focal adhesions; integrin-containing, 
multiprotein complexes which couple the actin cytoskeleton to the extracellular matrix 
(ECM; Vicente-Manzanares and Horwitz, 2011). Focal adhesion dynamics also play a 
central role during cell locomotion. In the leading edge of lamellipodia small adhesions 
form, containing integrins, talin, paxillin and vinculin. These immature adhesions are 
called focal complexes (Wozniak et al., 2004). Many focal complexes are transient: 
the dynamic protrusion and withdrawal of the actin in the leading edge means many 
focal complexes do not mature and are disassembled. However, in the net-protrusion 
of the leading edge, some adhesions mature into the larger and more stable focal 
adhesion. During maturation, focal adhesions sequentially recruit additional proteins, 
such as zyxin and tensin, (Zaidel-Bar et al., 2004). Through attachment to mature focal 
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adhesions, the actin cytoskeleton can exert force onto the ECM, generated by myosin 
activity, and in this way generate the traction needed for migration (Burridge and 
Guilluy, 2016). 
 
Focal adhesions remain stationary with respect to the ECM, and as a cell migrates 
forwards they arrive closer to the rear of a cell. In order for tail retraction, mature focal 
adhesions at the trailing edge of a migrating cell must be disassembled. The rate of 
deadhesion of a cell is often the limiting factor in migration speed, with cell types that 
migrate faster forming weaker adhesions (Mitchison and Cramer, 1996). 
 
While the actin cytoskeleton is the main driver of crawling motility in cells, microtubules 
have also been implicated in the process, as destruction of microtubules was found to 
inhibit protrusive lamellipodial activity in fibroblasts (Bershadsky et al., 1996). 
Disrupting microtubules has also been shown to activate the small GTPase Rho, 
resulting in increased focal adhesion size, as well as enhancing the phosphorylation 
of the focal adhesion-associated proteins paxillin and FAK (Bershadsky et al., 1996). 
Dynamic instability of microtubules also aids cell migration by allowing cells to rapidly 
remodel the cytoskeleton and focal adhesions, and microtubule inhibitors have been 
shown to hinder whole cell locomotion, and prevent migrating cells from effectively 
retracting their trailing edges, or tails (Yang et al., 2010; Kaverina and Straube, 2011; 
Ganguly et al., 2012). Microtubules also play a supporting and regulatory role to the 
actin cytoskeleton during migration, by transporting membrane vesicles to the leading 
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edge to help facilitate lamellipodial extension, by regulating actin polymerisation and 
controlling force-projection, and by aiding the disassembly of focal adhesions at the 
rear of the cell (Kaverina and Straube, 2011). 
 
1.5.2 Organisation of actin in migrating cells 
 
The reorganisation of the actin cytoskeleton provides the driving force for crawling 
migration, through the protrusion of the actin-rich lamellipodium at the leading edge, 
and the retraction of the tail at the cell rear. In a migrating cell, actin is organised into 
different structures which produce the two key functions required of the cytoskeleton 
for migration: pushing at the leading edge and pulling at the trailing edge (Figure 1.3; 
Mitchison and Cramer, 1996). As well as the actin structures in Figure 1.3, another 
type of specialised stress fibre is required for cell migration: perinuclear actin 
(Maninová et al., 2014; Maninová and Vomastek, 2016; Maninová, Caslavsky and 
Vomastek, 2017). 
 
Figure 1.3 provides an overview of the different types of actin structure found in a 
migrating cell. 
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Figure 1.3 Representation of actin cytoskeleton in a migrating cell. Protrusion of the cell at 
the leading edge is facilitated by the lamellipodium: a meshwork of actin filaments, which push 
the cell edge forward through actin polymerisation at the + end. Retraction at the trailing edge 
is facilitated by the stress fibres. Actin stress fibres form bipolar bundles with myosin (yellow), 
allowing the contractibility required for retraction, shown by the red arrows underneath the cell. 
+ and - indicate the polymerisation direction of the fibres. Focal adhesions are shown in green. 
 
1.5.3 The perinuclear actin cap is vital for directed cell migration 
 
Perinuclear actin cap fibres were first observed in rat fibroblasts in 1979, and were 
described as a sheath of highly organised actin over the top of the nucleus (Zigmond 
et al., 1979). Later on, Khatau et al., (2009) used confocal microscopy to observe the 
actin cap in MEFs, describing the cap as ‘thick actin filament bundles organised into a 
curved shell or cap above the nucleus’. Actin cap fibres are aligned in the direction of 
cell orientation, terminating in specialised focal adhesions (actin cap-associated focal 
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adhesions, or ACAFAs) at either end of the fibre at the cell peripheries (Figure 1.4). 
ACAFAs are physically and functionally distinct from other conventional focal 
adhesions. ACAFAs have a distinct morphology: they are larger and more elongated 
than conventional focal adhesions, due to higher levels of tension exerted by the actin 
cap fibres (Kim et al., 2012). Whereas other focal adhesions are distributed throughout 
a cell’s basal surface, ACAFAs are restricted to the cell periphery (Kim et al., 2012).    
 
 
Figure 1.4 Apical view of a migrating fibroblast. (a) Basolateral actin lies under the nucleus. 
(b) Perinuclear actin cap fibres cover the nucleus like a cap, orientated in the direction of 
migration. Arrow indicates direction of migration. 
A Basal actin 
 
  
B Apical actin 
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Perinuclear actin cap fibres are highly dynamic, more so than other types of stress 
fibre (Khatau et al., 2009). Association with Linker of Nucleoskeleton and Cytoskeleton 
(LINC) complexes help to stabilise cap fibres (Maninová et al., 2017). The LINC 
complex is a protein complex spanning across both inner and outer membranes of the 
nucleus. It is comprised of a KASH domain, a SUN domain, and nesprin (Starr and 
Fridolfsson, 2010; Figure 1.5).  
 
Figure 1.5 The LINC complex bridges both the inner and outer nuclear membranes, and 
provides the link between the perinuclear actin cap and the nucleus. 
 
This SUN-KASH nuclear bridge and its role in nuclear positioning was first identified 
in the model organism Caenorhabditis elegans presenting with mispositioned nuclei 
and defects in nuclear migration (Horvitz and Sulston, 1980; Sulston and Horvitz, 
1981). The LINC complex not only anchors the nucleus to the actin cytoskeleton (see 
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Figure 1.5), but also to the microtubule cytoskeleton and intermediate filaments, all of 
which are important for nuclear positioning (Starr and Han, 2002; Toivola et al., 2005; 
Ralston et al., 2006; Zhang et al., 2007; Zhou et al., 2009). Disruption of LINC 
complexes therefore results in nucleus mispositioning (Horvitz and Sulston, 1980; 
Sulston and Horvitz, 1981). As well as their function in LINC complexes, the SUN-
KASH proteins have been shown to be important to a number of processes outside of 
linking the cytoskeleton to the nucleus, including function in the global reorganisation 
of the cytoskeleton and associated organelle movement, centriole attachment to the 
nuclear envelope, movement of telomeres during meiosis, and a variety of other 
processes (see Starr and Fridolfsson, 2010 for a review of the many roles of SUN-
KASH proteins). 
 
At their N-terminus, the LINC complex SUN proteins interact directly with the lamina 
(Figure 1.5), and it has been suggested that this interaction leads to regulation of gene 
expression (Alam et al., 2016). LINC complexes provide a direct link between the 
lamina and the actin cap, and the actin cap fibres in turn terminate at the ACAFAs. 
These ACAFAs contain cell surface transmembrane receptors such as integrins, 
which associate with the ECM, and thus actin cap fibres provide a means of 
transmitting extracellular mechanical signals directly to the nucleus (Dechat et al., 
2008; Wang, Tytell and Ingber, 2009). As such, mechanical forces applied at the cell 
surface could promote the chemical conversion of signals at the nucleus. How the 
LINC complex is coupled to perinuclear actin cap fibres is not known. This connection 
 
46 
could either be direct, with actin fibres binding to the actin-binding domains at the N-
termini of certain isoforms of nesprin-1 and nesprin-2; or indirect, through association 
with ABPs such as fascin, amphiphysin-2, and FHOD1, which are able to bind to 
spectrin repeats of nesprins (Maninová, Caslavsky and Vomastek, 2017). 
Alongside the actin structures described in Figure 1.3, the perinuclear actin cap plays 
a vital role during cell migration (Khatau et al, 2012). Nuclear positioning and 
orientation are tightly regulated during cell migration: as a cell polarises, the nucleus 
moves towards the back of the cell, and is orientated to align in the direction of 
migration (Gomes et al., 2005; Luxton et al., 2010). This nuclear reorientation is 
controlled by the perinuclear actin cap, and disruption to the structure of the cap affects 
both nuclear reorientation and cell migration (Brosig et al., 2010). The actin cap can 
be disrupted by both destabilising the formation of the actin fibres, or by disrupting the 
LINC complexes (Khatau et al., 2009; Maninová and Vomastek, 2016). Disruption of 
the actin cap results in a change in cell morphology, and a decrease in the rate of cell 
migration (Khatau et al., 2012). 
 
1.5.4 Emerging evidence suggests that the actin cytoskeleton and cell 
migration are compromised in ciliopathies 
 
During embryonic development, cells undergo a series of complex steps that will 
ultimately define their position and role during organogenesis. Cell migration is a 
fundamental part of this developmental chain of events, as cell lineages move from 
one part of the embryo to another (such as the migration of neural crest cells during 
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early development). Defects to cell migration during embryogenesis therefore have 
severe and potentially lethal results, and are responsible for a multitude of human 
syndromes. Heart septation defects, neuronal migration disorders such as 
Lissencephaly, craniofacial disorders, Hirschsprung's disease and numerous other 
disorders all result from a defect in cell migration (Kurosaka and Kashina, 2008). 
 
Alterations to cellular migration have also been linked to ciliopathies. Inversin (linked 
to NPHP type 2) has been identified as having a role in cell migration, through 
transcriptional regulation of Wnt signalling and other pathways controlling the 
organisation of the cytoskeleton (Veland et al., 2013). Additionally, loss of the 
intraflagellar transport protein Ift88 disrupts the polarisation and migration of cells, 
independently of cilia function (Jones et al., 2012; Boehlke et al., 2015). Mutation in 
BBS-associated proteins Bbs4- and Bbs6- result in cellular migration defects, with 
cells unable to form lamellipodial and filopodial extensions. These migratory defects 
arose from disrupted actin stress fibre formation and over-abundant focal adhesions 
stemming from upregulated levels of RhoA (a small GTPase required for actin 
organisation and myosin contractibility; Hernandez-Hernandez et al., 2013). 
 
Comparable cellular phenotypes to those observed in BBS have been discovered in 
MKS cells. RhoA is upregulated in MKS cells, with corresponding defects to the actin 
cytoskeleton and migratory defects (Dawe et al., 2009; Valente et al., 2010; McIntosh, 
2016; Dawe lab, unpublished). However, while increased focal adhesions were 
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observed in BBS cells, focal adhesions in MKS cells have altered morphology and 
decreased levels of a number of adhesion proteins (Meadows, 2017). Additional 
migratory defects have recently been observed in MKS cells, adding to the evidence 
of extra-ciliary roles of MKS proteins. Loss of TMEM67 results in the loss of collective 
cell migration, with individual cells migrating faster, but with reduced directionality. 
Conversely, loss of TMEM216 leads to a reduction in cell migration speed (Dawe lab, 
unpublished). Aberrant nuclear rotation has also been observed in migrating cells 
lacking TMEM67, with the nucleus and centrosome being unaligned with the direction 
of cell polarisation and migration (Dawe lab, unpublished). Nuclear rotation and 
migratory defects are consistent with the aberrations to the actin cytoskeleton noted 
in the same TMEM67 cell line in Dawe et al., 2009, suggesting that the actin cap 
(which controls nucleus position during cell migration) could be disrupted in these 
cells. 
 
These non-ciliary roles suggest that ciliopathy proteins have multiple functionalities 
within the cell, and supports the idea that the variety of distinct pathologies of 
ciliopathies could be a result of other non-ciliary roles of the mutated proteins. 
However, there is limited information on how cell migration impacts on ciliopathy, and 
in most cases the reason for the migration defect is unknown. It is not known whether 
the migration defects are due to the loss of cilia and altered ciliary signalling, or 
whether the root of the defect is extra-ciliary. Additionally, MKS has recently been 
linked to defects in the cell’s extracellular environment (Meadows, 2017). The 
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extracellular environment and associated signalling is crucial to cell migration, and 
therefore to what extent the environment surrounding the cell contributes to the altered 
migration needs to be considered. 
 
1.6 Migrating animal cells are surrounded by the extracellular matrix 
 
The ECM is formed from a collection of extracellular molecules secreted by 
surrounding cells. The ECM not only functions as a physical scaffold for surrounding 
cells, but it also has an important role in cell-cell communication, cell differentiation, 
migration, gene expression, and acts as a repository for a number of growth factors 
(Rozario and DeSimone, 2010). In mammals, the ECM can be split into three major 
classes: structural proteins (including the collagens, fibrillins and elastin); other non-
structural proteins (including fibronectin, laminins, integrins); and proteoglycans. The 
roles of collagen, fibronectin and laminin, as well as the organisation and function of 
the ECM are discussed in more detail in the following sections (see Hynes and Naba, 
(2012) for a thorough review of the other ECM components and their function). 
 
1.6.1 Collagen 
 
Collagen is the most abundant protein type in the human body, forming around 25-
35% of its protein content (Di Lullo et al., 2002). It is the main structural protein forming 
connective tissue in humans, and is subsequently found mainly in fibrous tissues, 
including ligaments, skin, and tendons. At a molecular level, three single polypeptide 
chains twist together into a helical structure to form ‘tropocollagen’. Many 
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tropocollagens then associate to form fibrils, and many fibrils come together to form a 
collagen fibre. This structure gives collagen a high tensile strength of between 0.2 and 
0.86 GPa, around half the tensile strength of spider silk, allowing collagen to act as 
the main structural component in the human body (Griffiths and Salanitri, 1980; 
Svensson et al., 2010). To date, 26 collagen types have been identified, with collagen 
Type I being the most abundant collagen in humans, making up around 90% of the 
collagen content (Di Lullo et al., 2002; Gelse et al., 2003; Avila Rodríguez et al., 2018). 
The roles of the five most abundant collagens are laid out in Table 1.6. 
 
Table 1.6 Functions of the five most abundant collagens in the human body (reviewed in 
Gelse et al., 2003). 
Collagen Function 
Type I Skin; tendon; organs; bone 
Type II Cartilage 
Type III Reticulate 
Type IV Basal lamina 
Type V Cell surfaces; hair; placenta 
 
1.6.2 Laminin 
 
Laminins are important glycoproteins of the ECM and are the main constituent of the 
basal lamina, regulating cell differentiation, migration, and adhesion (Timpl et al., 
1979). Laminin is a heterotrimeric protein, consisting of an alpha, beta and gamma 
monomer (Figure 1.6). The three monomers associate to form a wind turbine-shaped 
structure, with the three individual monomers separately forming three short arms, 
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then associating into a long, coiled body (Aumailley et al., 2005; Domogatskaya et al., 
2012). The arms bind to other laminin molecules, allowing the formation of laminin 
sheets, while the coiled body binds to cells, forming the points of attachment between 
tissues and the basement membrane. There are five alpha laminin variants, four beta, 
and three gamma, which combine to form different variations, named according to 
their arrangement; for example, alpha-5, beta-2 and gamma-1 monomers form 
Laminin-521 (Aumailley et al., 2005). 
 
Figure 1.6 The heterotrimeric structure of laminin. 
 
1.6.3 Fibronectin 
 
Fibronectin is a high-molecular weight, multifunctional glycoprotein. There are two 
forms: the insoluble form synthesised by fibroblasts is a major constituent of the ECM, 
and a soluble form produced by hepatocytes is a major protein component of blood 
plasma. Alternative splicing of fibronectin mRNA creates upwards of 20 fibronectin 
!
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variants in humans, which vary both spatially and temporally across development and 
aging (Schwarzbauer et al., 1983; Ffrench-Constant and Hynes, 1989).  
 
In the ECM, fibronectins bind to other ECM components, including collagens, fibrins, 
and integrins. Fibronectins play major roles in cell migration, adhesion, growth, and 
differentiation, are major regulators of wound healing, and are required for embryonic 
development (reviewed in Hynes and Yamada, 1982).  
 
 
1.6.4 Organisation of the extracellular matrix 
 
In animals, the ECM includes the basement membrane and the interstitial matrix. The 
basement membrane is a sheet-like deposition of associated ECM molecules on 
which epithelial, mesothelial, or endothelial cells sit (Liotta et al., 1980; Jayadev and 
Sherwood, 2017). It separates these cells from the body’s connective tissue, both 
functioning as an anchor between these cell sheets and the looser connective tissue, 
but also as a mechanical barrier, preventing the invasion of malignant cells into deeper 
layers of tissue (Liotta et al., 1980). The four main basement membrane components 
are collagen IV (see Table 1.6), laminin, nidogen, and perlecan (Paulsson et al., 1992; 
LeBleu et al., 2007). Collagen IV is the major constituent of the basement membrane, 
and laminin is the most abundant non-collagenous component (LeBleu et al., 2007). 
Self-assembly of a collagen IV superstructure, and of laminin heterotrimers into 
integrin-associated polymers form the basement membrane scaffold. Nidogen and 
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perlecan stabilise the scaffold by bridging the networks. Basement membrane tissue 
specificity is generated through association of additional minor components to this 
core four (LeBleu et al., 2007). 
 
The interstitial matrix consists of gels of polysaccharide molecules and fibrous 
proteins, which amalgamate in the spaces between tissues, and act as a buffer to 
compressional stress (Frantz et al., 2010). 
 
1.6.5 The extracellular matrix and cell migration 
 
As covered in section 1.5.1, in order for a cell to migrate, it must adhere to its 
extracellular environment: adhesion is regulated by cell surface receptors, of which 
the major class is the integrins (Harburger and Calderwood, 2009). The cell must also 
polarise and have contractile force generated by the cytoskeleton (DiMilla et al., 1991). 
Net migration occurs when the contractile forces overcome the adhesive forces 
(DiMilla et al., 1991). Eukaryotic cell migration is driven through cytoskeletal changes 
and ECM-integrin binding. A number of ECM qualities have a direct effect on cell 
migration, including ECM rigidity, ECM concentration, protein composition, and ligand 
concentration (Palecek et al., 1997). 
 
ECM rigidity varies between cell types due to the balance of collagen and elastin within 
the matrix: this is one of the ways in which protein composition can influence cell 
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migration. Cells migrate slower on more rigid matrices, due to the relationship between 
the ECM stiffness and cell spreading (Pelham and Wang, 1997). Like a water droplet 
falling onto a surface, when a cell hits a substrate, it passively deforms and spreads. 
Similar to surface tension in a water droplet, a cell’s cortical tension holds them in a 
spherical shape. This cortical tension is driven by acto-myosin contractile tension 
(Vicente-Manzanares et al., 2009; Clark et al., 2014; Chugh et al., 2017). When a cell 
is not migrating, its cortical tension is large, and therefore the force it exerts on the 
substrate is large. A softer substrate deforms more in response to these forces than a 
more rigid substrate, reducing the resultant force against the cell, and under these 
circumstances cells are not able to maintain the high tensions required for spreading. 
This results in less cell spreading on a softer substrate compared to a harder substrate 
(Lange and Fabry, 2013); see Figure 1.7. 
 
As shown in Figure 1.7, on a more rigid matrix a cell spreads more, thus increasing 
the volume of engaged cell-matrix adhesions. This results in a decrease in migration 
speed as there are more adhesive forces for the cell to overcome (DiMilla et al., 1991; 
Metzner et al., 2007). Cell migration directed by ECM rigidity gradients is known as 
durotaxis. Through mechanosensing, whereby the cell responds to differences in 
applied forces, cells usually migrate from a low to a high rigidity (Pelham and Wang, 
1997). 
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Key: 
 
Figure 1.7 Cells spread less on softer substrates due to increased deformation of a soft 
substrate in response to a cell’s cortical tension.  
 
As well as the physical properties of matrix proteins, the second way in which protein 
composition of the ECM affects cell migration is the individual properties of matrix 
proteins: different matrix proteins affect cell adhesion and migration speed in different 
cell types (Strachan and Condic, 2003). For example, on matrices containing high 
laminin concentrations, cranial neural crest cells migrate faster than trunk neural crest 
cells due to the two cell types’ alternate regulation of ECM receptor expression 
(Strachan and Condic, 2003). 
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Concentration of ECM also affects cell migration. Migration speed follows a normal 
distribution with increasing ECM concentration, whereby an intermediate 
concentration favours fastest migration speeds (Palecek et al., 1997). At high levels 
of ECM concentration, cell detachment rate is low due to a high number of engaged 
cell adhesion sites, whereas at very low ECM concentrations, there are few adhesion 
sites and the lamellae are unstable – both conditions hamper migration. Fastest 
migration is therefore present on intermediate ECM concentrations, where adhesion 
and detachment are balanced (Palecek et al., 1997). Cell migration directed through 
cells sensing and responding to ECM concentration gradients is known as haptotaxis: 
cells migrate away from regions of low ECM concentration, where cell adhesion is 
weak, to areas of higher ECM concentration (Wen et al., 2015). 
 
The above ECM properties influence different cell types to varying degrees, and have 
direct implications on vertebrate development (Rozario and DeSimone, 2010). For 
example, neural crest cell migration is a highly coordinated process, and ECM has 
been identified as an important regulator of this process. Unique to vertebrates, neural 
crest cells are a temporary group of cells which arise during development from the 
embryonic ectoderm and then differentiate into numerous cell types, including 
connective tissue, craniofacial cartilage, craniofacial bone, melanocytes, neurons, and 
glia. Individual ECM components have been identified as supporting different 
migratory behaviours, for example, laminin α5 has been suggested to be important for 
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restricting cell migration into controlled lanes (Strachan and Condic, 2003; Coles et 
al., 2006; Rozario and DeSimone, 2010). 
 
Recently a link between loss of cilia and defects to the ECM has been uncovered. 
Giantin, a Golgi protein, is required for ECM assembly, with rodent models with loss-
of-function mutations in the protein showing extensive defects in ECM secretion and/or 
assembly (Katayama et al., 2011). Giantin is also required for normal ciliary function 
(Asante et al., 2013; Bergen et al., 2017). Similar phenotypes have been observed in 
MKS, with loss of MKS type 3 protein TMEM67 resulting in changes to the secretion 
levels of a number of ECM proteins (Meadows, 2017).  
 
1.6.6 Loss of MKS protein TMEM67 results in defects to the ECM 
 
The following study focuses on TMEM67. Sometimes referred to as Meckelin, 
TMEM67 is a 995-amino acid protein encoded by the TMEM67 gene, located at 
8q22.1 in the human genome (Smith et al., 2006). TMEM67 was originally implicated 
in MKS (Smith et al. 2006), but has since also been linked to BBS (as a modifier; Leitch 
et al., 2008), COACH (Brancati et al., 2009), JTBS (Delous et al., 2007), and NPHP 
(Otto et al., 2009). Mutations in TMEM67 are the most common cause of MKS 
(Szymanska et al., 2012). In situ hybridisation in human embryos has revealed that 
TMEM67 is expressed in the kidney, liver, retina, hindbrain, developing sphenoid 
bone, and the brain midline, with strong expression in the developing digits (Dawe et 
al., 2007). TMEM67 is a component of the transition zone, and is required for centriole 
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migration to the apical membrane during ciliogenesis (Dawe et al., 2007b; Yang et al., 
2015; Shi et al., 2017). Loss of the protein therefore disrupts ciliogenesis and cell types 
lacking the protein have significantly fewer cilia (Dawe et al., 2007b). 
 
The cytoplasmic region at the C terminus of TMEM67 interacts with Filamin A 
(encoded by the FLNA gene; Adams et al., 2012). Filamin A is an ABP which facilitates 
cross-linking of actin filaments (see Table 1.5), and aids anchoring of membrane 
proteins to the actin cytoskeleton, and is therefore an important protein in the 
remodelling of the actin cytoskeleton during cell migration. Knockdown of both FLNA 
and TMEM67 results in abnormal basal body positioning, loss of ciliogenesis, aberrant 
remodelling of the actin cytoskeleton, deregulation of RHOA and hyperactivation of 
canonical Wnt signalling (Dawe et al., 2009; Adams et al., 2012; McIntosh, 2016). The 
C-terminal coiled-coil domain of TMEM67 interacts with a structural maintenance of 
chromosomes (SMC) domain at the N terminus of Nesprin-2 (Dawe et al., 2009). A 
component of the LINC complex, Nesprin typically localises to the outer nuclear 
membrane (see Figure 1.5). However, knockdown of TMEM67 results in the aberrant 
re-localisation of Nesprin-2 to actin stress fibres and remodelling of the actin 
cytoskeleton (McIntosh, 2016). 
 
Recent research has also identified TMEM67 as a focal adhesion protein, required for 
the organisation of adhesions, probably through recruitment or retention of other 
adhesion proteins (Meadows, 2017). Analysis of focal adhesions of TMEM67 patient 
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cells revealed major alterations to the adhesome and associated morphological 
differences to adhesion patterning. As well as altered expression in adhesion-
associated genes, TMEM67 patient cells also exhibit altered ECM gene expression, 
with cell-derived matrix (CDM) isolated from TMEM67 patient cells containing reduced 
levels of collagen IV and laminin (Meadows, 2017). While TMEM67 is the most well 
studied of the MKS proteins, there are still large gaps in our understanding of its 
function, including its role at focal adhesions. 
 
1.7 Summary and scope of thesis 
 
Until recently, the primary cilium was thought by many people to be a vestigial 
organelle. However, it is now known to be a key regulator in a number of key 
developmental pathways, with the loss of formation or function of primary cilia being 
linked to a number of inherited diseases (Waters and Beales, 2011). Originally, 
research focused on the loss of ciliary function and how this linked to pathogenicity, 
however, this raised the question of how loss of function of a single organelle could 
result in multiple clinically distinct diseases. Recent studies highlighting the extra-
ciliary roles of ciliopathy proteins provides an answer: ciliopathy proteins have much 
wider roles in the cell than purely cilia-related functions. 
 
This study builds on previous research linking the loss of TMEM67 to aberrant actin 
organisation, and to defects in cellular migration and ECM deposition (Dawe et al., 
2009; Adams et al., 2012; McIntosh, 2016; Meadows, 2017; Dawe lab, unpublished). 
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We investigate whether the cellular migration defect and nuclear rotation during cell 
migration observed in TMEM67 patient fibroblasts stems from a reorganisation of the 
perinuclear actin cap through the visualisation of the actin cytoskeleton in migrating 
cells. We also investigate the relationship between the ECM and the actin 
cytoskeleton, testing if the defects to the extracellular environment previously 
characterised in TMEM67 patient cells are linked to the cytoskeletal abnormalities. In 
addition, we investigate TMEM67 function by studying the effects of six clinically 
relevant mutations across the protein on the actin cytoskeleton, and identify some 
novel binding partners of the protein. By detangling which regions of TMEM67 are 
important for particular functions, we aim to uncover more about the potential role of 
TMEM67 in the pathology of ciliopathies. In this study, we conclude that loss of 
TMEM67 results in a loss of the actin cap during cell migration, and uncover a novel 
role of TMEM67 in myosin motor activity. 
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2 Materials and Methods 
 
 
2.1 Cell culture 
 
hTERT immortalised TMEM67 [c.653G>T]+[c.755T>C] fibroblasts from human 
neonates and non-diseased, age-matched control fibroblasts (obtained from Colin 
Johnson, Leeds Institute for Molecular Medicine) were grown in Dulbecco’s Modified 
Eagle’s Medium: Nutrient Mixture F-12 (DMEM-F12), supplemented with 20% 
Fibroblast Growth Medium (FGM; AMS Biotech), 10% foetal bovine serum (FBS) and 
1% G418. Cells were cultured at 37 °C with 5% CO2, and split to sub-passage in 
TrypLE Express (Gibco) when approximately 70% confluent in a T-25 flask. All cells 
used were between passages 12 and 20. 
 
2.2  Isolation of cell-derived matrix 
 
To isolate cell-derived matrix, cells were incubated on sterile glass coverslips for four 
days at 37 °C with 5% CO2 post confluency. Cells were lysed using 20 mM NH4OH in 
0.5% Triton X-100-PBS for four minutes, and residual matrix was washed in PBS (Ca-
/Mg-, Gibco) twice to ensure complete removal of NH4OH. All coated coverslips were 
plated with fibroblasts immediately after the removal of fibroblasts. 
 
2.3 Scanning electron microscopy 
 
Cells were grown on coverslips in 4-well plates for the indicated times and fixed for 1 
hour in 2% glutaraldehyde + 2.5% formaldehyde in 100 mM sodium cacodylate (pH 
7.2). Cells were dehydrated in a series of ethanol concentrations, up to 100% ethanol. 
The samples were processed using the chemical drying agent Hexamethyldisilizane 
(HMDS). The samples were splutter coated and imaged at ×4000 using a Jeol JSM-
6390LV Scanning Electron Microscope. 
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2.4 Surface coating with extracellular matrix proteins 
 
Purified laminin, fibronectin, collagen I and collagen IV matrix proteins were obtained 
from Sigma-Aldrich: collagen I solution from rat tail (product code C3867), collagen IV 
derived from human placenta (product code C5533), human plasma fibronectin 
(product code F2006), laminin derived from human placenta (product code L6274).  
Sterile glass coverslips were coated overnight at 3 °C. All components were used at 
10 µg ml-1, diluted in PBS (Ca-/Mg-, Gibco) for laminin and fibronectin and 0.02 N acetic 
acid for collagen I and collagen IV. All coated coverslips were plated with fibroblasts 
immediately after the coating incubation. 
 
Recombinant laminins were obtained from Biolamina: LAMscreenTM laminin isoform 
kit (product code KT202-1). All recombinant laminins were used at 10 µg ml-1 diluted 
in DPBS (Ca+/Mg+, Gibco) according to the manufacturer’s instructions, and incubated 
on coverslips overnight at 3 °C. All coated coverslips were plated with fibroblasts 
immediately after the coating incubation. 
 
2.5 Wound assays 
 
Fibroblasts were grown on coverslips pre-coated in matrix proteins for four days at 
37 °C with 5% CO2 until a monolayer formed. A wound was induced using p200 pipette 
tip to scratch across centre of coverslip, and cells were incubated for a further 12 hours 
at 37 °C to allow migration into the wound. Cells were fixed and processed for 
fluorescence imaging immediately. Only cells with clear morphology indicating 
migration into the wound were quantified.  
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2.6 Immunofluorescence and cell staining 
 
Cells were grown on 13 mm #1.5 glass coverslips in 4-well plates for the indicated 
times and fixed in paraformaldehyde (PFA) for 20 minutes at room temperature (see 
Supplementary Table 1 for PFA concentrations, and antibody and stain dilutions). 
After fixation, cells were permeabilised in 0.5% Triton X-100-PBS for five minutes, 
followed by 0.1% Triton X-100-PBS for five minutes, and then blocked in 1% Bovine 
Serum Albumin in PBS-0.1% Triton X-100-PBS (AbDil) for 20 minutes at room 
temperature. After blocking, cells were incubated with primary antibodies or 
AlexaFluor 594 phalloidin diluted in AbDil at room temperature for one hour (20 
minutes for phalloidin) in a fluorescence chamber. Secondary antibodies were used at 
1:500 dilutions in AbDil and were incubated for 30 minutes at room temperature. DAPI 
was used at 1 µg ml-1 and was incubated for two minutes at room temperature. 
Coverslips were mounted in Vectashield mounting medium, sealed with clear nail 
varnish and stored at -20 °C until quantification. Immunofluorescence images were 
taken using a Zeiss Axio Observer Z1 inverted microscope equipped with a 40x 1.3 
NA oil objective, controlled by AxioVision software (Carl Zeiss). Images were acquired 
by a CoolSnap HQ2 camera (Photometrics) and processed in Fiji (ImageJ).  
 
2.7 siRNA knockdown 
 
Non-diseased control fibroblasts were cultured in a T-25 flask until 70-80% confluent 
before being trypsinised and centrifuged. The Amaxa Nucleofector electroporation 
device was used for transfection, using transfection kit R (Lonza). 400pmol of tmem67 
siRNA (Dharmacon ontarget plus smartpool L-016511-01-0005) was added to the 
pellet with 80 µl of transfection reagent (containing 65 μl nucleofector solution R and 
15 μl supplement 1). This cell suspension was loaded into an electroporation cuvette 
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(Lonza) and electroporated with program D-023. The cells were immediately 
transferred to coverslips in a 4-well plate and left to grow for five days before a wound 
assay was performed. 
 
2.8  Sequencing 
 
Plasmid purification was performed by Miniprep (QIAGEN® QIAprep®) using the 
manufacturer’s recommended protocol. Eurofins Genomics TubeSeq service was 
used for sequencing plasmids. Following Eurofins’ sample submission guidelines, all 
sample concentrations contained 50-100 nl µl-1 of plasmid DNA. See Supplementary 
Table 2 for sequencing primers used. Alignments were analysed using SnapGene® 
(v.2.6.2). 
 
2.9 Plasmid transfection 
 
HA-TMEM67 plasmids were all made by Katerina Szymanska and were provided by 
Colin Johnson (Leeds Institute for Molecular Medicine). Transfection of TMEM67 
fibroblasts and age-matched controls with HA-TMEM67 plasmids was performed 
using electroporation. The Amaxa Nucleofector electroporation device was used for 
transection, using transfection kit R (Lonza). For each transfection, a T-25 flask of cells 
at 70 % confluency were spun down and resuspended in 80 μl of transfection buffer, 
containing 65 μl nucleofector solution R, 15 μl supplement 1, and 1 μg of plasmid DNA. 
This cell suspension was loaded into an electroporation cuvette (Lonza) and 
electroporated with program D-023. Post-electroporation, the cells were immediately 
transferred into a T-25 flask with 3ml of fresh media. Cells were grown for four days 
before being fixed for IF. 
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2.10  GFP trap 
 
GFP-TMEM67-N1 FL (full length TMEM67 protein) and GFP-TMEM67-N1 DECL 
(TMEM67 lacking the large N terminal extracellular loop) plasmids were transfected 
into 3T3 cells as described above. Triplicate repeats were performed for each plasmid 
in the initial run, and the experiment was replicated for a second run to pool two 
separate datasets for each plasmid. The transfected cells were seeded into 10 cm 
dishes and left to grow for two days in media. To extract TMEM67, the media were 
removed and the cells were lysed on ice using a lysis buffer of 1% Nonidet NP-40, 
130mM NaCl, and 20mM Tris pH8. A cell scraper was used to harvest all the ECM 
components from each plate. The resultant extracts were rotated at 4 °C for 30 
minutes before centrifugation. The lysate was removed and incubated with GFP-
trap_A beads overnight at 4 °C according to the manufacturer’s specification. The 
bead solution was frozen at -80 °C in preparation for mass spectrometry (MS). DAVID 
Bioinformatics Resources 6.8 was used to annotate the gene list produced from the 
MS data. 
 
2.11 Western blot 
 
A polyacrylamide gel was made using 10% acrylamide. Whole cell lysate and 
immunoprecipitate samples were run on the gel using SDS-PAGE then transferred to 
a methanol-activated PVDF membrane overnight at 30 V. The membrane was blocked 
in PBS with 5% Marvel milk powder (Premier Foods Group) under continuous rotation 
for one hour at room temperature. Post-blocking, the membrane was incubated with 
anti-GFP primary antibody for one hour at room temperature with continuous rotation, 
washed x3 in PBS 0.1% Tween, and incubated in secondary antibody for 60 minutes 
under rotation at room temperature. Antibodies were diluted in PBS 2.5% Marvel milk 
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powder as described in Supplementary Table 1. To visualise protein, the membrane 
was treated with Amersham ECL Western Blotting Detection Reagent (GE Healthcare 
Life Sciences, Cat #RPN2106) and exposed to X-ray film (Super RX, FujiFilm). 
 
2.12 Image analysis and statistical analysis 
 
For SEM analysis of the ECM, images were randomly taken across the samples from 
three independent experiments and quantified. Significance between the number of 
images displaying a fibrillar and non-fibrillar matrix between MKS patient and non-
diseased control cells was determined using Chi Squared test.  
 
The number of bundles in the perinuclear actin cap were quantified using two methods. 
First, data were quantified according to the published literature (Woroniuk et al., 2018; 
Andrew Porter, personal communication). Briefly, Z-stacks were acquired, and the 
plane of focus just above the nucleus identified using the DAPI and Phalloidin 
channels. In most cases the cables were distinct enough to count manually by eye.  
Where this was not possible, 2 pixel line scans were drawn across the widest part of 
the nucleus, orthogonal to the longest axis nucleus, and the peaks of the line intensity 
plot were quantified. Two different researchers performed the analysis, and the 
information from both counts was combined to increase the robustness of the data. In 
an independent second approach, images from the same slides were acquired using 
a Zeiss LSM 880 confocal microscope equipped with AiryScan. The actin cap was 
identified as above, and bundles were analysed using FilaQuant software 
(Matschegewski et al., 2012; generously shared by Konrad Engel, University of 
Rostock) according to the User Guide. The analysis pipeline is summarised in Figure 
3.3a. The same conclusions were obtained using both methods. 
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Fluorescence intensity measurements were performed using linescan analysis in 
ImageJ and mean pixel intensity (a measure of brightness and therefore an indirect 
measure of F-actin levels) was calculated. For these analyses, the staining conditions, 
microscope objective, and camera exposures (based on the brightest images to 
ensure non-saturating exposure conditions for the whole dataset) were the same, and 
all measurements were made on unprocessed images. In each individual image, total 
fluorescence (sum of all grey levels) was measured by linescan and mean intensity 
recorded. Background fluorescence was measured at three points in each image, 
averaged, and subtracted from each data point. Three bundles per actin cap were 
measured and 50 cells were quantified per cell line. 
 
Numerical and statistical analyses were performed using Excel (Microsoft 
Corporation), and Prism (GraphPad). For all data, the Shapiro–Wilk test, which 
estimates the variance of the sample, was used to assess normality. This test exhibits 
high power, meaning that reliable conclusions can be drawn even with a small number 
of observations. Where the test statistic was smaller than the critical threshold, the 
assumption of a normal distribution was rejected and non-parametric testing methods 
used for those samples. 
 
For comparison of actin cap organisation and florescence intensity measurements in 
fibroblasts plated on their own matrices or on specific ECM components, the data were 
not normally distributed and thus the non-parametric Mann–Whitney test was used to 
compare TMEM67 or tmem67-silenced cells to the control. For analysis of actin cap 
organisation in cells plated onto purified laminin isoforms the data were not normally 
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distributed and thus the non-parametric Kruskal–Wallis test was used. Since multiple 
groups were to be compared to a single control, Dunn’s post-hoc correction for multiple 
comparisons was used to determine which groups were significantly altered. For 
analysis of actin cap bundles in cells expressing HA-TMEM67 variants, the Kruskal–
Wallis test with Dunn’s post hoc was used for the same reason.  
 
Mass spectrometry data were aligned to the human proteome using SEQUEST, 
corrected for false-discovery rate, and analysed according to the workflow 
summarised in Figure 3.10. Functional annotation clustering was performed using the 
online DAVID resource (https://david.ncifcrf.gov/). 
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3 Results 
 
3.1 TMEM67 patient fibroblasts synthesise a morphologically and 
biochemically altered cell matrix 
 
Previous research into the ECM of TMEM67 patient fibroblasts revealed aberrant 
levels of a number of matrix associated proteins (Meadows, 2017). Tandem Mass Tag 
Mass Spectrometry (TMT MS) undertaken by Meadows (2017) revealed that 
compared to age-matched, non-diseased control fibroblasts, TMEM67 patient 
fibroblasts secreted decreased levels of a number of important ECM proteins, 
including laminins, collagens, fibronectin, fibrillins 1 and 2, and thrombospondin 1 and 
2.1 These proteins showed a decrease in representation compared to non-diseased 
control cells, from 12-70% (Figure 3.1a). In order to establish the effect of these altered 
protein levels on ECM architecture, we utilised an immortalised human embryonic cell 
line from a patient with MKS, who was compound heterozygous for the missense and 
truncating mutations [c.653G>T]+[c.755T>C] in TMEM67. These TMEM67 patient 
cells produce reduced levels of the TMEM67 protein (Dawe et al., 2009). TMEM67 
patient fibroblasts were left to grow for four days on glass coverslips to allow secretion 
of ECM proteins. The cells were stripped, leaving this cell-derived matrix (CDM) intact, 
and the matrix was fixed for analysis by scanning electron microscopy (SEM). 
                                               
1 The Tandem Mass Tag Mass Spectrometry data in this section was performed by Ben Meadows as 
part of his PhD at the University of Exeter (awarded 2017). Data relevant to this thesis was filtered out 
of the main dataset by A. Toynbee (author of this thesis) to identify which ECM proteins would be 
most relevant to investigate in relation to the present study. 
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Micrographs revealed that TMEM67 patient fibroblasts secrete an altered CDM, with 
the loss of the thick ECM depositions seen in non-diseased control cell CDM (Figure 
3.1b). Only 21% of images of the patient fibroblasts scored as having a fibrillar matrix, 
compared to 86% of the non-diseased control cells (TMEM67 patient cells: n = 52 
images taken over 3 experiments; non-diseased control cells: n = 43 images taken 
over 3 experiments; p < 0.05, Chi Squared test). 
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Figure 3.1 TMEM67 patient fibroblasts secrete a biochemically and morphologically altered 
cell matrix. (a) TMT MS of TMEM67 patient CDM showing % decrease in protein level of the 
ECM compared to age-matched, non-diseased control fibroblasts. A number of other 
structural ECM components were not identified or not significantly changed compared to the 
control. TMT MS sample prepared by B. Meadows, and data extracted from dataset by me. 
(b) SEM of a four day control CDM versus a four day TMEM67 patient CDM. Scale bar = 5 
µm.  
 
3.2 SEM analysis reveals TMEM67 patient fibroblasts do not degrade 
the ECM 
 
The ECM morphology defect could be due to either assembly failure or to excess ECM 
degradation by matrix metalloproteinases. To identify whether the aberrant ECM 
morphology arises because TMEM67 patient cells alter ECM architecture post-
secretion, the cells were plated on a control CDM and the matrix was observed after 
four days.  
 
Using the same method as in section 3.1, non-diseased control fibroblasts were plated 
on glass coverslips and left to produce matrix for four days. The cells were then 
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Figur  1 TMEM67 patient fibroblasts produce an altered cell matrix. (A) Data on cell 
matrix components obtained from a wider transcriptomics study in TMEM67 cells (Dawe 
lab, unpublished). Laminins are shades of blue and collagens are red. (B) Scanning 
electron microscopy of cell derived matrices (CDM), showing TMEM67 cells do not 
degrade the matrix, and are capable of synthesising matrix when plated on a pre-made 
control matr x. White arrowheads indicate hick collagen bundles. Note lack of thick
collagen bundles present in TMEM67 CDM. Black arrow indicates underlying control 
matrix under overlaying TMEM67 matrix. 
 
 
Sample is prepared and waiting to be 
imaged 
B control CDM TMEM67 CDM 
+ TMEM67 cells + control cells 
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Non-diseased control CDM 
TMEM67 
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stripped, leaving their CDM isolated on the coverslip, and TMEM67 patient fibroblasts 
were plated on top and left for a further four days. The TMEM67 patient cells were 
removed and the residual matrix fixed for SEM. SEM analysis revealed that TMEM67 
patient fibroblasts did not cause visible degradation to the ECM, as the characteristic 
thick control CDM was still observable (Figure 3.2, right, white arrow head). 75% of 
images scored as having a fibrillar matrix (n = 61 cells, images taken over 3 
experiments) and this was not a significant difference compared to the non-diseased 
fibroblast matrix quantified in section 3.1 (p > 0.05, chi squared test). Concurrent with 
the data presented in Figure 3.1a, these data suggest that the altered ECM 
architecture observable by SEM is either due to decreased levels of protein secretion 
or a failure to assemble or anchor the matrix (thus leaving it soluble in media), and not 
due to degradation post-secretion. This result also provided a control for future ECM 
experiments, by confirming that TMEM67 patient cells would not degrade the ECM 
environment to an extent that would interfere with data interpretation. Furthermore, in 
many cases, two distinct layers of ECM could be observed that presumably 
correspond to the initial layer of CDM (Figure 3.2 right panel, white arrow head) with 
subsequent depositions lying on top (Figure 3.2 right panel, black arrow head). This 
suggests that when given a scaffold ECM, TMEM67 fibroblasts regained the ability to 
synthesise CDM effectively. Similarly, the CDM of the control cells plated on the 
TMEM67 CDM (Figure 3.2 left panel) appeared visibly thinner than it appeared in 
Figure 3.1b. 
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Figure 3.2 TMEM67 patient cells do not degrade the ECM and are able to assemble matrix 
when plated onto a control matrix scaffold. White arrow head indicates the underlying control 
CDM; black arrowhead indicates the overlying TMEM67 CDM. Scale bar = 5 µm.   
 
Taken together, these data indicate that several important qualities of the ECM are 
disrupted in TMEM67 patient fibroblasts, including protein composition, ECM 
morphology and density, and therefore likely ECM rigidity. As discussed in section 
1.6.5, ECM qualities impact multiple cellular processes, including cell migration. Cell 
migration defects have been observed in MKS patient cells (Dawe lab, unpublished), 
but the molecular cause is unknown. We hypothesised that the altered ECM 
Non-diseased control CDM + TMEM67 
[c.653G>T]+[c.785T>C] cells 
 
TMEM67 [c.653G>T]+[c.785T>C] CDM 
+ non-diseased control cells 
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composition is a contributing factor to the migration phenotype, and therefore sought 
to investigate how ECM composition impacts cell migration in MKS patient cells 
compared with age-matched controls. 
 
 
3.3 TMEM67 is required for the correct organisation of the perinuclear 
actin cap 
 
TMEM67 patient fibroblasts migrate more quickly than control fibroblasts in vitro, but 
take the same length of time to close the wound in a scratch assay due to a loss of 
directionality (Dawe lab, unpublished). The nuclear–centrosome axis is also affected 
in MKS patient fibroblasts (Dawe lab, unpublished). One structure that is vital for the 
maintenance of directionality during cell migration is the perinuclear actin cap, which 
is also responsible for the orientation of the nucleus (Brosig et al., 2010). As the actin 
cytoskeleton is known to be disrupted in the MKS patient cell line used in this thesis 
(Dawe et al., 2009; Adams et al., 2012; McIntosh, 2016) we postulated that a 
disruption to the perinuclear actin cap could underlie the directionality defect in 
TMEM67 patient fibroblasts. 
 
In order to investigate this hypothesis, fibroblasts were grown to confluency for four 
days; the time at which previous actin defects in TMEM67 patient cells have been 
observed (McIntosh, 2016), and the time corresponding to the SEM analyses above. 
A scratch assay was performed by introducing a wound through the cell monolayer 
using a pipette tip, and the cells were left to migrate into the wound for 12 hours. The 
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cells were then fixed and F-actin and DNA were labelled with fluorescent phalloidin 
and DAPI, respectively. Phase contrast was used to view cell morphology, and only 
cells with clear polarised morphology that were migrating into the wound were imaged. 
Actin on the basal cell surface appeared similar in the two cell types (Figure 3.3b and 
d, compare the control cells in the left panels with the MKS patient cells in the right 
panels). In contrast, the apical actin cap in TMEM67 patient fibroblasts had fewer 
bundles visible (Figure 3.3b, compare the top right insets). We quantified this using 
two independent methods of actin bundle quantification (Matschegewski et al., 2012; 
Woroniuk et al., 2018; Figure 3.3c) and observed similar results with each. Compared 
to the age-matched control fibroblasts, TMEM67 patient fibroblasts had significantly 
fewer actin bundles in the perinuclear actin cap (Figure 3.3c; Mann–Whitney Test, p < 
0.0001). The mean number of bundles in the cap of TMEM67 fibroblasts was 4.7 ± 0.3 
(linescan analysis) and 4.1 ± 0.7 (FilaQuant analysis) compared to 9.4 ± 0.4 (linescan 
analysis) and 9.1 ± 1.5 (FilaQuant analysis) in the control fibroblasts (n = at least 150 
cells per cell line, over three independent experiments). Complete loss of the actin cap 
was frequently observed in cells with wide and ruffled lamellopodia; a characteristic 
phenotype of TMEM67 patient cells (McIntosh, 2016). To distinguish between reduced 
bundle numbers of unchanged thickness (i.e. reduced total actin) and increased actin 
bundling and therefore fewer but thicker bundles (i.e. unchanged total actin), we 
imaged the phalloidin-stained actin cap under constant camera conditions and 
quantified fluorescence intensity of individual actin bundles by linescan analysis. 
There was no significant difference in fluorescence intensity of bundles within the actin 
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cap when patient cells were compared to controls (3850 ± 169 versus 4223 ± 145, n 
= 50 cells from three independent experiments per condition; Mann–Whitney test, p = 
0.08). Therefore, it is unlikely that the reduction in actin cap bundle number seen in 
patient cells is a result of increased actin bundling, and instead may indicate that there 
is less F-actin between the apical surface of the nucleus and the plasma membrane. 
 
siRNA-mediated silencing of tmem67 in non-diseased control fibroblasts confirmed 
the link between TMEM67 and the actin cap. Control fibroblasts were transfected with 
tmem67 siRNA and a scratch assay carried out, following the same method as above. 
Successful knockdown was judged by immunofluorescence and Western blotting 
using an anti-TMEM67 antibody (Figure 3.3d bottom right insets, and Figure 3.3f) and 
only cells which were clearly polarised but with low levels of TMEM67 fluorescence 
were analysed. Similar results were observed to those from the patient cells (Figure 
3.3d, compare the top right insets). WT cell + tmem67 siRNA fibroblasts had 
significantly fewer actin bundles in the perinuclear actin cap, compared to age-
matched control + control siRNA (Figure 3.3e). Once again, we quantified the number 
of actin bundles within the cap using both linescan analysis and FilaQuant software 
and found that quantification method did not make a significant difference to the results 
(Figure 3.3e, n = at least 150 cells per cell line, over three independent experiments). 
The mean number of bundles in the actin cap of the cells treated with tmem67 siRNA 
was 6.5 ± 0.5 (Mann–Whitney test, p < 0.0001, linescan analysis) and 5.5 ± 1.1 (Mann–
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Whitney test, p < 0.0001, FilaQuant analysis) compared to 9.5 ± 0.6 (linescan analysis) 
and 9.6 ± 1.9 (FilaQuant analysis) in the fibroblasts treated with control siRNA. 
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Figure 3.3 TMEM67 is required for the maintenance of the perinuclear actin cap in polarised 
migrating fibroblasts. (a) Workflow showing stages of the FilaQuant bundle quantification 
software. (b, d) Basolateral F-actin staining using phalloidin in control cells (left panels), 
TMEM67 patient cells (b, right panel) and tmem67 siRNA treated cells (d, right panel). Scale 
bar = 20 μm. The position of the actin cap was identified from the nucleus image (DAPI, top 
left inset in all panels), and the phalloidin image captured (top right inset in all panels). (c, e) 
Quantification of the number of bundles in the perinuclear cap in each condition, expressed 
as mean ± s.e.m. In both graphs the first two columns are derived from manual line-scan 
analysis of the actin cap, and the second two columns represent quantification obtained using 
FilaQuant software. See methods for details. Note that method of quantification does not affect 
the results. **** P < 0.0001, *** P < 0.001, Mann–Whitney test. (f) and (d, bottom right inset) 
tmem67 siRNA effectively reduces cellular TMEM67 as determined by Western blotting (f) and 
anti-TMEM67 immunofluorescence (d).  
 
 
3.4 Plating cells onto laminin rescues the formation of the perinuclear 
actin cap in TMEM67 patient fibroblasts 
 
As it is known that ECM environment has profound effects on cellular migration and 
the actin cap, we thus investigated the role of individual matrix proteins in the formation 
of the perinuclear actin cap. As laminin, collagen and fibronectin levels were all shown 
to be reduced in the TMT MS data presented in Figure 3.1a, these ECM proteins were 
identified as targets for further investigation. Glass coverslips were coated in four 
different commercially available purified matrix proteins: collagen I, collagen IV, 
fibronectin and laminin.  Equal concentrations of each protein were used, at 10 µg ml-
1: the concentration determined experimentally by our laboratory to be sufficient for 
effective coverage (Meadows, 2017). Equal numbers ofTMEM67 patient fibroblasts 
were seeded onto each of the matrix proteins and left to grow to confluency for four 
days. A scratch assay was performed following the same method used in section 3.3, 
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and the actin cap was examined (Figure 3.4; n = 170–200 cells per condition, from 
three independent experiments). ECM composition did not affect formation of the actin 
cap in control cells (Figure 3.4a, top right insets and Figure 3.4c, closed symbols; 
mean bundle number 9.3 ± 0.8 to 10.0 ± 0.9 derived from pooled linescan and 
FilaQuant data). However, when patient fibroblasts were plated on laminin, the 
appearance of the actin cap was rescued (Figure 3.4 compare a and b, top right insets 
of “laminin” panels) and the number of bundles in the actin cap (8.5 ± 0.6, Figure 3.4c 
open squares) was restored to that seen in the control cells (9.3 ± 0.7, Figure 3.4c 
closed squares; Mann–Whitney test, p > 0.05). In contrast, there was no change in 
actin cap appearance or actin bundle number observed in TMEM67 patient fibroblasts 
on any other ECM type compared to the patient fibroblasts on their own CDM (collagen 
1: 4.1 ± 0.4; collagen IV: 4.3 ± 0.5; fibronectin: 4.6 ± 0.5), nor in the control cells on 
any ECM protein compared to that of control cells on their own CDM (Supplementary 
Figure 1).  
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Figure 3.4 Laminin restores actin cap formation in TMEM67 patient cells. (a, b) Basolateral 
F-actin staining using phalloidin in control cells (a), and TMEM67 patient cells (b), plated onto 
purified ECM components as indicated. Scale bar = 20μm. The position of the actin cap was 
identified from the nucleus image (DAPI, top left inset in all panels), and the phalloidin image 
captured (top right inset in all panels). (c) Quantification of the number of bundles in the 
perinuclear cap in control cells (filled shapes) and TMEM67 patient cells (open shapes) plated 
as indicated. Graph represents mean ± s.e.m of at least 170 cells per condition, from three 
independent experiments. Note that the number of actin cap bundles when cells are plated 
onto Laminin is indistinguishable in control and patient cells. **** P < 0.0001, Mann–Whitney 
test. 
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3.5 All combinations of laminin isoforms tested rescue the formation 
of the perinuclear actin cap 
 
To narrow down the root of the laminin rescue, we asked whether there was a 
specific laminin isoform that would rescue cap formation. The TMT MS data shows 
that laminins a2, a4, b1, b2 and g1 are all greatly reduced in the TMEM67 cell CDM 
(Figure 3.1a). We plated fibroblasts on commercially available recombinant forms of 
laminin (BioLamina), with eight different combinations of alpha, beta and gamma 
chains (Table 3.1).  
 
Table 3.1 Combinations of laminin chains tested.  
a b g 
1 
1 
1 
2 
2 
1 
2 
4 
1 
2 
5 
1 
2 
 
TMEM67 patient fibroblasts were left for four days to grow to confluency, and a scratch 
assay was performed, following the same method used in section 3.3. Cells were left 
to migrate into the wound for 12 hours, before being fixed and stained for F-actin and 
the nucleus. Fluorescent imaging of the actin cap revealed that for all laminin 
combinations tested (Table 3.1), there was no significant difference between the 
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number of bundles in TMEM67 fibroblast actin caps on the recombinant laminins and 
WT cells on their own CDM.  
 
 
Figure 3.5 All laminin isoforms tested rescue the perinuclear actin cap in TMEM67 patient 
fibroblasts. There was no significant difference in the number of actin bundles in the cap in 
TMEM67 patient fibroblasts compared to non-diseased control fibroblasts on their own CDM 
(blue). Graph represents mean ± s.e.m of at least 150 cells for cells on CDM and at least 70 
cells on recombinant Laminins, from three independent experiments. **** P < 0.0001, Mann–
Whitney test, ns = not significant; all red datasets (patient cells) have been compared to blue 
dataset (non-diseased control cells). 
 
There were no commercially available laminins with an alternate gamma isoform at 
the time of investigation. As such, we were not able to establish whether this rescue 
is due to the presence of laminin g1, which was found to be the second most decreased 
**** ns           ns           ns            ns           ns           ns           ns           ns 
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laminin in the TMEM67 matrix (Figure 3.1a). There were no overall trends between 
the presence or absence of any alpha or beta isoforms, lending further support to the 
hypothesis that the rescue may be a gamma chain-dependent phenomenon. 
 
3.6 TMEM67 is a transmembrane protein, with a large extracellular 
loop at the N terminus 
 
TMEM67 is the best studied of the MKS proteins, however there are still large gaps in 
the understanding of its structure and function. There are two main splice variants of 
TMEM67. Isoform 1 of TMEM67 is the canonical isoform, consisting 995 amino acids 
(Uniprot: Q5HYA8-1; Supplementary Figure 2). At the time of writing, there are 10 
identified TMEM67 isoforms available on Uniprot, where isoform 1 and 2 are 
confirmed, and isoforms thereafter are computationally predicted. Only Isoform 1 has 
experimental data available (UniProt: Q5HYA8). There are conflicting data on the 
membrane-folding structure of TMEM67. Originally reported as having seven 
transmembrane regions (Smith et al., 2006), other sources have reported only three 
(Dawe et al., 2009), while at time of writing UniProt reports six (UniProt ID: Q5HYA8; 
UniProt Consortium, 2018). To better understand the membrane-folding architecture 
of TMEM67, Isoform 1 was put into transmembrane helix predictor TMHMM Server (v. 
2.0). It was predicted that TMEM67 contains seven transmembrane domains with a 
large extracellular loop towards the N terminus (Figure 3.6). Six of these domains 
match with the six transmembrane regions predicted by UniProt, but UniProt does not 
report the N-terminal transmembrane region between amino acids 7–29. For the 
model in the present study, we have included the seventh domain.  
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Figure 3.6 The predicted structure of TMEM67. Ruler indicates amino acid position. SP = 
signal peptide, CR = cysteine-rich domain, CC = coiled-coil domain. 
 
The lack of consensus over the presence of a transmembrane domain between amino 
acids 7–29 does not impact the structure of the regions under investigation in this 
study: the large extracellular domain at the N terminus is universally predicted in all 
databases and source literature. 
 
To date, the functional understanding of TMEM67 has been restricted to the protein’s 
intracellular interactions: the function of the large extracellular loop containing the 
cysteine-rich repeat region has not been elucidated. So far we have shown that 
TMEM67 is required for the maintenance of the perinuclear actin cap in migrating cells, 
and that loss of TMEM67 corresponds to a loss of the actin cap which could be 
restored by plating cells on laminin. Previous work from our laboratory has shown that 
TMEM67 is a novel focal adhesion protein required for ECM organisation (Meadows, 
2017). Therefore, we hypothesized that TMEM67 might provide a link between actin 
cap-associated focal adhesions and the ECM and, more specifically, that this might 
be mediated by the large N-terminal extracellular loop (Figure 3.6). 
To test this hypothesis, we studied the effects of three clinically relevant mutations 
present in the N-terminal extracellular loop of TMEM67 (p.M252T, p.L349S and 
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p.R440Q) on actin cap formation. We expect that mutations effecting the formation or 
function of the extracellular loop will have a significant negative impact on the 
formation of the actin cap if our hypothesis that TMEM67 functions as a link between 
the actin cap and the ECM is correct. We also studied three further mutations in 
regions across TMEM67, two in intracellular loops of the protein, and one in a 
transmembrane region (p.R549C, p.C615R and p.F919del), in order to test the 
importance of these regions for actin cap formation.  
 
Table 3.2 Plasmid sequencing for TMEM67 allelic series. All variants are derived from 
ciliopathy patient sequences and are reported as pathogenic. 
 
 
Plasmid 
name 
Codon 
change 
Amino acid 
change 
Mutation Diseases 
reported  
Reference 
252 c.755T>C p.Met252Thr Missense MKS 
JBTS 
NPHP 
Consugar et al., 2007; Otto et al., 2009; 
Tallila et al., 2009; Iannicelli et al., 
2010; Chaki et al., 2011; Bachmann-
Gagescu et al., 2015 
 
349 c.1046T>C p.Leu349Ser Missense MKS 
JBTS 
NPHP  
COACH 
Khaddour et al., 2007; Iannicelli et al., 
2010; Chaki et al., 2011; Bachmann-
Gagescu et al., 2015 
440 c.1319G>A p.Arg440Gln Missense MKS 
COACH 
Consugar et al., 2007; Khaddour et al., 
2007; Brancati et al., 2009; Tallila et al., 
2009; Iannicelli et al., 2010 
 
549 c.1645C>T p.Arg549Cys Missense MKS Szymanska et al., 2012; Zhang et al., 
2015 
615 c.1843T>C p.Cys615Arg Missense  JBTS 
NPHP 
Gunay-Agun et al., 2009; Chaki et al., 
2011; Bachmann-Gagescu et al., 2015 
919 c.2754_2756
delCTT 
p.Phe919del In-frame 
deletion 
MKS Adams et al., 2012 
 
 
Primers used for sequencing can be found in Supplementary Table 2.  
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Figure 3.7 The six mutations in TMEM67 tested span across the protein. Ruler indicates 
amino acid position. SP = signal peptide, CR = cysteine-rich domain, CC = coiled coil 
domain. 
 
 
 
3.7 Mutations that affect actin cap formation are associated with 
Meckel-Gruber syndrome 
 
To ascertain which regions of TMEM67 are required for the maintenance of the 
perinuclear actin cap, we transfected TMEM67 patient fibroblasts with plasmids 
carrying the HA-tagged forms of the TMEM67 mutants in Table 3.2, with an HA-only 
plasmid as a control. The fibroblasts were plated onto glass coverslips and left to grow 
to confluency for four days. Following the same protocol as previous scratch assays, 
the cell monolayer was scratched and cells were left to migrate into the wound for 12 
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hours before fixing and staining for IF microscopy. Transfected cells were identified 
using immunofluorescence with an anti-HA antibody. Analysis of the actin cap 
demonstrated that the cap was disrupted in all but one of the TMEM67 variants, with 
significantly fewer actin bundles compared to TMEM67 patient fibroblasts transfected 
with wild-type HA-TMEM67 (Figure 3.8, graph represents pooled linescan and 
FilaQuant data from 100 cells per condition, over 3 experiments, P < 0.0001 to P < 
0.001, Kruskal–Wallis test with Dunn’s post hoc analysis). Actin bundle number in 
TMEM67 fibroblasts transfected with an HA-only plasmid (3.9 ± 0.3) was 
indistinguishable compared to TMEM67 patient cells (no transfection, 4.1 ± 0.7), 
confirming the HA-plasmid was not having any influence on the results. However, the 
C615R variant was able to rescue actin cap formation to the same extent as the non-
diseased control HA-TMEM67 construct. This is the only variant tested that has a 
mutation within a predicted transmembrane domain, perhaps pointing to a less 
deleterious effect on specific aspects of TMEM67 function. In support of this, TMEM67 
C615R is the only construct tested that is associated with Joubert syndrome and 
nephronophthisis, but not the neonatal lethal Meckel-Gruber syndrome, although other 
non-Meckel-Gruber syndrome-associated variants would need to be assessed to 
further test this idea. 
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Figure 3.8 Mutations affecting actin cap formation are all associated with Meckel-Gruber 
syndrome. TMEM67 patient cells were transfected with a series of HA-tagged constructs 
that model clinically relevant TMEM67 mutations, and their ability to restore actin cap 
formation assessed. The graph shows quantification of the number of bundles in the 
perinuclear cap in each condition, expressed as mean ± s.e.m of at least 100 cells per 
condition, from three independent experiments. Grey bars indicate control transfections with 
full length wild-type (FL) HA-tagged TMEM67 or vector only. Red bars indicate clinically 
relevant TMEM67 mutations. Note that only the C615R construct, which models a mutation 
associated with Joubert Syndrome and Nephronophthisis but not Meckel-Gruber syndrome, 
can rescue actin cap formation to the same extent as non-diseased control TMEM67. **** P 
< 0.0001 and *** P < 0.001, Kruskal–Wallis test with Dunn’s post hoc analysis. 
 
However, the rescue of the actin cap in variant 615 could also be a reflection of the 
contribution of multiple factors regulating the actin cap. For example, the extracellular 
environment can affect the actin cytoskeleton, and reduced ECM levels can result in 
a dysregulation to the actin cap. This rescue of cap fibres observed in variant 615 
could potentially be as a result of an intermediate phenotype, whereby the actin fibres 
themselves are not disrupted directly, but the aberrations to the ECM phenotype are 
 
89 
still in place (or vice versa), resulting in a partial increase in actin fibres in these 
variants, but not a full increase to control levels. To further investigate this hypothesis 
in the future, the ECM produced by these variants could be visualised by SEM to 
establish the effects of mutation in these regions on ECM architecture. 
 
3.8 GFP-trap of TMEM67 suggests a role of the protein in organising 
membrane-actin cytoskeleton linkages at adhesion sites 
 
In order to explore the hypothesis that the N-terminal extracellular loop (ECL) of 
TMEM67 could provide a link between actin cap-associated focal adhesions and the 
ECM further, we utilised a GFP-tagged mutant TMEM67 lacking this ECL: TMEM67 
DECL. To investigate the function of this ECL, we compared binding partners of 
TMEM67 full length and TMEM67 DECL using a GFP-Trap® to isolate the target 
proteins and their binding partners, followed by mass spectrometry to identify the 
proteins pulled out. The TMEM67 full length and TMEM67 DECL constructs were 
cloned into a pEGFP-N1 plasmid, 3T3 fibroblasts were transfected with these 
plasmids, and the cells left to grow to 60% confluency. A GFP-only plasmid was used 
as a control. As we hypothesised TMEM67 to interact with the ECM, we harvested the 
cells and the ECM, and incubated the resultant extracts with Chromotek GFP-Trap® 
beads to isolate the GFP-TMEM67 constructs and their binding partners. The 
constructs were successfully detected by western blot in both the whole cell lysate 
sample and the precipitate from post-incubation with 10% GFP-Trap® beads (Figure 
3.9). Protein concentration was markedly increased in the 10% bead sample 
compared to the whole cell lysate in both repeats (A and B), demonstrating that 
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incubation with the GFP-Trap® beads successfully concentrated the tagged GFP-
TMEM67 constructs.  
 
 
Figure 3.9 Western blot confirming successful concentration of GFP-TMEM67 full length (FL) 
and GFP-TMEM67 DECL after incubation with GFP-Trap® beads compared to in the whole 
cell lysate, in two separate repeats (A and B). 
 
Initial data obtained from the mass spectrometry of our protein lysate were filtered 
according to the process illustrated in Figure 3.10 to produce a list of high-confidence 
hits to be taken forward for further analysis. Both GFP-TMEM67 full length and GFP-
TMEM67 DECL were compared against a negatives list from our GFP-only control to 
remove any non-specific hits. Proteins detected exclusively in GFP-TMEM67 or GFP-
TMEM67 DECL samples were considered true positives, as were proteins in the 
negatives list that had at least a 2.5-fold increase in score. Data from two independent 
replicates were pooled, and proteins appearing in both lists were considered high-
confidence double-positive hits that represent putative GFP-TMEM67 (n = 352) or 
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GFP-TMEM67 DECL (n = 525) interacting proteins (see Supplementary Table 3 for 
the full double positive lists for GFP-TMEM67 and GFP-TMEM67 DECL). 179 double 
positives were shared between GFP-TMEM67 and GFP-TMEM67 DECL, while 173 
proteins that were identified in the full length TMEM67 samples were lost in the DECL 
mutant. TMEM67 itself and known TMEM67-interacting protein Nesprin were double 
positives, suggesting that our approach had been successful at pulling down 
TMEM67-associated proteins (Dawe et al., 2009). Proteins known to interact with 
TMEM67 at the ciliary transition zone were not identified, however this can be 
attributed to the fact that the fibroblasts used for the GFP-Trap® were in a cycling 
culture and therefore non-ciliated. This supports the idea of TMEM67 having multiple 
functions within the cell with distinct cilium-independent roles, as it appears to interact 
with a unique set of proteins outside the context of the cilium. This is a proof-of-
principal that GFP-Trap® is a good tool for studying TMEM67 associated proteins. In 
the future, a more thorough GFP-Trap® investigation could be completed with cells at 
different cell cycle stages to better elucidate TMEM67s protein-protein interactions as 
they change throughout the cell cycle. 
 
Functional annotation clustering using DAVID 6.8 software (Huang et al., 2009a; 
Huang et al., 2009b) revealed that our initial hypothesis for TMEM67 functioning at 
actin cap-associated focal adhesions as an interactor with the ECM is unlikely. While 
ECM proteins were enriched in the TMEM67 samples, grouping by cellular 
compartment (GOTERM_CC_5) placed ‘basement membrane’ at 14th position and 
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‘proteinaceous extracellular matrix’ in 15th (Figure 3.11a). Grouping by biological 
process (GOTERM_BP_5) placed ‘proteoglycan formation’ in 8th, and ‘extracellular 
matrix organisation’ at 15th (Figure 3.11b). Three collagens were identified (12a1, 
3a1, 4a1), together with fibulin-2, laminin a3, and the non-integrin 37/67-kDa laminin 
receptor Rpsa. All but collagen IVa1 and laminin a3 were found associated with the 
DECL mutant, suggesting that the N-terminal ECL is not required for linkage with the 
ECM, as these would have been otherwise absent in our mutant. Laminin a3 was 
not available for the actin cap studies described above at the point of investigation, 
and so its role in actin cap formation could not be determined within this thesis. 
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Figure 3.10 Filtering steps taken on GFP-trap data for the TMEM67 full length sample (blue) 
and the TMEM67 DECL sample (purple) to produce list of high confidence, double positive 
hits. The double positive lists for the two variants were then compared to investigate function 
of the N-terminal ECL of TMEM67. 
Proteins identified in TMEM67 full length 
GFP-Trap®
Proteins identified in TMEM67 ∆ECL GFP-
Trap®
Is the protein identified in the 
GFP-only control data set?
Is the protein identified in the 
GFP-only control data set?
Y N YN
Is there a > 2.5× fold increase 
in the protein score in the 
TMEM67 full length 
compared to the GFP-only 
control?
Is there a > 2.5× fold increase 
in the protein score in the 
TMEM67 full length 
compared to the GFP-only 
control?
True positives for TMEM67 full length True positives for TMEM67 ∆ECL 
Y N YN
Exclude Exclude
Compare lists of double positives
• List of proteins shared (n = 179)
• List of proteins lost in TMEM67 ∆ECL (n = 173)
• List of proteins gained in TMEM67 ∆ECL (n = 346)
Compare true positives from repeat 1 
with list generated from repeat 2
Compare true positives from repeat 1 
with list generated from repeat 2
Double positives for TMEM67 full length 
(n = 352)
Double positives for TMEM67 ∆ECL 
(n = 525)
Is the protein identified 
in both lists?
Is the protein identified 
in both lists?
Y N YN
ExcludeExclude
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Figure 3.11 Clustering of GFP-trap data by (a) Cellular Compartment (CC) and (b) Biological 
Process (BP) sheds light on function of TMEM67. For both analyses, acto-myosin roles for 
TMEM67 came out as the top function. 
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Actin- and myosin-related functions were the most significant hits for both cellular 
compartment and biological process clustering (Figure 3.11). Within the top 15 hits for 
biological process was also cilium morphogenesis, cellular compartment organisation, 
G protein-coupled receptor (GPCR) signalling and protein phosphorylation that, 
alongside actin-related functions, align with previous described cellular roles for 
TMEM67 (Smith et al., 2006; Dawe et al., 2007b; Avasthi et al., 2012; Abdelhamed et 
al., 2015) and provide confidence that our GFP-Trap® approach had been successful.  
 
Most enriched were proteins involved in the biological process ‘myosin motor activity’, 
and cellular compartment myosin complex, with enrichment scores of 11.28 and 
11.82, respectively. Further examination of the myosin cluster revealed many different 
classes of motor protein were identified (Table 3.3), including all three conventional 
non-muscular class II myosins, the minus end-directed motor myosin VI, and several 
class I myosins, which can all form dynamic links between the actin cytoskeleton and 
the plasma membrane/intracellular vesicles.   
 
As well as these well-characterised myosins, the dataset also contained several less 
studied unconventional myosins. Myosin XVIIIa is related to Myosin II, but is a weak 
motor that probably functions as a tether as it can link transmembrane receptors to 
the cytoskeleton (Masters, Kendrick-Jones and Buss, 2017). Myosin X is important for 
filopodia formation, binds integrins, and facilitates their transport at filopodia tips 
(Zhang et al., 2004), while myosin VIIa’s role in linking adhesion proteins to the 
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cytoskeleton is also well described in processes such as cell spreading and migration 
(Tuxworth et al., 2001), where it may also function as a tension sensor (Nyitrai and 
Geeves, 2004).  
 
Table 3.3 Myosins (a) shared, (b) lost, and (c) gained between TMEM67 full length and 
TMEM67 DECL constructs 
 
(a) Myosins shared 
Myosin Gene name 
Unconventional myosin-Ib  Myo1b 
Unconventional myosin-Ic  Myo1c 
Unconventional myosin-Id  Myo1d 
Unconventional myosin-Ie  Myo1e 
Unconventional myosin-VI  Myo6 
Unconventional myosin-X  Myo10 
Unconventional myosin-XVIIIa  Myo18a 
Myosin-9  Myh9 
Myosin-10  Myh10 
Myosin-14  Myh14 
Myosin regulatory light chain 12B  Myl12b 
Myosin light polypeptide 6  Myl6 
 
(b) Myosins lost in TMEM67 DECL 
Myosin Gene name 
Myosin-11 Myh11 
Unconventional myosin-Va  Myo5a 
Unconventional myosin-VIIa  Myo7a 
Myosin light chain 6b Myl6b 
 
(c) Myosin gained in TMEM67 DECL 
Myosin Gene name 
Unconventional myosin-IXb (Fragment)  Myo9b 
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The majority of these myosins (13/18) were shared between the full length TMEM67 
and the DECL mutant, however, Myosin-11, the unconventional myosins Va and VIIa, 
and myosin light chain 6b were lost. TMEM67 DECL also gained an association with 
motor myosin IXb, which has a RhoGAP domain and may function in the regulation of 
actin organisation via negative feedback of Rho signalling (van den Boom et al., 2007). 
As a minority of myosin associations (4/18) were lost with the deletion of TMEM67’s 
N-terminal ECL, this suggests that this region of the protein plays only a slight role for 
myosin association. The most likely candidate for myosin association is the C-terminal 
coiled-coil domain, which is known to associate with other actin binding proteins (Dawe 
et al., 2009; Adams et al., 2012).  
 
Biological processes ‘mRNA processing’, ‘endocytosis’, and ‘regulation of translation’ 
have not been previously linked to TMEM67 function, and appeared 3rd, 4th, and 7th 
most enriched protein clusters respectively in this dataset. This appears consistent 
with some of the functions of the myosins listed in in Table 3.3, specifically Myosin-10, 
which is involved in the stabilisation of collagen I mRNAs, Myosin-Ic which has a 
nuclear isoform which associates with RNA polymerase I and II to help initiate 
transcription, and Myosin-VI, which has been implicated in clathrin-mediated 
endocytosis (Masters, Kendrick-Jones and Buss, 2017). Concurrently, mutations in 
TMEM67 have been reported to lead to nuclear morphology defects (Dawe et al., 
2009). 
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Taking these results together, we hypothesise a potential role for TMEM67 in 
organising or regulating membrane-actin cytoskeleton linkages at adhesion sites, 
where it could be tethered by myosin XVIII and possibly aids tension sensing through 
myosin VIIa and the contractile myosin IIs. There was no clear relationship between 
mutation of the first extracellular loop and loss of a particular gene ontology group, 
making it difficult to draw any conclusions about the function of this region of TMEM67, 
despite its obvious importance for the development of ciliopathy. Within the scope of 
this thesis it was not possible to validate the potential myosin–TMEM67 interaction 
suggested by our GFP-trap® data. In order to draw a more conclusive hypothesis on 
the role of TMEM67, an alternate method, such as co-immunoprecipitation of the 
protein should be performed in order to confirm these early indicators. 
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4 Discussion 
 
4.1 Summary 
 
This thesis builds upon several lines of research from the Dawe research group into 
the extra-ciliary roles of TMEM67. Outside of the ciliation defect, our laboratory group 
has characterised numerous cellular abnormalities directly linked to the loss of 
TMEM67, including defective ECM production, alterations to the adhesome, loss of 
directed cell migration, widespread alterations to the actin cytoskeleton and 
associated signalling pathway RhoA, and alterations to Golgi and nucleus morphology 
(Dawe et al., 2009; McIntosh, 2016; Meadows, 2017; Dawe lab, unpublished 
observations). In this thesis, it has been shown that loss of TMEM67 results in a 
defective perinuclear actin cap, which is the most likely cause of the loss of 
directionality in migrating TMEM67 patient cells. Additionally, we characterised 
potential novel interactions between TMEM67 and a number of myosins which localise 
to focal adhesions. Together, we hypothesise a possible role of TMEM67 in organising 
or tethering membrane–actin cytoskeleton linkages at adhesion sites. 
 
4.2 Link between extra-ciliary functions of TMEM67 and the cellular 
phenotypes observed 
 
4.2.1 TMEM67-associated defects in the ECM could contribute to the 
increased speed of migrating patient cells 
 
SEM analysis of the TMEM67 patient cell ECM revealed dramatically different 
architecture compared to the ECM secreted by non-diseased cells, reflective of the 
decreased protein levels in the matrix characterised previously (Meadows, 2017). 
Reciprocal plating of TMEM67 cells on WT matrix and WT cells on TMEM67 matrix 
and subsequent imaging of the resultant matrix revealed that TMEM67 patient cells 
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do not degrade the matrix, despite higher expression levels of matrix 
metallopeptidases (Meadows, 2017). We were therefore confident that increased 
metallopeptide secretion was not a factor effecting observed ECM phenotypes 
continuing forward, and instead we are confident that our observations are canonically 
TMEM67 mutation related. 
 
The ECM plays a number of important biological functions to the cell. It provides both 
structural and biochemical support to the cell, facilitating cell adhesion, 
communication, and differentiation, and is vital for growth and wound healing (Rozario 
and DeSimone, 2010). The ECM also sequesters a number of important growth factors 
(Rozario and DeSimone, 2010). It thus follows that disruption to the ECM would have 
widespread cellular, as well as developmental, consequences. At the cellular level, a 
number of physical and biochemical qualities of the ECM directly impact migration 
(Palecek et al., 1997; Strachan and Condic, 2003; Lange and Fabry, 2013; Wen et al., 
2015), and the defects to the matrix observed with loss of TMEM67 could help explain 
some of the migration defects observed in TMEM67 patient cells. The data presented 
in Figure 3.1 highlight that the protein levels of the TMEM67 CDM are disrupted 
compared to WT levels, and that there is an overall decrease in production of ECM 
proteins leading to visible architectural differences in the CDM. As well as a reduction 
in overall ECM concentration, reduced protein levels in the CDM are likely to have 
knock-on effects on matrix rigidity, as reductions in collagens and altered balances of 
proteins change the physical properties of the matrix (DiMilla et al., 1993; Strachan 
and Condric, 2003). As loss of TMEM67 results in quite major aberrations to the ECM 
(Meadows, 2017), it seems likely that this could be contributing to the migration defect 
in patient fibroblasts. 
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There are two separate defects in migration linked to the loss of TMEM67: 1) cells 
migrate faster, and 2) cells migrate with reduced directionality. The aforementioned 
ECM qualities are likely to be a key influencer to the increase in speed of the TMEM67 
cells. Speed of cell migration is mostly dictated by one factor: the number of engaged 
adhesions (DiMilla et al., 1991; Lange and Fabry, 2013). For a cell to migrate, 
adhesions must be made at the front of the cell to stabilise the extending 
lamellipodium, and adhesions must be disassociated at the rear of the cell to allow 
retraction of the tail. Tension on the actin cytoskeleton from the dynamic formation and 
turnover of these adhesions is the main driver of cell migration (DiMilla et al., 1991; 
DiMilla et al., 1993; Metzner et al., 2007). With high numbers of engaged adhesions, 
the rate at which de-adhesion at the cell rear occurs becomes a limiting factor to speed 
of migration. However, with too few engaged adhesions, the lamellipodium is not 
stable and there is less tension through the actin cytoskeleton, hampering forward 
movement (DiMilla et al., 1991; DiMilla et al., 1993). The changes observed in the 
ECM as a result of the loss of TMEM67 are likely to contribute to the migration defects 
in patient cells. Firstly, with the low ECM concentration found with TMEM67 patient 
cells, there are fewer sites for ECM-cell attachment directly resulting in fewer engaged 
adhesions. As a result, the adhesive force the cell needs to overcome in order to 
generate movement is reduced, and this could partly explain the faster migration 
speeds observed in TMEM67 patient fibroblasts. Changes in ECM concentration and 
protein composition are likely to influence matrix rigidity, and as shown in the model 
in Figure 1.7, matrix rigidity can also influence the number of engaged adhesions due 
to changes in cell cortical tension and resultant cell spreading. On more rigid 
substrates, there is more resultant force exerted on the cell from the matrix, which 
facilitates cell spreading, thus increasing the number of cell-matrix adhesions. The 
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present study did not directly investigate the rigidity of the CDM produced by TMEM67 
patient cells, and so conclusions on the effect of differences in rigidity of the patient 
cell CDM on the migration defects cannot be drawn, however, from our knowledge of 
matrix properties and the alterations to protein level, it could tentatively be suggested 
that the ECM produced by TMEM67 patient fibroblasts would be less rigid: collagens 
provide tensile strength and provide resistance to deformation, and increased collagen 
concentration has been directly linked to increased matrix rigidity (Yunoki et al., 2011; 
Li et al., 2017). As collagen production is reduced in TMEM67 patient cells, it follows 
that the ECM would be less rigid.  
 
The image however is not this simple: while these physical matrix properties can 
influence migration speed, the factor that underpins migration speed is the number of 
engaged adhesions. Therefore, we cannot reliably link the physical matrix properties 
alone to migration speed unless there is no other factor influencing the engagement 
of adhesions. This is not the case in MKS type 3: TMEM67 has been shown to be a 
focal adhesion protein, where loss of the protein results in major changes to the 
adhesome (Meadows, 2017). Therefore, it could be the case that the matrix produced 
by TMEM67 patient cells is more rigid, but reduced numbers of functional adhesions 
result in faster migration, up until the point where the lamellipodia become unstable. 
Testing the rigidity of the matrix produced by TMEM67 patient fibroblasts using atomic 
force microscopy to analyse the deformation of the matrix will help to classify which 
factors are contributing to the migration abnormalities. 
 
4.2.2 TMEM67 is required for maintenance of the perinuclear actin cap 
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Loss of TMEM67 has been shown to result in decreased directionality during cell 
migration, a rotating nucleus and a mispositioned centrosome (Dawe lab, unpublished 
observations). The data presented in this thesis suggest that this directionality defect 
is due to a failure to assemble or maintain the perinuclear actin cap. 
 
The actin cytoskeleton is organised into a highly complex three-dimensional structure 
(see Figure 1.3). While there are a number of tools for image analysis, problems with 
blurring and imaging-related artefacts can arise due to high throughput automation 
methods or the structure of the filaments. The latter particularly comes into play when 
actin filaments pass through different focal planes, which when imaged by two-
dimensional microscopy methods often exhibit blurring. As the perinuclear actin cap 
is formed of actin filaments terminating at the basal surface and moving up to the 
apical plane (see Figure 1.4), it therefore poses a challenge for automated analysis. 
In addition, limited research thus far has investigated the number of actin bundles in 
the actin cap, with the majority of studies only quantifying the presence, absence or 
disruption of the actin cap (Khatau et al., 2009; Kim et al., 2012; Maninová and 
Vomastek, 2016; Thakar and Carroll, 2017). A limitation of these studies is the use of 
discontinuous grouping systems: where does the boundary lie between ‘presence’ and 
‘disruption’ of the actin cap? A quality of the actin caps of MKS patient cells observed 
in this study was well organised actin bundles in the cap, but larger gaps between 
bundles, or fewer bundles in the cap and thus it is difficult to draw the distinction 
between actin cap presence and disruption. In order to overcome both of these 
limitations to the analysis of the actin cap, we used a continuous quantification method 
by quantifying the number of actin bundles in the nuclear area, and also used two 
quantification methodologies, one manual (linescan analysis; Woroniuk et al., 2018), 
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and one automated approach (FilaQuant anaysis; Matschegewski et al., 2012) to 
increase the robustness of our data. 
 
Perinuclear actin cap fibres hold more tension than other basal actin stress fibres (Kim 
et al., 2012). In order to accommodate this tension and stabilise the perinuclear actin 
cap, actin cap-associated focal adhesions are elongated and larger than normal focal 
adhesions (Kim et al., 2012). Disruption to these specialised focal adhesions results 
in the breakdown of the actin cap. Disruption to the LINC complexes, which tether the 
actin cap fibres to the nucleus also results in the breakdown of the cap (Khatau et al., 
2012). TMEM67 associates with both LINC complexes and focal adhesions (Khatau 
et al., 2012; Meadows, 2017). Thus, if TMEM67 is involved in actin binding at both 
locations, loss of the protein could result in a potential decrease in tension held at 
these adhesion points, and cause a breakdown of the actin cap. 
 
The perinuclear actin cap is also affected by the ECM. On softer substrates, the cap 
is not present, as the fibres are not able to hold enough tension through their focal 
adhesions for the fibres to stabilise (Kim et al., 2012). Following our hypothesis that 
the TMEM67 matrix would be less rigid than a control matrix due to reduced 
expression of collagens, it follows that the physical ECM properties could be 
contributing to our actin cap phenotype. If this were the case, we would expect the 
plating of cells on collagen matrices to rescue the actin cap. However, our data show 
that only laminin rescued the cap, with no significant increase of actin cap fibres on 
any other matrix protein tested, including collagen I and IV. This therefore suggests 
that the altered physical properties of the TMEM67 patient cell matrix are not the major 
influence on our observed cap phenotype.  
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We have shown that laminin rescues actin cap appearance, but within the scope of 
this thesis it wasn’t possible to test whether the directionality defect was rescued. 
However, as the cap is integral to the maintenance of directed cell migration, we 
hypothesise that a rescue would be likely. A point for further examination would 
therefore be to test the directionality of migrating fibroblasts in live culture on laminin. 
The substrate-specific differences in cap rescue in TMEM67 patient cells suggest that 
the underlying defect for the directionality defect is not physical properties: i.e., it is not 
driven by the overall decrease in ECM. As integrins are substrate-specific and are a 
major component of focal adhesions (Vicente-Manzanares and Horwitz, 2011), it 
follows that our substrate-specific actin cap rescue could be a result of defects to a 
specific integrin in TMEM67 fibroblasts, reversible by the presence of extra-cellular 
laminin.  
 
While our data suggest that the defective ECM is not the main underlying cause of the 
actin cap defect, the aberrant matrix could affect engagement of adhesions. Fewer 
engaged adhesions as a result of the lower levels of ECM produced by TMEM67 
patient cells, as well as defects to the overall structure of adhesions observed with 
loss of TMEM67 could both be contributing to the loss of actin cap fibres observed in 
patient cells. 
 
4.2.3 TMEM67 may function in organising or recruiting membrane-actin 
cytoskeleton linkages at focal adhesions through an interaction with myosin 
 
Based on our initial data, we originally hypothesised that TMEM67 functioned in the 
coupling of the actin cytoskeleton to the ECM at focal adhesions, where TMEM67 is 
known to localise (Meadows, 2017). TMEM67 associates with filamin A, an actin 
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binding protein, at its intracellular C-terminal coiled-coil domain. Based on the 
structure of the protein, we hypothesised that the N-terminal extracellular loop could 
be the point of association with ECM proteins.  
 
To establish whether the N-terminal ECL of TMEM67 does indeed bind with the ECM, 
we performed a GFP-Trap® on GFP-TMEM67 and a mutant GFP-TMEM67 which 
lacks this N-terminal ECL. Interestingly, while ECM proteins were enriched in the 
TMEM67 samples, ‘proteinaceous extracellular matrix’ and ‘extracellular matrix 
organisation’ were included at the bottom of our cellular compartment and biological 
process lists respectively (Figure 3.11). Additionally, all but two of the ECM proteins 
identified in our GFP-TMEM67 dataset were also found in our GFP-TMEM67 ΔECL 
mutant, suggesting that this domain is not required for linkage with the ECM, as 
otherwise we could have expected all ECM proteins to be absent in our mutant 
dataset.  
 
Our findings instead suggest that instead of TMEM67 functioning as a linker with the 
ECM, it could potentially be involved with organising or regulating membrane-actin 
linkages at adhesion sites through association with a number of myosins. Table 4.1 
summarises the function of the myosins identified by our GFP-trap®. 
 
 
  
 
107 
Table 4.1 Summary of the functions of myosins (a) shared, (b) lost, and (c) gained between 
TMEM67 full length and TMEM67 DECL constructs. Protein function summarised from 
UniProtKB, the Human Genome Database, and (Masters et al., 2017). 
 
(a) Myosins shared 
Myosin 
class Myosin 
Gene 
name Protein function  
Class I 
Unconventional 
myosin-Ib  
Myo1b 
Can directly associate with membranes. Is 
required for directed cell migration. Involved 
in neurite outgrowth and vesicular transport. 
Class I 
Unconventional 
myosin-Ic  
Myo1c 
Can directly associate with membranes. 
Multiple transcript variants encoding different 
isoforms identified, with variety of functions, 
including exocytosis, hair cell adaptation, 
regulation of actin organisation during cell 
migration. A nuclear isoform associates with 
RNA polymerase I to promote transcription 
activity. 
Class I 
Unconventional 
myosin-Id  
Myo1d 
Can directly associate with membranes. 
Required for membrane trafficking to apical 
domain in polarised epithelial cells, and for 
maintenance of rotational planar cell polarity 
in ciliated tracheal and ependymal cells. 
Class I 
Unconventional 
myosin-Ie  
Myo1e 
Can directly associate with membranes. 
Functions in intracellular movement and 
membrane trafficking. Is required for normal 
kidney function. Tail domain crosslinks actin 
filaments.  
Class II Myosin-9  Myh9 
Conventional non-muscular class II myosin.  
Functions in cytokinesis, cell shape, 
secretion and capping, and cytoskeleton 
reorganisation, focal adhesion formation (in 
the periphery but not the centre of spreading 
cells), and lamellipodial extension during cell 
spreading. 
Class II Myosin-10  Myh10 
Conventional non-muscular class II myosin.  
Functions in cytokinesis, cell shape, 
secretion and capping, cytoskeleton 
reorganisation, focal adhesion formation (in 
the centre but not the periphery of spreading 
cells), and lamellipodial retraction during cell 
spreading. 
Involved with LARP6 in the stabilization of 
type I collagen mRNAs for CO1A1 and 
CO1A2.  
Class II Myosin-14  Myh14 Conventional non-muscular class II myosin.  
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Functions in cytokinesis, cell shape, 
secretion and capping.  
Class VI 
Unconventional 
myosin-VI  
Myo6 
Reverse-direction motor protein. 
Functions in vesicular membrane trafficking, 
cell migration, structural integrity of Golgi 
apparatus, clathrin-mediated endocytosis in 
polarized epithelial cells. Regulator of F-actin 
dynamics, and has an important role in 
anchoring plasma membrane domains to 
actin filaments. 
Class X 
Unconventional 
myosin-X  
Myo10 
Binds to integrins, mediates cargo transport 
along actin filaments. Regulates cell shape, 
cell spreading and cell adhesion. Stimulates 
the formation and elongation of filopodia.  
Class XVIII 
Unconventional 
myosin-XVIIIa  
Myo18a 
Binds GOLPH3, linking the Golgi to the 
cytoskeleton and influencing Golgi 
membrane trafficking. Regulates retrograde 
flow of actomyosin in lamellipodia. Facilitates 
cell-cell contact.  
n/a 
Myosin 
regulatory light 
chain 12B  
Myl12b 
Myosin regulatory subunit that plays an 
important role in regulation of both smooth 
muscle and non-muscle cell contractile 
activity via its phosphorylation. 
Phosphorylation triggers actin polymerization 
in vascular smooth muscle. Implicated in 
cytokinesis, receptor capping, and cell 
locomotion. 
n/a 
Myosin light 
polypeptide 6  
Myl6 
Regulatory light chain of myosin. 
n/a 
Myosin 
phosphatase 
Rho-interacting 
protein  
Mprip 
Targets myosin phosphatase to the actin 
cytoskeleton. Required for the regulation of 
the actin cytoskeleton by RhoA and ROCK1. 
 
 
(b) Myosins lost in TMEM67 DECL 
Myosin 
class Myosin 
Gene 
name Protein function  
Class II Myosin-11 Myh11 Major contractile protein in smooth muscle. 
Class V 
Unconventional 
myosin-Va  
Myo5a 
High duty ratio motor. Functions in 
cytoplasmic vesicle transport and 
anchorage, spindle-pole alignment and 
mRNA translocation. 
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Class VII 
Unconventional 
myosin-VIIa  
Myo7a 
Tension generator/sensor or anchor for 
membrane receptors. Can bind to adhesion 
proteins and the cytoskeleton, facilitating 
cell-cell and cell-matrix adhesion, with 
important functions in cell spreading, 
migration, and phagocytosis. 
Functions in opsin transport in cilia, 
potentially maintaining selection barrier. 
n/a 
Myosin light 
chain 6b 
Myl6b 
Alkali light chain expressed in both slow-
twitch skeletal muscle and in non-muscle 
tissue.  
 
(c) Myosin gained in TMEM67 DECL 
Myosin 
class Myosin 
Gene 
name Protein function  
Class IX 
Unconventional 
myosin-IXb 
(Fragment)  
Myo9b Functions in the regulation of cell migration 
through RhoA GTPase activation.  
 
It was not possible within the scope of this thesis to establish whether these TMEM67-
myosin interactions are direct or indirect, or validate these possible interactions using 
an alternate methodology. Therefore, further experiments to validate these 
interactions using a second approach, for example, co-immunoprecipitation should be 
performed to gain confidence in this data. 
 
Common qualities of these myosins is their ability to bind to membranes, and their 
presence at adhesions. As TMEM67 is a transmembrane protein that has been 
observed to localise at adhesions (Meadows, 2017), a possible point of contact 
between TMEM67 and these myosins could be at these adhesion points.  The sole 
class VI myosin identified in our GFP-trap® data is a regulator of F-actin dynamics and 
has an important role in anchoring plasma membrane domains to actin filaments, and 
the Class VII myosin is known to bind adhesion proteins and the cytoskeleton. All three 
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non-muscular class II myosins were found, and these also have important roles in 
focal adhesion dynamics (Masters et al., 2017).  
 
Loss of TMEM67 has also been found to result in thicker actin stress fibres, and 
TMEM67 mislocalises to these actin bundles in patient fibroblasts (Dawe et al., 2009; 
Adams et al., 2012; McIntosh, 2016). The presence of thicker actin stress fibres in 
TMEM67 patient cells has been hypothesised to be due to hyperactive RhoA (Dawe 
et al., 2009; McIntosh, 2016), however, an association between TMEM67 and myosins 
could provide an additional explanation: myosins are important regulators of actin 
dynamics, for example, controlling actin bundling. Aberrant localisation of TMEM67 to 
actin could result in irregular myosin activity at stress fibres, potentially resulting in 
changes to stress bundle architecture, as observed. 
 
At the transition zone, TMEM67 interacts with a number of other proteins linked with 
MKS (see Figure 1.1), however, none of these were identified in our GFP-trap® data. 
This is likely due to the fact that the cells from which GFP-TMEM67 was isolated were 
not ciliated, and there is no evidence that the transition zone complex exists outside 
of the primary cilium. The only two known interacting proteins of TMEM67 outside of 
the cilium, Nesprin and Filamin A, were both found in our GFP-trap® data. Nesprin was 
found on the final double positive list, however Filamin A was identified in the original 
list of proteins from the GFP-Trap® but excluded from the true positives list (see Figure 
3.10 for a schematic of the filtering steps) as it was also found in the GFP-only control 
dataset. There are an expanding number of extra-ciliary roles for ciliopathy proteins 
being reported (Quarmby and Parker, 2005; Dawe et al., 2007b; Plotnikova et al., 
2009; Böttinger, 2010; O’Toole et al., 2010; Valente et al., 2010; Adams et al., 2012; 
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Chaki et al., 2012; Polakis, 2012; Hoff et al., 2013; Hanna and Shevde, 2016; 
Pampliega and Cuervo, 2016; Walz, 2017). The molecular basis of these are as yet 
not well understood, but there are several pieces of evidence to indicate that ciliopathy 
proteins have different binding partners in different cellular contexts. For example, 
CEP290, one of the causative genes for MKS, is a component of the transition zone 
but also localises to the centrosome and nucleus in a cell cycle-dependent manner, 
and interacts with a number of centriolar satellite proteins and the transcription factor 
ATF4 independently from its function at the transition zone (Sayer et al., 2006; Kim et 
al., 2008; Stowe et al., 2012). These extra-ciliary interacting complexes have also 
been found in other ciliopathy proteins, including BBS proteins which interact with the 
Exocyst, Flotillins, and Aldolase B amongst others (Oeffner et al., 2008; Novas et al., 
2015). This supports the hypothesis of cilium-independent roles of TMEM67, 
suggesting that the potential myosin-TMEM67 interaction happens independently of 
the protein’s role at the transition zone, and thus explains why we did not identify the 
transition zone proteins in our GFP-trap® from non-ciliated cells. In order to further 
explore this hypothesis, a more thorough GFP-Trap® investigation could be completed 
with cells at different cell cycle stages to better elucidate TMEM67s protein-protein 
interactions as they change throughout the cell cycle. 
 
4.3 Proposed model for TMEM67’s role at ACAFAs and future work 
 
We hypothesise that TMEM67 could function as a potential linker between the actin 
cytoskeleton and the plasma membrane at focal adhesions through an association, 
either direct or indirect, with various myosins. Figure 4.1 summarises our hypothesised 
function of TMEM67 at ACAFAs based on the results in this thesis. In normal focal 
adhesions (Figure 4.1a), alpha and beta integrin subunits (light and dark orange 
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respectively) associate with a number of proteins (the adhesome: shown as a cluster 
of green ellipses) and form a link between the ECM proteins (shown in grey) and the 
actin cytoskeleton (shown in red). Multiple integrins cluster to form a mature focal 
adhesion. We hypothesise that TMEM67 (Figure 4.1b; shown in black), a 
transmembrane protein, is functioning as a tether between myosins and the plasma 
membrane at these adhesion points. TMEM67 is required for the maintenance of the 
actin cap and thus directed cell migration. Loss of the TMEM67 protein has been found 
to result in alterations to the adhesome (Meadows, 2017) and we have demonstrated 
a loss of the actin cap in this thesis (Figure 4.1c). This results in a loss of directed cell 
migration, likely due to failure to correctly align, and subsequently maintain the 
alignment of the nucleus. 
 
In order to test this hypothesis, the localisation of the myosins identified by the GFP-
trap® in non-diseased control cells and TMEM67 patient cells could be investigated by 
immunofluorescence: do myosins localise to the perinuclear actin cap in non-diseased 
control cells? If yes, where do they localise in our MKS patient cells? In addition, the 
HA-TMEM67 plasmids used in this study could give insight into potential myosin 
binding regions of TMEM67 by investigating whether any of the mutations in the 
intracellular regions of the protein abrogate myosin binding. CRISPR-Cas9 non-
homologous end joining-based gene knockout of variety of target myosins identified 
in our GFP-trap® (Table 3.3) followed by protein pull down assays using TMEM67 as 
the bait protein could allow us to better understand the potential relationship between 
TMEM67 and associated myosins. For example, this would allow us to probe myosin-
binding hierarchy: are specific myosin–TMEM67 interactions required for further 
myosin–myosin interactions, or do myosins bind to TMEM67 independently? 
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Functional studies of these knockouts will help to identify the role of myosins in the 
pathogenicity of MKS – it could be hypothesised that similar cellular phenotypes as 
seen in TMEM67 patient cells would be observed when we knock out the myosins 
identified in our GFP-trap® if our model in Figure 4.1 is correct. 
A 
  
B 
C 
 
ACTIN CAP ASSOCIATED FOCAL ADHESION
ACTIN CAP STRESS FIBRE
N
C TMEM67
Myosin
intracellular
extracellular
Directed cell migration
Loss of directed cell 
migration
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Figure 4.1 Potential model for the function of TMEM67. (a) Structure of a normal focal 
adhesion, showing alpha and beta integrin subunits (light and dark orange respectively) 
associating with a number of proteins (the adhesome: cluster of green) and forming a link 
between the ECM proteins (grey) and the actin cytoskeleton (red). (b) TMEM67 (black), a 
transmembrane protein, may function as a tether between myosins (blue) and the plasma 
membrane at these adhesion points. TMEM67 is required for the maintenance of the actin cap 
and directed cell migration. (c) Loss of TMEM67 protein results in alterations to the adhesome 
and a loss of the actin cap. This results in a loss of directed cell migration. 
 
 
In addition, in order to improve understanding of the membrane-folding architecture of 
TMEM67, recent advances in cryo-electron microscopy of membrane proteins could 
be utilised (Thonghin et al., 2018). As previously mentioned, there are conflicting 
reports of the number of transmembrane regions in TMEM67 (Smith et al., 2006; Dawe 
et al., 2009; UniProt Consortium, 2018), and uncovering the protein’s structure could 
help to shed some light on the functions of the different internal and external domains. 
 
 
4.4 Extra-ciliary roles of MKS proteins help explain the clinical 
presentation of severe ciliopathy 
 
While it explains some, the ciliary roles of MKS proteins cannot account for the full 
spectrum of phenotypes observed in patients. The link between the underlying cellular 
defects and polydactyly is easy to link to the primary cilium: cilia and IFT are required 
for Hh signalling (Huangfu et al., 2003), which is responsible for the patterning of the 
digits (Ehlen et al., 2006). Disruption to the cilium in MKS is therefore likely to disrupt 
the Hh concentration and thus result in the polydactyly observed in patients. The other 
key MKS phenotypes are more difficult to link directly to a defect in the primary cilium, 
but the recently uncovered extra-ciliary roles of TMEM67 help to explain these. 
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The primary cilium has important roles in renal cystogenesis: modelling of total loss of 
cilia, structural abnormalities of cilia, and disruptions to the protein composition of 
ciliary membranes have all shown to produce fibrocystic kidneys (Bialas et al., 2009; 
Weatherbee et al., 2009; Cui et al., 2011; Garcia-Gonzalo et al., 2011; Ma et al., 2017). 
Defects to the cilium’s mechanosensory and chemosensory functions were thought to 
be main contributors to the renal cyst phenotype in ciliopathies, however the extra-
ciliary defects presented in this thesis could also contribute to the phenotype. The 
differences in ECM production are likely to contribute to polycystic kidneys as the ECM 
serves several functions during branching morphogenesis. The balance of ECM 
proteins and matrix metallopeptidases are important regulators of the tissue 
development, and the ECM also acts as an important reservoir for a number of 
morphogenesis molecules (Shah et al., 2004). Furthermore, cell-ECM attachment and 
subsequent migration and cellular mechanotransduction are also required during 
kidney morphogenesis (Shah et al., 2004). In this thesis we have described alterations 
to the ECM of TMEM67 patient cells and actin cytoskeletal defects. The latter, coupled 
with TMEM67’s potential function at focal adhesions are likely to impair the cell’s 
mechanotransduction pathways. Taken together, it follows that these cellular 
phenotypes associated with the loss of TMEM67 are likely to affect kidney 
development and contribute to the polycystic kidneys observed as one of the hallmarks 
of MKS. 
 
The third phenotype of the MKS diagnostic triad, occipital encephalocele, could also 
be influenced by the migration and ECM defect observed in MKS patient cells. 
Encephalocele occurs due to a failure to completely close the neural tube during 
development: a process dependent on cell adhesion and migration, and the loss of 
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directed cell migration and major changes to the cell adhesome associated with the 
loss of TMEM67 are likely to affect this tightly controlled process.  
 
4.5 Cell migration and ciliopathy: an emerging link 
 
Aberrations to stress fibres and focal adhesions, as well as defective cell migration 
have been linked to other ciliopathies. Identically to our TMEM67 patient cells, Jones 
et al., (2012) reported that oak ridge polycystic kidney (Tg737orpk/orpk; ORPK) mouse 
cells (model of polycystic kidney disease) migrate faster than non-diseased control 
cells but with reduced directionality, as well as migrating individually instead of as a 
monolayer as the control cells do. However, they also found that Tg737orpk/orpk cells 
have reduced actin stress fibres and smaller focal adhesions compared to non-
diseased control cells, unlike TMEM67 patient cells, which have more prominent actin 
stress fibres, but no significant difference in adhesion size (Jones et al., 2012; 
Meadows, 2017). The Jones et al. (2012) study concluded that defects to the primary 
cilium results in alterations to the actin cytoskeleton and focal adhesion assembly, 
which leads to impaired directional migration. However, the data from this thesis, taken 
in conjunction with that previously published from our laboratory provide an alternate 
conclusion to the cytoskeletal, adhesion, and migration defects: if the differences 
Jones et al. reported in Tg737orpk/orpk cells were due to the defect to the structure of the 
cilium, then it would follow that we would see the same cellular phenotypes in our MKS 
cells (and indeed in cells from other ciliopathies) as they all intrinsically have defects 
to the cilium. As this is not the case, this supports our hypothesis of dual functionality 
of ciliopathy proteins influencing different cellular phenotypes. Indeed, cilium 
independent roles IFT proteins IFT88 (the gene mutated in the ORPK mouse) and 
IFT20 have been reported (Finetti et al., 2009; Boehlke et al., 2015).  
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The data presented in this thesis suggest that the migration defect observed in the 
ORPK mouse could be due to the loss of the actin cap as the directionality defect 
observed is the same as in our TMEM67 cells. However, as the underlying actin stress 
fibre phenotypes of these cell types are different, it is unlikely that the mechanism of 
disruption is the same. As Jones et al. have reported decreased levels of basal actin 
stress fibres, it’s likely that the loss of actin cap would be due to this same defect as 
actin cap fibres are specialised stress fibres and are more responsive to disruption 
than basal stress fibres (Khatau et al., 2009). From this, we can hypothesise that the 
extra-ciliary functions of the ciliopathy proteins do not interact in the same way they 
do at the cilium, that is, they do not come together to form a complex outside of the 
cilium in the same way they form the transition zone complex at the cilium for example. 
Supporting this theory, we did not identify IFT88 in our GFP-Trap as an interactor of 
TMEM67.  
 
Migration and cytoskeletal defects have also been reported in the ciliopathy BBS 
(Hernandez-Hernandez et al., 2013). Bbs4- and Bbs6-decifient cells exhibit poor 
migration, with delayed wound closure, and an over-abundance of apical actin 
aggregates (Hernandez-Hernandez et al., 2013). This, taken together with the data 
presented in this thesis and from Jones et al., (2012) covered above suggest a general 
role for ciliopathy proteins in cell migration. It is not currently known whether there are 
ECM defects in BBS cells, however loss of cilia and resultant defects to the ECM have 
been linked in rodent models with loss-of-function mutations in the protein Giantin 
(Katayama et al., 2011), as well as in MKS cells (Meadows, 2017), and so a pertinent 
point of future study would be to investigate the ECM in BBS. Conversely to TMEM67 
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cells which migrate faster, BBS cells migrate slower, which further supports the 
hypothesis that the extraciliary roles of ciliopathy proteins do not function together in 
a complex like they do at the cilium. 
 
4.6 Conclusion 
 
While once thought to be a vestigial organelle, the primary cilium is now recognised 
as a key player in vertebrate development. After the discovery that its dysfunction 
resulted in disruption to several key development pathways, research was focused on 
the proteins of the primary cilium and how their mutation affected the organelle and 
the subsequent knock-on effects on ciliary signalling. How mutation to one organelle 
could result in multiple clinically distinct diseases was thought to be due to the severity 
of the mutation and the degree to which it disrupted ciliary signalling, but the discovery 
of dual functionality of a number of ciliopathy proteins provided a new mechanism of 
pathology: extra-ciliary secondary roles of cilia-associated proteins could contribute to 
the phenotypes. This thesis has characterised the underlying directionality defect of 
TMEM67 patient cells, finding an ECM-dependent loss of the perinuclear actin cap 
associated with the loss of TMEM67. We have also identified a potential TMEM67–
myosin association, and taking our data together we hypothesise a role for TMEM67 
as an organiser or tether of myosin-actin assemblages at ACAFAs, expanding its role 
beyond the cilium.  
 
The continued identification of multi-faceted roles for these ciliopathy proteins will help 
towards therapeutic advances for the treatment of ciliopathy, however, it also raises a 
number of questions. What are the relative contributions of the ciliary and non-ciliary 
phenotypes to the clinical presentation of ciliopathy? Is dysfunction of the cilium the 
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key cellular phenotype, or is this a downstream consequence of another defect, such 
as aberrations to the actin cytoskeleton, ECM, or loss of cell polarity? How could we 
disentangle these? It is clear that cilia, the actin cytoskeleton, and the ECM are linked 
but as of now, it is not clear how. Continued investigation of the extra-ciliary roles of 
ciliopathy proteins will allow these questions to be answered, and not only facilitate 
better understanding of the pathology of ciliopathies and allow the development of 
effective treatments for these diseases, but will also deepen our understanding of 
human development. 
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6 Supplementary Information 
 
 
 
 
Supplementary Figure 1 There was no significant different between non-diseased control 
fibroblasts on their CDM and non-diseased control cells plated on collagen I, collagen IV, 
fibronectin or laminin.  
 
 
>sp|Q5HYA8|MKS3_HUMAN Meckelin OS=Homo sapiens OX=9606 GN=TMEM67 PE=1 SV=2 
MATRGGAGVAMAVWSLLSARAVTAFLLLFLPRFLQAQTFSFPFQQPEKCDNNQYFDISAL 
SCVPCGANQRQDARGTSCVCLPGFQMISNNGGPAIICKKCPENMKGVTEDGWNCISCPSD 
LTAEGKCHCPIGHILVERDINGTLLSQATCELCDGNENSFMVVNALGDRCVRCEPTFVNT 
SRSCACSEPNILTGGLCFSSTGNFPLRRISAARYGEVGMSLTSEWFAKYLQSSAAACWVY 
ANLTSCQALGNMCVMNMNSYDFATFDACGLFQFIFENTAGLSTVHSISFWRQNLPWLFYG 
DQLGLAPQVLSSTSLPTNFSFKGENQNTKLKFVAASYDIRGNFLKWQTLEGGVLQLCPDT 
ETRLNAAYSFGTTYQQNCEIPISKILIDFPTPIFYDVYLEYTDENQHQYILAVPVLNLNL 
QHNKIFVNQDSNSGKWLLTRRIFLVDAVSGRENDLGTQPRVIRVATQISLSVHLVPNTIN 
GNIYPPLITIAYSDIDIKDANSQSVKVSFSVTYEMDHGEAHVQTDIALGVLGGLAVLASL 
LKTAGWKRRIGSPMIDLQTVVKFLVYYAGDLANVFFIITVGTGLYWLIFFKAQKSVSVLL 
PMPIQEERFVTYVGCAFALKALQFLHKLISQITIDVFFIDWERPKGKVLKAVEGEGGVRS 
ATVPVSIWRTYFVANEWNEIQTVRKINSLFQVLTVLFFLEVVGFKNLALMDSSSSLSRNP 
PSYIAPYSCILRYAVSAALWLAIGIIQVVFFAVFYERFIEDKIRQFVDLCSMSNISVFLL 
SHKCFGYYIHGRSVHGHADTNMEEMNMNLKREAENLCSQRGLVPNTDGQTFEIAISNQMR 
QHYDRIHETLIRKNGPARLLSSSASTFEQSIKAYHMMNKFLGSFIDHVHKEMDYFIKDKL 
LLERILGMEFMEPMEKSIFYNDEGYSFSSVLYYGNEATLLIFDLLFFCVVDLACQNFILA 
SFLTYLQQEIFRYIRNTVGQKNLASKTLVDQRFLI 
Supplementary Figure 2 The amino acid sequence of TMEM67 isoform 1 (Uniprot: 
Q5HYA8-1) 
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Supplementary Table 1 Dilutions and fixation conditions for primary and secondary 
antibodies used. 
Antigen 
Host 
species Company 
IF fixation 
condition IF dilution 
WB 
dilution 
Primary antibodies  
HA (7C9) rat Chromotek 2% PFA 1:100  
TMEM67 rabbit ProteinTech 2% PFA 1:500  
GFP mouse Roche 4% PFA 1:200 1:1000 
Secondary antibodies  
anti-rabbit Alexa 
Fluor 488 Fab 
fragment 
goat Molecular 
Probes 
 1:500  
anti-mouse 
Alexa Fluor 488 
Fab fragment 
goat Molecular 
Probes 
 1:500  
anti-rat Alexa 
Fluor 488 Fab 
fragment 
goat Molecular 
Probes 
 1:500  
Anti-mouse IGG goat Sigma 
Aldrich 
  1:40 000 
 
Alexa Fluor 594 phallotoxin phalloidin (Molecular Probes) was used at a dilution of 1:250, in 
4% PFA for isolated filamentous actin staining, and in 2% PFA for experiments when co-
stained with anti-HA for IF. 
DAPI was used at 1 µg ml-1 to counterstain nuclei in all IF experiments. 
 
 
Supplementary Table 2 Primer details for sequencing HA-TMEM67 plasmids (sequence in 
pCMV plasmid). 
 
Primer name Primer sequence 
CMVfor CGCAAATGGGCGGTAGGCGTG 
M13rev (-29) CAGGAAACAGCTATGACC 
TMEM67-Seq1 (for) GAAGATGGCTGGAACTGCAT 
TMEM67-Seq2 (for) CAGCTTTGTCCAGACACAGA 
TMEM67-Seq3 (for) CATCACAGTGGGAACAGGTC 
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Supplementary Table 3 Full double positive lists of proteins identified in GFP-Trap® of (a) 
GFP-TMEM67 full length and (b) GFP-TMEM67 DECL. 
 
(a) GFP-TMEM67 full length 
Uniprot 
Accession Description 
Q8VDD5 Myosin-9 OS=Mus musculus GN=Myh9 PE=1 SV=4 - [MYH9_MOUSE] 
P60710 Actin, cytoplasmic 1 OS=Mus musculus GN=Actb PE=1 SV=1 - [ACTB_MOUSE] 
Q3UBP6 Putative uncharacterized protein OS=Mus musculus GN=Actb PE=2 SV=1 - [Q3UBP6_MOUSE] 
Q9QXS1 Plectin OS=Mus musculus GN=Plec PE=1 SV=3 - [PLEC_MOUSE] 
Q61879 Myosin-10 OS=Mus musculus GN=Myh10 PE=1 SV=2 - [MYH10_MOUSE] 
P20152 Vimentin OS=Mus musculus GN=Vim PE=1 SV=3 - [VIME_MOUSE] 
Q9WTI7 Unconventional myosin-Ic OS=Mus musculus GN=Myo1c PE=1 SV=2 - [MYO1C_MOUSE] 
Q6ZWQ9 MCG5400 OS=Mus musculus GN=Myl12a PE=1 SV=1 - [Q6ZWQ9_MOUSE] 
P68033 Actin, alpha cardiac muscle 1 OS=Mus musculus GN=Actc1 PE=1 SV=1 - [ACTC_MOUSE] 
E9QPE7 Myosin-11 OS=Mus musculus GN=Myh11 PE=1 SV=1 - [E9QPE7_MOUSE] 
Q5SYD0 Unconventional myosin-Id OS=Mus musculus GN=Myo1d PE=1 SV=1 - [MYO1D_MOUSE] 
Q8BFZ3 Beta-actin-like protein 2 OS=Mus musculus GN=Actbl2 PE=1 SV=1 - [ACTBL_MOUSE] 
Q5SWZ5 
Myosin phosphatase Rho-interacting protein OS=Mus musculus GN=Mprip PE=1 SV=1 - 
[Q5SWZ5_MOUSE] 
P97434 
Myosin phosphatase Rho-interacting protein OS=Mus musculus GN=Mprip PE=1 SV=2 - 
[MPRIP_MOUSE] 
Q05CR3 Plec1 protein (Fragment) OS=Mus musculus GN=Plec PE=2 SV=1 - [Q05CR3_MOUSE] 
A0A0R4J221 Plectin (Fragment) OS=Mus musculus GN=Plec PE=1 SV=1 - [A0A0R4J221_MOUSE] 
Q3THE2 Myosin regulatory light chain 12B OS=Mus musculus GN=Myl12b PE=1 SV=2 - [ML12B_MOUSE] 
Q6PAC1 Gelsolin, isoform CRA_c OS=Mus musculus GN=Gsn PE=2 SV=1 - [Q6PAC1_MOUSE] 
Q60605 Myosin light polypeptide 6 OS=Mus musculus GN=Myl6 PE=1 SV=3 - [MYL6_MOUSE] 
D3YZ62 Unconventional myosin-Va OS=Mus musculus GN=Myo5a PE=1 SV=1 - [D3YZ62_MOUSE] 
P46735 Unconventional myosin-Ib OS=Mus musculus GN=Myo1b PE=1 SV=3 - [MYO1B_MOUSE] 
E9Q634 Unconventional myosin-Ie OS=Mus musculus GN=Myo1e PE=1 SV=1 - [MYO1E_MOUSE] 
E9QNH6 Unconventional myosin-Ib OS=Mus musculus GN=Myo1b PE=1 SV=1 - [E9QNH6_MOUSE] 
A0A0J9YUQ8 Gelsolin (Fragment) OS=Mus musculus GN=Gsn PE=1 SV=1 - [A0A0J9YUQ8_MOUSE] 
B9EHJ3 Tight junction protein ZO-1 OS=Mus musculus GN=Tjp1 PE=1 SV=1 - [B9EHJ3_MOUSE] 
Q642K0 MCG140959, isoform CRA_a OS=Mus musculus GN=Myl6 PE=2 SV=1 - [Q642K0_MOUSE] 
E9Q175 Unconventional myosin-VI OS=Mus musculus GN=Myo6 PE=1 SV=1 - [E9Q175_MOUSE] 
Q9JJ28 Protein flightless-1 homolog OS=Mus musculus GN=Flii PE=1 SV=1 - [FLII_MOUSE] 
K3W4R2 Myosin-14 OS=Mus musculus GN=Myh14 PE=1 SV=1 - [K3W4R2_MOUSE] 
Q9EP71 Ankycorbin OS=Mus musculus GN=Rai14 PE=1 SV=1 - [RAI14_MOUSE] 
Q2KN98 Cytospin-A OS=Mus musculus GN=Specc1l PE=1 SV=1 - [CYTSA_MOUSE] 
Q9ERG0 LIM domain and actin-binding protein 1 OS=Mus musculus GN=Lima1 PE=1 SV=3 - [LIMA1_MOUSE] 
Q61553 Fascin OS=Mus musculus GN=Fscn1 PE=1 SV=4 - [FSCN1_MOUSE] 
Q8VCQ8 Caldesmon 1 OS=Mus musculus GN=Cald1 PE=1 SV=1 - [Q8VCQ8_MOUSE] 
K3W4L0 Unconventional myosin-XVIIIa OS=Mus musculus GN=Myo18a PE=1 SV=1 - [K3W4L0_MOUSE] 
Q7TPR4 Alpha-actinin-1 OS=Mus musculus GN=Actn1 PE=1 SV=1 - [ACTN1_MOUSE] 
P27659 60S ribosomal protein L3 OS=Mus musculus GN=Rpl3 PE=1 SV=3 - [RL3_MOUSE] 
A0A0U1RNK7 
Dedicator of cytokinesis protein 7 OS=Mus musculus GN=Dock7 PE=1 SV=1 - 
[A0A0U1RNK7_MOUSE] 
Q9D8E6 60S ribosomal protein L4 OS=Mus musculus GN=Rpl4 PE=1 SV=3 - [RL4_MOUSE] 
E9Q3Z5 Supervillin OS=Mus musculus GN=Svil PE=1 SV=1 - [E9Q3Z5_MOUSE] 
E9PYF4 LIM domain only 7 OS=Mus musculus GN=Lmo7 PE=1 SV=1 - [E9PYF4_MOUSE] 
P62141 
Serine/threonine-protein phosphatase PP1-beta catalytic subunit OS=Mus musculus GN=Ppp1cb 
PE=1 SV=3 - [PP1B_MOUSE] 
P08752 
Guanine nucleotide-binding protein G(i) subunit alpha-2 OS=Mus musculus GN=Gnai2 PE=1 SV=5 - 
[GNAI2_MOUSE] 
 
145 
Q62261 
Spectrin beta chain, non-erythrocytic 1 OS=Mus musculus GN=Sptbn1 PE=1 SV=2 - 
[SPTB2_MOUSE] 
P62137 
Serine/threonine-protein phosphatase PP1-alpha catalytic subunit OS=Mus musculus GN=Ppp1ca 
PE=1 SV=1 - [PP1A_MOUSE] 
Q8R422 CD109 antigen OS=Mus musculus GN=Cd109 PE=1 SV=1 - [CD109_MOUSE] 
E9PX70 Collagen alpha-1(XII) chain OS=Mus musculus GN=Col12a1 PE=1 SV=1 - [E9PX70_MOUSE] 
F6TFN2 LIM domain only 7 (Fragment) OS=Mus musculus GN=Lmo7 PE=1 SV=1 - [F6TFN2_MOUSE] 
Q9DBR7 
Protein phosphatase 1 regulatory subunit 12A OS=Mus musculus GN=Ppp1r12a PE=1 SV=2 - 
[MYPT1_MOUSE] 
B2CY77 Laminin receptor (Fragment) OS=Mus musculus GN=Rpsa PE=2 SV=1 - [B2CY77_MOUSE] 
Q9QZF2 Glypican-1 OS=Mus musculus GN=Gpc1 PE=1 SV=1 - [GPC1_MOUSE] 
F6SVV1 Uncharacterized protein OS=Mus musculus GN=Gm9493 PE=4 SV=1 - [F6SVV1_MOUSE] 
Q5SQB0 Nucleophosmin OS=Mus musculus GN=Npm1 PE=1 SV=1 - [Q5SQB0_MOUSE] 
Q08509 
Epidermal growth factor receptor kinase substrate 8 OS=Mus musculus GN=Eps8 PE=1 SV=2 - 
[EPS8_MOUSE] 
Q3TRK3 Putative uncharacterized protein OS=Mus musculus GN=Dbn1 PE=2 SV=1 - [Q3TRK3_MOUSE] 
P62880 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 OS=Mus musculus GN=Gnb2 PE=1 
SV=3 - [GBB2_MOUSE] 
Q9DC51 
Guanine nucleotide-binding protein G(k) subunit alpha OS=Mus musculus GN=Gnai3 PE=1 SV=3 - 
[GNAI3_MOUSE] 
Q8R0W0 Epiplakin OS=Mus musculus GN=Eppk1 PE=1 SV=2 - [EPIPL_MOUSE] 
Q9Z0U1 Tight junction protein ZO-2 OS=Mus musculus GN=Tjp2 PE=1 SV=2 - [ZO2_MOUSE] 
B1AZ46 
Brain-specific angiogenesis inhibitor 1-associated protein 2 OS=Mus musculus GN=Baiap2 PE=1 
SV=1 - [B1AZ46_MOUSE] 
Q8BK67 Protein RCC2 OS=Mus musculus GN=Rcc2 PE=1 SV=1 - [RCC2_MOUSE] 
Q3TFA9 Putative uncharacterized protein OS=Mus musculus GN=Tmod3 PE=2 SV=1 - [Q3TFA9_MOUSE] 
G3X9T8 Ceruloplasmin OS=Mus musculus GN=Cp PE=1 SV=1 - [G3X9T8_MOUSE] 
E9Q3E2 Synaptopodin OS=Mus musculus GN=Synpo PE=1 SV=1 - [E9Q3E2_MOUSE] 
A0A1L1SUX8 
Thy-1 membrane glycoprotein (Fragment) OS=Mus musculus GN=Thy1 PE=1 SV=1 - 
[A0A1L1SUX8_MOUSE] 
Q6IRU2 Tropomyosin alpha-4 chain OS=Mus musculus GN=Tpm4 PE=1 SV=3 - [TPM4_MOUSE] 
Q3U561 Ribosomal protein OS=Mus musculus GN=Rpl10a PE=2 SV=1 - [Q3U561_MOUSE] 
Q9CVB6 
Actin-related protein 2/3 complex subunit 2 OS=Mus musculus GN=Arpc2 PE=1 SV=3 - 
[ARPC2_MOUSE] 
D3Z2H9 Uncharacterized protein OS=Mus musculus GN=Tpm3-rs7 PE=3 SV=1 - [D3Z2H9_MOUSE] 
P50580 Proliferation-associated protein 2G4 OS=Mus musculus GN=Pa2g4 PE=1 SV=3 - [PA2G4_MOUSE] 
F7DBB3 
AHNAK nucleoprotein 2 (Fragment) OS=Mus musculus GN=Ahnak2 PE=1 SV=1 - 
[F7DBB3_MOUSE] 
Q0KL02 Triple functional domain protein OS=Mus musculus GN=Trio PE=1 SV=3 - [TRIO_MOUSE] 
Q3THB3 Putative uncharacterized protein OS=Mus musculus GN=Hnrnpm PE=1 SV=1 - [Q3THB3_MOUSE] 
Q3TZU7 Sorting nexin OS=Mus musculus GN=Snx9 PE=2 SV=1 - [Q3TZU7_MOUSE] 
Q3TEU8 Coronin OS=Mus musculus GN=Coro1c PE=2 SV=1 - [Q3TEU8_MOUSE] 
P28301 Protein-lysine 6-oxidase OS=Mus musculus GN=Lox PE=1 SV=1 - [LYOX_MOUSE] 
A0A1D5RLW5 60S ribosomal protein L18a OS=Mus musculus GN=Rpl18a PE=1 SV=1 - [A0A1D5RLW5_MOUSE] 
G3X9J0 
Signal-induced proliferation-associated 1-like protein 3 OS=Mus musculus GN=Sipa1l3 PE=1 SV=1 - 
[SI1L3_MOUSE] 
P67984 60S ribosomal protein L22 OS=Mus musculus GN=Rpl22 PE=1 SV=2 - [RL22_MOUSE] 
P62270 40S ribosomal protein S18 OS=Mus musculus GN=Rps18 PE=1 SV=3 - [RS18_MOUSE] 
P31001 Desmin OS=Mus musculus GN=Des PE=1 SV=3 - [DESM_MOUSE] 
Q60597 
2-oxoglutarate dehydrogenase, mitochondrial OS=Mus musculus GN=Ogdh PE=1 SV=3 - 
[ODO1_MOUSE] 
Q3TCE7 Putative uncharacterized protein OS=Mus musculus GN=Arpc1b PE=2 SV=1 - [Q3TCE7_MOUSE] 
Q3TJ01 tRNA-splicing ligase RtcB homolog OS=Mus musculus GN=Rtcb PE=2 SV=1 - [Q3TJ01_MOUSE] 
Q3TF41 
Nucleosome assembly protein 1-like 1, isoform CRA_d OS=Mus musculus GN=Nap1l1 PE=2 SV=1 - 
[Q3TF41_MOUSE] 
Q60598 Src substrate cortactin OS=Mus musculus GN=Cttn PE=1 SV=2 - [SRC8_MOUSE] 
Q01721 Growth arrest-specific protein 1 OS=Mus musculus GN=Gas1 PE=2 SV=2 - [GAS1_MOUSE] 
P31230 
Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 OS=Mus musculus 
GN=Aimp1 PE=1 SV=2 - [AIMP1_MOUSE] 
P28352 
DNA-(apurinic or apyrimidinic site) lyase OS=Mus musculus GN=Apex1 PE=1 SV=2 - 
[APEX1_MOUSE] 
A0A0R4J169 
Leucine-rich repeat flightless-interacting protein 2 OS=Mus musculus GN=Lrrfip2 PE=1 SV=1 - 
[A0A0R4J169_MOUSE] 
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Q4VBF8 Sipa1l1 protein OS=Mus musculus GN=Sipa1l1 PE=2 SV=1 - [Q4VBF8_MOUSE] 
Q6R891 Neurabin-2 OS=Mus musculus GN=Ppp1r9b PE=1 SV=1 - [NEB2_MOUSE] 
Q8CBM2 
Aspartyl/asparaginyl beta-hydroxylase OS=Mus musculus GN=Asph PE=1 SV=1 - 
[Q8CBM2_MOUSE] 
Q8K173 Col3a1 protein (Fragment) OS=Mus musculus GN=Col3a1 PE=2 SV=1 - [Q8K173_MOUSE] 
Q3TJZ6 Protein FAM98A OS=Mus musculus GN=Fam98a PE=1 SV=1 - [FA98A_MOUSE] 
Q8BR76 Meckelin OS=Mus musculus GN=Tmem67 PE=1 SV=2 - [MKS3_MOUSE] 
Q9D0P6 Putative uncharacterized protein OS=Mus musculus PE=2 SV=1 - [Q9D0P6_MOUSE] 
P14115 60S ribosomal protein L27a OS=Mus musculus GN=Rpl27a PE=1 SV=5 - [RL27A_MOUSE] 
P32067 Lupus La protein homolog OS=Mus musculus GN=Ssb PE=1 SV=1 - [LA_MOUSE] 
Q3TWV4 AP-2 complex subunit mu OS=Mus musculus GN=Ap2m1 PE=1 SV=1 - [Q3TWV4_MOUSE] 
P51655 Glypican-4 OS=Mus musculus GN=Gpc4 PE=1 SV=2 - [GPC4_MOUSE] 
P42669 
Transcriptional activator protein Pur-alpha OS=Mus musculus GN=Pura PE=1 SV=1 - 
[PURA_MOUSE] 
A0A1L1SVG0 
Uveal autoantigen with coiled-coil domains and ankyrin repeats OS=Mus musculus GN=Uaca PE=1 
SV=1 - [A0A1L1SVG0_MOUSE] 
P63037 
DnaJ homolog subfamily A member 1 OS=Mus musculus GN=Dnaja1 PE=1 SV=1 - 
[DNJA1_MOUSE] 
Q3U026 Putative uncharacterized protein OS=Mus musculus GN=Mogs PE=2 SV=1 - [Q3U026_MOUSE] 
A0A0J9YTU3 Cytospin-B OS=Mus musculus GN=Specc1 PE=1 SV=1 - [A0A0J9YTU3_MOUSE] 
Q3TAH3 Putative uncharacterized protein OS=Mus musculus GN=Npm3 PE=2 SV=1 - [Q3TAH3_MOUSE] 
P54823 
Probable ATP-dependent RNA helicase DDX6 OS=Mus musculus GN=Ddx6 PE=1 SV=1 - 
[DDX6_MOUSE] 
Q3TQY2 Putative uncharacterized protein OS=Mus musculus GN=Dctn4 PE=2 SV=1 - [Q3TQY2_MOUSE] 
Q6PDM2 Serine/arginine-rich splicing factor 1 OS=Mus musculus GN=Srsf1 PE=1 SV=3 - [SRSF1_MOUSE] 
A0A0J9YUR2 Cytospin-B OS=Mus musculus GN=Specc1 PE=1 SV=1 - [A0A0J9YUR2_MOUSE] 
Q8BG95 
Protein phosphatase 1 regulatory subunit 12B OS=Mus musculus GN=Ppp1r12b PE=1 SV=2 - 
[MYPT2_MOUSE] 
B2RQQ7 
CDC42 binding protein kinase beta OS=Mus musculus GN=Cdc42bpb PE=2 SV=1 - 
[B2RQQ7_MOUSE] 
Q925B0 PRKC apoptosis WT1 regulator protein OS=Mus musculus GN=Pawr PE=1 SV=2 - [PAWR_MOUSE] 
Q9CX86 
Heterogeneous nuclear ribonucleoprotein A0 OS=Mus musculus GN=Hnrnpa0 PE=1 SV=1 - 
[ROA0_MOUSE] 
Q3UDS4 Putative uncharacterized protein OS=Mus musculus GN=Sqrdl PE=2 SV=1 - [Q3UDS4_MOUSE] 
B2RSW8 Pericentriolar material 1 OS=Mus musculus GN=Pcm1 PE=2 SV=1 - [B2RSW8_MOUSE] 
Q8K258 Srp68 protein OS=Mus musculus GN=Srp68 PE=2 SV=1 - [Q8K258_MOUSE] 
E9Q0Y4 
Signal-induced proliferation-associated protein 1 OS=Mus musculus GN=Sipa1 PE=1 SV=1 - 
[E9Q0Y4_MOUSE] 
Q3TQP7 Putative uncharacterized protein OS=Mus musculus GN=Acat1 PE=2 SV=1 - [Q3TQP7_MOUSE] 
Q3UMU9 
Hepatoma-derived growth factor-related protein 2 OS=Mus musculus GN=Hdgfrp2 PE=1 SV=1 - 
[HDGR2_MOUSE] 
Q3UFZ6 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Caprin1 PE=2 SV=1 - 
[Q3UFZ6_MOUSE] 
Z4YJL4 
182 kDa tankyrase-1-binding protein OS=Mus musculus GN=Tnks1bp1 PE=1 SV=1 - 
[Z4YJL4_MOUSE] 
P27641 
X-ray repair cross-complementing protein 5 OS=Mus musculus GN=Xrcc5 PE=1 SV=4 - 
[XRCC5_MOUSE] 
Q8CI43 Myosin light chain 6B OS=Mus musculus GN=Myl6b PE=1 SV=1 - [MYL6B_MOUSE] 
Q91XV3 Brain acid soluble protein 1 OS=Mus musculus GN=Basp1 PE=1 SV=3 - [BASP1_MOUSE] 
E9Q740 Signal recognition particle 72 OS=Mus musculus GN=Srp72 PE=1 SV=1 - [E9Q740_MOUSE] 
Q8BGH2 
Sorting and assembly machinery component 50 homolog OS=Mus musculus GN=Samm50 PE=1 
SV=1 - [SAM50_MOUSE] 
Q3TGL4 Fibulin 2, isoform CRA_b OS=Mus musculus GN=Fbln2 PE=2 SV=1 - [Q3TGL4_MOUSE] 
E9QAH1 
Golgi autoantigen, golgin subfamily b, macrogolgin 1 OS=Mus musculus GN=Golgb1 PE=1 SV=1 - 
[E9QAH1_MOUSE] 
Q05DU4 Msn protein (Fragment) OS=Mus musculus GN=Msn PE=2 SV=1 - [Q05DU4_MOUSE] 
P05533 Lymphocyte antigen 6A-2/6E-1 OS=Mus musculus GN=Ly6a PE=1 SV=1 - [LY6A_MOUSE] 
P0DP27 Calmodulin-2 OS=Mus musculus GN=Calm2 PE=1 SV=1 - [CALM2_MOUSE] 
A0A0G2JDW7 
40S ribosomal protein S27 (Fragment) OS=Mus musculus GN=Rps27 PE=1 SV=1 - 
[A0A0G2JDW7_MOUSE] 
P49817 Caveolin-1 OS=Mus musculus GN=Cav1 PE=1 SV=1 - [CAV1_MOUSE] 
Q8R081 
Heterogeneous nuclear ribonucleoprotein L OS=Mus musculus GN=Hnrnpl PE=1 SV=2 - 
[HNRPL_MOUSE] 
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P59999 
Actin-related protein 2/3 complex subunit 4 OS=Mus musculus GN=Arpc4 PE=1 SV=3 - 
[ARPC4_MOUSE] 
A0A0N4SV32 
Plasminogen activator inhibitor 1 RNA-binding protein OS=Mus musculus GN=Serbp1 PE=1 SV=1 - 
[A0A0N4SV32_MOUSE] 
F8WIT2 Annexin OS=Mus musculus GN=Anxa6 PE=1 SV=1 - [F8WIT2_MOUSE] 
P51863 V-type proton ATPase subunit d 1 OS=Mus musculus GN=Atp6v0d1 PE=1 SV=2 - [VA0D1_MOUSE] 
G3UXT7 RNA-binding protein FUS (Fragment) OS=Mus musculus GN=Fus PE=1 SV=1 - [G3UXT7_MOUSE] 
Q9D699 Putative uncharacterized protein OS=Mus musculus GN=Gas2 PE=2 SV=1 - [Q9D699_MOUSE] 
A0A0N5E9G7 Replication factor C subunit 1 OS=Mus musculus GN=Rfc1 PE=1 SV=1 - [A0A0N5E9G7_MOUSE] 
Q9WUM5 
Succinate--CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial OS=Mus musculus 
GN=Suclg1 PE=1 SV=4 - [SUCA_MOUSE] 
G5E8E1 
Leucine rich repeat (In FLII) interacting protein 1, isoform CRA_e OS=Mus musculus GN=Lrrfip1 
PE=1 SV=1 - [G5E8E1_MOUSE] 
E9QN08 Elongation factor 1-delta (Fragment) OS=Mus musculus GN=Eef1d PE=1 SV=1 - [E9QN08_MOUSE] 
F8VQB6 Unconventional myosin-X OS=Mus musculus GN=Myo10 PE=1 SV=1 - [MYO10_MOUSE] 
O88398 Advillin OS=Mus musculus GN=Avil PE=1 SV=2 - [AVIL_MOUSE] 
Q9D7S7 60S ribosomal protein L22-like 1 OS=Mus musculus GN=Rpl22l1 PE=1 SV=1 - [RL22L_MOUSE] 
A0A0H3XWX3 
Insulin-like growth factor 2 mRNA binding protein 1 dN CRDBP-2 OS=Mus musculus GN=Igf2bp1 
PE=2 SV=1 - [A0A0H3XWX3_MOUSE] 
P50396 Rab GDP dissociation inhibitor alpha OS=Mus musculus GN=Gdi1 PE=1 SV=3 - [GDIA_MOUSE] 
F8VPU2 
FERM, RhoGEF and pleckstrin domain-containing protein 1 OS=Mus musculus GN=Farp1 PE=1 
SV=1 - [FARP1_MOUSE] 
Q99JY0 
Trifunctional enzyme subunit beta, mitochondrial OS=Mus musculus GN=Hadhb PE=1 SV=1 - 
[ECHB_MOUSE] 
E9Q9H2 
DnaJ homolog subfamily C member 2 OS=Mus musculus GN=Dnajc2 PE=1 SV=1 - 
[E9Q9H2_MOUSE] 
Q8K335 
Glutamate-rich WD repeat containing 1 OS=Mus musculus GN=Grwd1 PE=2 SV=1 - 
[Q8K335_MOUSE] 
Q02013 Aquaporin-1 OS=Mus musculus GN=Aqp1 PE=1 SV=3 - [AQP1_MOUSE] 
O89086 RNA-binding protein 3 OS=Mus musculus GN=Rbm3 PE=1 SV=1 - [RBM3_MOUSE] 
Q3TFP8 Putative uncharacterized protein OS=Mus musculus GN=Pgrmc1 PE=2 SV=1 - [Q3TFP8_MOUSE] 
B7ZMP1 Probable Xaa-Pro aminopeptidase 3 OS=Mus musculus GN=Xpnpep3 PE=1 SV=1 - [XPP3_MOUSE] 
Q99LS8 Pbx1 protein OS=Mus musculus GN=Pbx1 PE=2 SV=1 - [Q99LS8_MOUSE] 
O35682 
Myeloid-associated differentiation marker OS=Mus musculus GN=Myadm PE=1 SV=2 - 
[MYADM_MOUSE] 
P49718 DNA replication licensing factor MCM5 OS=Mus musculus GN=Mcm5 PE=1 SV=1 - [MCM5_MOUSE] 
Q9DB77 
Cytochrome b-c1 complex subunit 2, mitochondrial OS=Mus musculus GN=Uqcrc2 PE=1 SV=1 - 
[QCR2_MOUSE] 
A1L0U3 Histone H3 (Fragment) OS=Mus musculus GN=Hist1h3e PE=2 SV=1 - [A1L0U3_MOUSE] 
A2AW05 
FACT complex subunit SSRP1 (Fragment) OS=Mus musculus GN=Ssrp1 PE=1 SV=1 - 
[A2AW05_MOUSE] 
B2RXP1 
Leucine-rich repeat and calponin homology domain-containing protein 3 OS=Mus musculus 
GN=Lrch3 PE=1 SV=1 - [B2RXP1_MOUSE] 
Q3TP69 Putative uncharacterized protein OS=Mus musculus GN=Gpc6 PE=2 SV=1 - [Q3TP69_MOUSE] 
Q922K7 
Probable 28S rRNA (cytosine-C(5))-methyltransferase OS=Mus musculus GN=Nop2 PE=1 SV=1 - 
[NOP2_MOUSE] 
Q8R5L1 
Complement component 1 Q subcomponent-binding protein, mitochondrial OS=Mus musculus 
GN=C1qbp PE=1 SV=1 - [Q8R5L1_MOUSE] 
E9QL13 MCG8382, isoform CRA_c OS=Mus musculus GN=Rbm14 PE=1 SV=2 - [E9QL13_MOUSE] 
P60122 RuvB-like 1 OS=Mus musculus GN=Ruvbl1 PE=1 SV=1 - [RUVB1_MOUSE] 
Q9CYL5 
Golgi-associated plant pathogenesis-related protein 1 OS=Mus musculus GN=Glipr2 PE=1 SV=3 - 
[GAPR1_MOUSE] 
Q8BG67 Protein EFR3 homolog A OS=Mus musculus GN=Efr3a PE=1 SV=1 - [EFR3A_MOUSE] 
Q08288 Cell growth-regulating nucleolar protein OS=Mus musculus GN=Lyar PE=1 SV=2 - [LYAR_MOUSE] 
A0A067XG53 
Peripheral plasma membrane protein CASK (Fragment) OS=Mus musculus GN=Cask PE=1 SV=1 - 
[A0A067XG53_MOUSE] 
Q9DCW4 Electron transfer flavoprotein subunit beta OS=Mus musculus GN=Etfb PE=1 SV=3 - [ETFB_MOUSE] 
Q60737 Casein kinase II subunit alpha OS=Mus musculus GN=Csnk2a1 PE=1 SV=2 - [CSK21_MOUSE] 
P10605 Cathepsin B OS=Mus musculus GN=Ctsb PE=1 SV=2 - [CATB_MOUSE] 
Q3UA95 Histone H2A OS=Mus musculus GN=H2afz PE=2 SV=1 - [Q3UA95_MOUSE] 
O35646 Calpain-6 OS=Mus musculus GN=Capn6 PE=1 SV=2 - [CAN6_MOUSE] 
Q9QWJ3 Alpha-1-globin (Fragment) OS=Mus musculus PE=2 SV=1 - [Q9QWJ3_MOUSE] 
H7BWZ3 
Actin-related protein 2/3 complex subunit 3 OS=Mus musculus GN=Arpc3 PE=1 SV=1 - 
[H7BWZ3_MOUSE] 
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G3UYU4 Flotillin-1 OS=Mus musculus GN=Flot1 PE=1 SV=1 - [G3UYU4_MOUSE] 
A0A1D5RM23 
Cleavage and polyadenylation-specificity factor subunit 5 OS=Mus musculus GN=Nudt21 PE=1 SV=1 
- [A0A1D5RM23_MOUSE] 
Q6ZPF4 Formin-like protein 3 OS=Mus musculus GN=Fmnl3 PE=1 SV=2 - [FMNL3_MOUSE] 
P26231 Catenin alpha-1 OS=Mus musculus GN=Ctnna1 PE=1 SV=1 - [CTNA1_MOUSE] 
P01027 Complement C3 OS=Mus musculus GN=C3 PE=1 SV=3 - [CO3_MOUSE] 
Q03963 
Interferon-induced, double-stranded RNA-activated protein kinase OS=Mus musculus GN=Eif2ak2 
PE=1 SV=2 - [E2AK2_MOUSE] 
Q3UGJ5 Putative uncharacterized protein OS=Mus musculus GN=Rasa3 PE=2 SV=1 - [Q3UGJ5_MOUSE] 
Q3THA0 
Eukaryotic translation initiation factor 3 subunit G OS=Mus musculus GN=Eif3g PE=2 SV=1 - 
[Q3THA0_MOUSE] 
Q99JX4 
Eukaryotic translation initiation factor 3 subunit M OS=Mus musculus GN=Eif3m PE=1 SV=1 - 
[EIF3M_MOUSE] 
Q04736 Tyrosine-protein kinase Yes OS=Mus musculus GN=Yes1 PE=1 SV=3 - [YES_MOUSE] 
Q9D4P2 Putative uncharacterized protein OS=Mus musculus GN=Spag16 PE=2 SV=1 - [Q9D4P2_MOUSE] 
Q3TCX4 Putative uncharacterized protein OS=Mus musculus GN=Zfp622 PE=2 SV=1 - [Q3TCX4_MOUSE] 
Q99M31 Heat shock 70 kDa protein 14 OS=Mus musculus GN=Hspa14 PE=1 SV=2 - [HSP7E_MOUSE] 
Q8R346 Aars protein (Fragment) OS=Mus musculus GN=Aars PE=2 SV=2 - [Q8R346_MOUSE] 
E9PZJ8 
Activating signal cointegrator 1 complex subunit 3 OS=Mus musculus GN=Ascc3 PE=1 SV=1 - 
[ASCC3_MOUSE] 
P70199 ERF1 (Fragment) OS=Mus musculus GN=Etf1 PE=2 SV=1 - [P70199_MOUSE] 
Q64339 Ubiquitin-like protein ISG15 OS=Mus musculus GN=Isg15 PE=1 SV=4 - [ISG15_MOUSE] 
Q80VD1 Protein FAM98B OS=Mus musculus GN=Fam98b PE=1 SV=1 - [FA98B_MOUSE] 
Q8C8X9 Putative uncharacterized protein OS=Mus musculus GN=Camk2d PE=2 SV=1 - [Q8C8X9_MOUSE] 
A0A0G2JG59 Nexilin (Fragment) OS=Mus musculus GN=Nexn PE=1 SV=1 - [A0A0G2JG59_MOUSE] 
B8JJM3 Complement factor B (Fragment) OS=Mus musculus GN=Cfb PE=3 SV=1 - [B8JJM3_MOUSE] 
Q9ERU9 E3 SUMO-protein ligase RanBP2 OS=Mus musculus GN=Ranbp2 PE=1 SV=2 - [RBP2_MOUSE] 
Q8BWX1 Putative uncharacterized protein OS=Mus musculus GN=Atxn10 PE=2 SV=1 - [Q8BWX1_MOUSE] 
Q3UC76 Putative uncharacterized protein OS=Mus musculus GN=Eif1a PE=2 SV=1 - [Q3UC76_MOUSE] 
Q3UF75 Alpha-parvin OS=Mus musculus GN=Parva PE=1 SV=1 - [Q3UF75_MOUSE] 
P62315 
Small nuclear ribonucleoprotein Sm D1 OS=Mus musculus GN=Snrpd1 PE=1 SV=1 - 
[SMD1_MOUSE] 
Q5SS83 Flotillin 2, isoform CRA_a OS=Mus musculus GN=Flot2 PE=1 SV=1 - [Q5SS83_MOUSE] 
Q543N4 Putative uncharacterized protein OS=Mus musculus GN=Bysl PE=2 SV=1 - [Q543N4_MOUSE] 
A0A1D5RM32 Dipeptidase (Fragment) OS=Mus musculus GN=Dpep1 PE=1 SV=1 - [A0A1D5RM32_MOUSE] 
H7BX99 Prothrombin OS=Mus musculus GN=F2 PE=1 SV=1 - [H7BX99_MOUSE] 
Q3TN28 Putative uncharacterized protein OS=Mus musculus GN=Xrcc1 PE=2 SV=1 - [Q3TN28_MOUSE] 
Q99KA3 Atp6v1b1 protein (Fragment) OS=Mus musculus GN=Atp6v1b1 PE=2 SV=1 - [Q99KA3_MOUSE] 
Q3UXI9 Putative uncharacterized protein OS=Mus musculus GN=Ilf2 PE=2 SV=1 - [Q3UXI9_MOUSE] 
P30412 Peptidyl-prolyl cis-trans isomerase C OS=Mus musculus GN=Ppic PE=1 SV=1 - [PPIC_MOUSE] 
Q62446 
Peptidyl-prolyl cis-trans isomerase FKBP3 OS=Mus musculus GN=Fkbp3 PE=1 SV=2 - 
[FKBP3_MOUSE] 
Q8CAQ9 Putative uncharacterized protein OS=Mus musculus GN=Exoc4 PE=2 SV=1 - [Q8CAQ9_MOUSE] 
F6UY19 Islet cell autoantigen 1 (Fragment) OS=Mus musculus GN=Ica1 PE=1 SV=1 - [F6UY19_MOUSE] 
D3Z765 
Putative RNA-binding protein Luc7-like 1 (Fragment) OS=Mus musculus GN=Luc7l PE=1 SV=1 - 
[D3Z765_MOUSE] 
Q3TJA9 
DnaJ (Hsp40) homolog, subfamily A, member 3, isoform CRA_b OS=Mus musculus GN=Dnaja3 
PE=2 SV=1 - [Q3TJA9_MOUSE] 
Q9D1R9 60S ribosomal protein L34 OS=Mus musculus GN=Rpl34 PE=1 SV=2 - [RL34_MOUSE] 
A0A0G2JDL9 MCG10748, isoform CRA_b OS=Mus musculus GN=Rap1a PE=1 SV=1 - [A0A0G2JDL9_MOUSE] 
Q3TXS7 
26S proteasome non-ATPase regulatory subunit 1 OS=Mus musculus GN=Psmd1 PE=1 SV=1 - 
[PSMD1_MOUSE] 
A0A0G2JDI9 
ATP-binding cassette sub-family D member 3 OS=Mus musculus GN=Abcd3 PE=1 SV=1 - 
[A0A0G2JDI9_MOUSE] 
A0A0U1RPX7 Unconventional myosin-VIIa OS=Mus musculus GN=Myo7a PE=1 SV=1 - [A0A0U1RPX7_MOUSE] 
E9Q7G6 
RNA-binding motif, single-stranded-interacting protein 2 OS=Mus musculus GN=Rbms2 PE=1 SV=1 - 
[E9Q7G6_MOUSE] 
Q91ZU6 Dystonin OS=Mus musculus GN=Dst PE=1 SV=2 - [DYST_MOUSE] 
Q07417 
Short-chain specific acyl-CoA dehydrogenase, mitochondrial OS=Mus musculus GN=Acads PE=1 
SV=2 - [ACADS_MOUSE] 
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D3Z1B9 
V-type proton ATPase catalytic subunit A (Fragment) OS=Mus musculus GN=Atp6v1a PE=1 SV=1 - 
[D3Z1B9_MOUSE] 
Q6A075 MKIAA0394 protein (Fragment) OS=Mus musculus GN=Gas7 PE=2 SV=1 - [Q6A075_MOUSE] 
Q3U5K8 Putative uncharacterized protein OS=Mus musculus GN=Ifit1 PE=2 SV=1 - [Q3U5K8_MOUSE] 
P62965 
Cellular retinoic acid-binding protein 1 OS=Mus musculus GN=Crabp1 PE=1 SV=2 - 
[RABP1_MOUSE] 
F8VQ42 Kinesin-like protein (Fragment) OS=Mus musculus GN=Kif2a PE=1 SV=1 - [F8VQ42_MOUSE] 
V9GXA5 Zinc finger transcription factor Trps1 OS=Mus musculus GN=Trps1 PE=1 SV=1 - [V9GXA5_MOUSE] 
Q6P9Q4 FH1/FH2 domain-containing protein 1 OS=Mus musculus GN=Fhod1 PE=1 SV=3 - [FHOD1_MOUSE] 
Q3UUU0 Putative uncharacterized protein OS=Mus musculus GN=Emilin1 PE=2 SV=1 - [Q3UUU0_MOUSE] 
Q80TP6 
MKIAA0890 protein (Fragment) OS=Mus musculus GN=mKIAA0890 PE=4 SV=3 - 
[Q80TP6_MOUSE] 
F6RB63 
PC4 and SFRS1-interacting protein (Fragment) OS=Mus musculus GN=Psip1 PE=1 SV=1 - 
[F6RB63_MOUSE] 
Q99JY8 Phospholipid phosphatase 3 OS=Mus musculus GN=Plpp3 PE=1 SV=1 - [PLPP3_MOUSE] 
K7Q751 Focal ashension kinase 1 OS=Mus musculus GN=Ptk2 PE=2 SV=1 - [K7Q751_MOUSE] 
O08842 GDNF family receptor alpha-2 OS=Mus musculus GN=Gfra2 PE=1 SV=2 - [GFRA2_MOUSE] 
Q99J62 Replication factor C subunit 4 OS=Mus musculus GN=Rfc4 PE=1 SV=1 - [RFC4_MOUSE] 
H3BLG5 Syntenin-1 (Fragment) OS=Mus musculus GN=Sdcbp PE=1 SV=1 - [H3BLG5_MOUSE] 
Q8BGU5 Cyclin-Y OS=Mus musculus GN=Ccny PE=1 SV=1 - [CCNY_MOUSE] 
F6YRQ2 
DnaJ homolog subfamily B member 6 (Fragment) OS=Mus musculus GN=Dnajb6 PE=1 SV=1 - 
[F6YRQ2_MOUSE] 
P26516 
26S proteasome non-ATPase regulatory subunit 7 OS=Mus musculus GN=Psmd7 PE=1 SV=2 - 
[PSMD7_MOUSE] 
Q80UU9 
Membrane-associated progesterone receptor component 2 OS=Mus musculus GN=Pgrmc2 PE=1 
SV=2 - [PGRC2_MOUSE] 
Q4VAA7 Sorting nexin-33 OS=Mus musculus GN=Snx33 PE=1 SV=1 - [SNX33_MOUSE] 
Q99M55 V-type proton ATPase subunit a OS=Mus musculus GN=Atp6v0a1 PE=2 SV=1 - [Q99M55_MOUSE] 
Q8R2U0 Nucleoporin SEH1 OS=Mus musculus GN=Seh1l PE=2 SV=1 - [SEH1_MOUSE] 
Q9DBR1 5'-3' exoribonuclease 2 OS=Mus musculus GN=Xrn2 PE=1 SV=1 - [XRN2_MOUSE] 
P10833 Ras-related protein R-Ras OS=Mus musculus GN=Rras PE=1 SV=1 - [RRAS_MOUSE] 
Q8R2X0 Ehd2 protein OS=Mus musculus GN=Ehd2 PE=2 SV=1 - [Q8R2X0_MOUSE] 
Q8C1L7 40S ribosomal protein S21 OS=Mus musculus GN=mCG_6739 PE=2 SV=1 - [Q8C1L7_MOUSE] 
A0A0R4J2A5 Suprabasin OS=Mus musculus GN=Sbsn PE=1 SV=1 - [A0A0R4J2A5_MOUSE] 
Q8CD98 Putative uncharacterized protein OS=Mus musculus GN=Pfkl PE=2 SV=1 - [Q8CD98_MOUSE] 
Q5XJX8 Mrps9 protein (Fragment) OS=Mus musculus GN=Mrps9 PE=2 SV=1 - [Q5XJX8_MOUSE] 
A0A1D5RM74 
Casein kinase II subunit alpha' (Fragment) OS=Mus musculus GN=Csnk2a2 PE=1 SV=1 - 
[A0A1D5RM74_MOUSE] 
Q3UJP8 
Trifunctional purine biosynthetic protein adenosine-3 OS=Mus musculus GN=Gart PE=2 SV=1 - 
[Q3UJP8_MOUSE] 
P28660 Nck-associated protein 1 OS=Mus musculus GN=Nckap1 PE=1 SV=2 - [NCKP1_MOUSE] 
B7ZP28 Dennd2a protein OS=Mus musculus GN=Dennd2a PE=2 SV=1 - [B7ZP28_MOUSE] 
Q6PAH8 Gatad2b protein (Fragment) OS=Mus musculus GN=Gatad2b PE=2 SV=1 - [Q6PAH8_MOUSE] 
Q9QZB9 Dynactin subunit 5 OS=Mus musculus GN=Dctn5 PE=1 SV=1 - [DCTN5_MOUSE] 
Q9EP69 
Phosphatidylinositide phosphatase SAC1 OS=Mus musculus GN=Sacm1l PE=1 SV=1 - 
[SAC1_MOUSE] 
Q3TK56 
Actin-related protein 2/3 complex subunit 5 (Fragment) OS=Mus musculus GN=Arpc5 PE=2 SV=1 - 
[Q3TK56_MOUSE] 
E9PZC4 Flavin reductase (NADPH) OS=Mus musculus GN=Blvrb PE=1 SV=1 - [E9PZC4_MOUSE] 
S4R294 Protein PRRC2C OS=Mus musculus GN=Prrc2c PE=1 SV=1 - [S4R294_MOUSE] 
Q3UT80 Putative uncharacterized protein OS=Mus musculus GN=Gm1587 PE=2 SV=1 - [Q3UT80_MOUSE] 
O08543 Ephrin-A5 OS=Mus musculus GN=Efna5 PE=1 SV=1 - [EFNA5_MOUSE] 
A2AG47 
Melanoma antigen, family D, 2 (Fragment) OS=Mus musculus GN=Maged2 PE=1 SV=1 - 
[A2AG47_MOUSE] 
Q9CZX0 Elongator complex protein 3 OS=Mus musculus GN=Elp3 PE=1 SV=1 - [ELP3_MOUSE] 
B7ZN65 Il5ra protein OS=Mus musculus GN=Il5ra PE=2 SV=1 - [B7ZN65_MOUSE] 
Q91YN9 
BAG family molecular chaperone regulator 2 OS=Mus musculus GN=Bag2 PE=1 SV=1 - 
[BAG2_MOUSE] 
Q922M3 
BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 3 OS=Mus 
musculus GN=Kctd10 PE=1 SV=1 - [BACD3_MOUSE] 
Q45VK5 Interleukin enhancer-binding factor 3 OS=Mus musculus GN=Ilf3 PE=1 SV=1 - [Q45VK5_MOUSE] 
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Q3UX26 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Pak1ip1 PE=2 SV=1 - 
[Q3UX26_MOUSE] 
B1AXI9 5-azacytidine induced gene 1 OS=Mus musculus GN=Cep131 PE=1 SV=1 - [B1AXI9_MOUSE] 
A0A0G2JF66 
Coiled-coil domain-containing 149 OS=Mus musculus GN=Ccdc149 PE=4 SV=1 - 
[A0A0G2JF66_MOUSE] 
Q3TLT9 Putative uncharacterized protein OS=Mus musculus GN=Cd44 PE=2 SV=1 - [Q3TLT9_MOUSE] 
Q9EPK2 Protein XRP2 OS=Mus musculus GN=Rp2 PE=1 SV=3 - [XRP2_MOUSE] 
Q91Y95 Thioredoxin reductase 1 (Fragment) OS=Mus musculus GN=Txnrd1 PE=4 SV=1 - [Q91Y95_MOUSE] 
Q9CQ62 
2,4-dienoyl-CoA reductase, mitochondrial OS=Mus musculus GN=Decr1 PE=1 SV=1 - 
[DECR_MOUSE] 
Q99L68 Stom protein OS=Mus musculus GN=Stom PE=2 SV=1 - [Q99L68_MOUSE] 
Q6ZQM3 
cDNA fis, clone TRACH3010757, highly similar to Interferon-gamma inducible protein MG11 OS=Mus 
musculus GN=Samhd1 PE=2 SV=1 - [Q6ZQM3_MOUSE] 
Q3ULP8 Putative uncharacterized protein OS=Mus musculus GN=Pus7 PE=2 SV=1 - [Q3ULP8_MOUSE] 
A0A0U1RPS0 AP-2 complex subunit sigma OS=Mus musculus GN=Ap2s1 PE=1 SV=1 - [A0A0U1RPS0_MOUSE] 
Q5XG71 
Small subunit processome component 20 homolog OS=Mus musculus GN=Utp20 PE=1 SV=2 - 
[UTP20_MOUSE] 
D6RET7 
GRAM domain-containing protein 4 OS=Mus musculus GN=Gramd4 PE=1 SV=1 - 
[D6RET7_MOUSE] 
Q9D4G5 
Processing of precursor 1, ribonuclease P/MRP family, (S. cerevisiae) OS=Mus musculus GN=Pop1 
PE=1 SV=1 - [Q9D4G5_MOUSE] 
Q6PFQ7 Ras GTPase-activating protein 4 OS=Mus musculus GN=Rasa4 PE=1 SV=1 - [RASL2_MOUSE] 
Q9CR32 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Snrnp70 PE=2 SV=3 - 
[Q9CR32_MOUSE] 
Q9QZB7 Actin-related protein 10 OS=Mus musculus GN=Actr10 PE=1 SV=2 - [ARP10_MOUSE] 
P27048 
Small nuclear ribonucleoprotein-associated protein B OS=Mus musculus GN=Snrpb PE=1 SV=1 - 
[RSMB_MOUSE] 
Q9D898 
Actin-related protein 2/3 complex subunit 5-like protein OS=Mus musculus GN=Arpc5l PE=1 SV=1 - 
[ARP5L_MOUSE] 
Q9WTX2 
Interferon-inducible double-stranded RNA-dependent protein kinase activator A OS=Mus musculus 
GN=Prkra PE=1 SV=1 - [PRKRA_MOUSE] 
B1AQR8 Galectin OS=Mus musculus GN=Lgals9 PE=1 SV=1 - [B1AQR8_MOUSE] 
Q3TZG4 Putative uncharacterized protein OS=Mus musculus GN=Elmo3 PE=2 SV=1 - [Q3TZG4_MOUSE] 
Q3TT24 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Ptprf PE=2 SV=1 - 
[Q3TT24_MOUSE] 
Q3TGN4 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Arhgap6 PE=2 SV=1 - 
[Q3TGN4_MOUSE] 
Q3UAP7 S-adenosylmethionine synthase OS=Mus musculus GN=Mat2a PE=2 SV=1 - [Q3UAP7_MOUSE] 
O54784 Death-associated protein kinase 3 OS=Mus musculus GN=Dapk3 PE=1 SV=1 - [DAPK3_MOUSE] 
Q3UEW8 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Pdpk1 PE=2 SV=1 - 
[Q3UEW8_MOUSE] 
A2AFI4 
RNA-binding motif protein, X chromosome (Fragment) OS=Mus musculus GN=Rbmx PE=1 SV=1 - 
[A2AFI4_MOUSE] 
Q3U8N1 Putative uncharacterized protein OS=Mus musculus GN=Sars PE=2 SV=1 - [Q3U8N1_MOUSE] 
Q3TIV5 
Zinc finger CCCH domain-containing protein 15 OS=Mus musculus GN=Zc3h15 PE=1 SV=2 - 
[ZC3HF_MOUSE] 
Q5MJS3 
Extracellular serine/threonine protein kinase FAM20C OS=Mus musculus GN=Fam20c PE=1 SV=1 - 
[FA20C_MOUSE] 
D3Z710 Kinesin light chain 3 OS=Mus musculus GN=Klc3 PE=1 SV=1 - [D3Z710_MOUSE] 
G3UXX5 
DNA-directed RNA polymerases I and III subunit RPAC1 (Fragment) OS=Mus musculus GN=Polr1c 
PE=1 SV=1 - [G3UXX5_MOUSE] 
Q3TJP6 Putative uncharacterized protein OS=Mus musculus GN=Cd34 PE=2 SV=1 - [Q3TJP6_MOUSE] 
Q8HW98 IgLON family member 5 OS=Mus musculus GN=Iglon5 PE=2 SV=2 - [IGLO5_MOUSE] 
Q3U1G4 Putative uncharacterized protein OS=Mus musculus GN=Exoc1 PE=2 SV=1 - [Q3U1G4_MOUSE] 
Q9D4I1 Putative uncharacterized protein OS=Mus musculus GN=Myo18b PE=2 SV=1 - [Q9D4I1_MOUSE] 
Q3TLK3 Putative uncharacterized protein OS=Mus musculus GN=Ncbp1 PE=2 SV=1 - [Q3TLK3_MOUSE] 
Q3UPF5 
Zinc finger CCCH-type antiviral protein 1 OS=Mus musculus GN=Zc3hav1 PE=1 SV=1 - 
[ZCCHV_MOUSE] 
E0CZH6 
Mitochondrial amidoxime reducing component 2 (Fragment) OS=Mus musculus GN=Marc2 PE=1 
SV=1 - [E0CZH6_MOUSE] 
F6V8R7 
Replication protein A 32 kDa subunit (Fragment) OS=Mus musculus GN=Rpa2 PE=1 SV=1 - 
[F6V8R7_MOUSE] 
D3YUY3 
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha OS=Mus musculus GN=Pip5k1a PE=1 SV=1 
- [D3YUY3_MOUSE] 
P30677 
Guanine nucleotide-binding protein subunit alpha-14 OS=Mus musculus GN=Gna14 PE=1 SV=2 - 
[GNA14_MOUSE] 
Q9CRB5 Prolactin-7C1 OS=Mus musculus GN=Prl7c1 PE=2 SV=1 - [PR7C1_MOUSE] 
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Q8K314 Atp2b1 protein (Fragment) OS=Mus musculus GN=Atp2b1 PE=2 SV=1 - [Q8K314_MOUSE] 
A3KG81 Multiple PDZ domain protein OS=Mus musculus GN=Mpdz PE=1 SV=1 - [A3KG81_MOUSE] 
Q80U19 
Disheveled-associated activator of morphogenesis 2 OS=Mus musculus GN=Daam2 PE=1 SV=4 - 
[DAAM2_MOUSE] 
F6U8X4 
Serine/threonine-protein kinase SIK3 (Fragment) OS=Mus musculus GN=Sik3 PE=1 SV=1 - 
[F6U8X4_MOUSE] 
Q61425 
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial OS=Mus musculus GN=Hadh PE=1 SV=2 - 
[HCDH_MOUSE] 
Q0KK56 Protein FAM184B OS=Mus musculus GN=Fam184b PE=2 SV=1 - [F184B_MOUSE] 
P62869 Elongin-B OS=Mus musculus GN=Elob PE=1 SV=1 - [ELOB_MOUSE] 
A2BDX3 
Adenylyltransferase and sulfurtransferase MOCS3 OS=Mus musculus GN=Mocs3 PE=1 SV=1 - 
[MOCS3_MOUSE] 
P62915 Transcription initiation factor IIB OS=Mus musculus GN=Gtf2b PE=1 SV=1 - [TF2B_MOUSE] 
A0A0A6YXS8 Antithrombin-III OS=Mus musculus GN=Serpinc1 PE=1 SV=1 - [A0A0A6YXS8_MOUSE] 
Q8CI33 CWF19-like protein 1 OS=Mus musculus GN=Cwf19l1 PE=1 SV=2 - [C19L1_MOUSE] 
Q6ZQK4 MKIAA0044 protein (Fragment) OS=Mus musculus GN=Ppp2r5c PE=2 SV=1 - [Q6ZQK4_MOUSE] 
D3Z2D9 
Peroxisome proliferator-activated receptor gamma coactivator-related protein 1 (Fragment) OS=Mus 
musculus GN=Pprc1 PE=4 SV=8 - [D3Z2D9_MOUSE] 
Q6LAL7 Beta-2 glycoprotein I (Fragment) OS=Mus musculus PE=4 SV=1 - [Q6LAL7_MOUSE] 
Q2M4I5 Sp3 (Fragment) OS=Mus musculus GN=Sp3 PE=4 SV=1 - [Q2M4I5_MOUSE] 
B2RWU2 
Immunodeficiency virus type I enhancer binding protein 2 OS=Mus musculus GN=Hivep2 PE=2 SV=1 
- [B2RWU2_MOUSE] 
P43267 Protein SOX-15 OS=Mus musculus GN=Sox15 PE=1 SV=3 - [SOX15_MOUSE] 
O09164 
Extracellular superoxide dismutase [Cu-Zn] OS=Mus musculus GN=Sod3 PE=1 SV=1 - 
[SODE_MOUSE] 
Q8R0S2 
IQ motif and SEC7 domain-containing protein 1 OS=Mus musculus GN=Iqsec1 PE=1 SV=2 - 
[IQEC1_MOUSE] 
Q14C53 
Solute carrier family 39 (Zinc transporter), member 7 OS=Mus musculus GN=Slc39a7 PE=2 SV=1 - 
[Q14C53_MOUSE] 
E9Q5I9 
26S proteasome non-ATPase regulatory subunit 13 OS=Mus musculus GN=Psmd13 PE=1 SV=1 - 
[E9Q5I9_MOUSE] 
B7FAT3 
CDNA sequence BC005537 (Fragment) OS=Mus musculus GN=BC005537 PE=4 SV=1 - 
[B7FAT3_MOUSE] 
Q8BU35 Putative uncharacterized protein OS=Mus musculus GN=Rbm25 PE=2 SV=1 - [Q8BU35_MOUSE] 
Q3TJI4 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Amd1 PE=2 SV=1 - 
[Q3TJI4_MOUSE] 
A0A0A6YY78 
Serine/threonine-protein kinase MARK1 (Fragment) OS=Mus musculus GN=Mark1 PE=1 SV=1 - 
[A0A0A6YY78_MOUSE] 
A2ADN1 Frem1 protein OS=Mus musculus GN=Frem1 PE=2 SV=1 - [A2ADN1_MOUSE] 
P61082 NEDD8-conjugating enzyme Ubc12 OS=Mus musculus GN=Ube2m PE=1 SV=1 - [UBC12_MOUSE] 
Q9EQY0 
Serine/threonine-protein kinase/endoribonuclease IRE1 OS=Mus musculus GN=Ern1 PE=1 SV=1 - 
[ERN1_MOUSE] 
Q3V415 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Mtmr2 PE=2 SV=1 - 
[Q3V415_MOUSE] 
Q91W97 Putative hexokinase HKDC1 OS=Mus musculus GN=Hkdc1 PE=2 SV=1 - [HKDC1_MOUSE] 
D6RHA2 N-acylglucosamine 2-epimerase OS=Mus musculus GN=Renbp PE=1 SV=2 - [D6RHA2_MOUSE] 
D3K2X3 Truncated DJ-1 variant SV4,5DEL OS=Mus musculus GN=Park7 PE=2 SV=1 - [D3K2X3_MOUSE] 
 
 
 
(b) GFP-TMEM67 DECL 
Uniprot Accession Description 
Q9QXS1 Plectin OS=Mus musculus GN=Plec PE=1 SV=3 - [PLEC_MOUSE] 
Q6S385 Plectin 10 OS=Mus musculus GN=Plec PE=2 SV=1 - [Q6S385_MOUSE] 
Q8VDD5 Myosin-9 OS=Mus musculus GN=Myh9 PE=1 SV=4 - [MYH9_MOUSE] 
Q3UBP6 
Putative uncharacterized protein OS=Mus musculus GN=Actb PE=2 SV=1 - 
[Q3UBP6_MOUSE] 
Q61879 Myosin-10 OS=Mus musculus GN=Myh10 PE=1 SV=2 - [MYH10_MOUSE] 
Q3UFT0 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Myh9 PE=2 SV=1 - 
[Q3UFT0_MOUSE] 
P20152 Vimentin OS=Mus musculus GN=Vim PE=1 SV=3 - [VIME_MOUSE] 
Q9WTI7 Unconventional myosin-Ic OS=Mus musculus GN=Myo1c PE=1 SV=2 - [MYO1C_MOUSE] 
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Q05CR3 Plec1 protein (Fragment) OS=Mus musculus GN=Plec PE=2 SV=1 - [Q05CR3_MOUSE] 
A0A0R4J221 Plectin (Fragment) OS=Mus musculus GN=Plec PE=1 SV=1 - [A0A0R4J221_MOUSE] 
E9Q634 Unconventional myosin-Ie OS=Mus musculus GN=Myo1e PE=1 SV=1 - [MYO1E_MOUSE] 
Q5SWZ5 
Myosin phosphatase Rho-interacting protein OS=Mus musculus GN=Mprip PE=1 SV=1 - 
[Q5SWZ5_MOUSE] 
Q5SYD0 
Unconventional myosin-Id OS=Mus musculus GN=Myo1d PE=1 SV=1 - 
[MYO1D_MOUSE] 
P46735 Unconventional myosin-Ib OS=Mus musculus GN=Myo1b PE=1 SV=3 - [MYO1B_MOUSE] 
B9EHJ3 Tight junction protein ZO-1 OS=Mus musculus GN=Tjp1 PE=1 SV=1 - [B9EHJ3_MOUSE] 
E9QNH6 
Unconventional myosin-Ib OS=Mus musculus GN=Myo1b PE=1 SV=1 - 
[E9QNH6_MOUSE] 
Q7TPR4 Alpha-actinin-1 OS=Mus musculus GN=Actn1 PE=1 SV=1 - [ACTN1_MOUSE] 
Q8BFZ3 Beta-actin-like protein 2 OS=Mus musculus GN=Actbl2 PE=1 SV=1 - [ACTBL_MOUSE] 
P11087 Collagen alpha-1(I) chain OS=Mus musculus GN=Col1a1 PE=1 SV=4 - [CO1A1_MOUSE] 
Q6PAC1 Gelsolin, isoform CRA_c OS=Mus musculus GN=Gsn PE=2 SV=1 - [Q6PAC1_MOUSE] 
Q9EP71 Ankycorbin OS=Mus musculus GN=Rai14 PE=1 SV=1 - [RAI14_MOUSE] 
P62737 Actin, aortic smooth muscle OS=Mus musculus GN=Acta2 PE=1 SV=1 - [ACTA_MOUSE] 
A3KGU5 
Spectrin alpha chain, non-erythrocytic 1 OS=Mus musculus GN=Sptan1 PE=1 SV=1 - 
[A3KGU5_MOUSE] 
A0A0J9YUQ8 Gelsolin (Fragment) OS=Mus musculus GN=Gsn PE=1 SV=1 - [A0A0J9YUQ8_MOUSE] 
E9Q175 Unconventional myosin-VI OS=Mus musculus GN=Myo6 PE=1 SV=1 - [E9Q175_MOUSE] 
Q61553 Fascin OS=Mus musculus GN=Fscn1 PE=1 SV=4 - [FSCN1_MOUSE] 
Q2KN98 Cytospin-A OS=Mus musculus GN=Specc1l PE=1 SV=1 - [CYTSA_MOUSE] 
E9PX70 
Collagen alpha-1(XII) chain OS=Mus musculus GN=Col12a1 PE=1 SV=1 - 
[E9PX70_MOUSE] 
Q9ERG0 
LIM domain and actin-binding protein 1 OS=Mus musculus GN=Lima1 PE=1 SV=3 - 
[LIMA1_MOUSE] 
Q8K4L3 Supervillin OS=Mus musculus GN=Svil PE=1 SV=1 - [SVIL_MOUSE] 
E9Q3Z5 Supervillin OS=Mus musculus GN=Svil PE=1 SV=1 - [E9Q3Z5_MOUSE] 
Q6ZWQ9 MCG5400 OS=Mus musculus GN=Myl12a PE=1 SV=1 - [Q6ZWQ9_MOUSE] 
Q62261 
Spectrin beta chain, non-erythrocytic 1 OS=Mus musculus GN=Sptbn1 PE=1 SV=2 - 
[SPTB2_MOUSE] 
E9Q3E2 Synaptopodin OS=Mus musculus GN=Synpo PE=1 SV=1 - [E9Q3E2_MOUSE] 
B7ZND7 
2310014H01Rik protein OS=Mus musculus GN=Ppp1r18 PE=2 SV=1 - 
[B7ZND7_MOUSE] 
A0A1B0GX25 
Histone deacetylase 6 (Fragment) OS=Mus musculus GN=Hdac6 PE=1 SV=1 - 
[A0A1B0GX25_MOUSE] 
Q60605 Myosin light polypeptide 6 OS=Mus musculus GN=Myl6 PE=1 SV=3 - [MYL6_MOUSE] 
Q9DBR7 
Protein phosphatase 1 regulatory subunit 12A OS=Mus musculus GN=Ppp1r12a PE=1 
SV=2 - [MYPT1_MOUSE] 
Q642K0 
MCG140959, isoform CRA_a OS=Mus musculus GN=Myl6 PE=2 SV=1 - 
[Q642K0_MOUSE] 
P07901 
Heat shock protein HSP 90-alpha OS=Mus musculus GN=Hsp90aa1 PE=1 SV=4 - 
[HS90A_MOUSE] 
K3W4R2 Myosin-14 OS=Mus musculus GN=Myh14 PE=1 SV=1 - [K3W4R2_MOUSE] 
Q3URM4 
Putative uncharacterized protein OS=Mus musculus GN=Erp44 PE=2 SV=1 - 
[Q3URM4_MOUSE] 
Q3THE2 
Myosin regulatory light chain 12B OS=Mus musculus GN=Myl12b PE=1 SV=2 - 
[ML12B_MOUSE] 
P08752 
Guanine nucleotide-binding protein G(i) subunit alpha-2 OS=Mus musculus GN=Gnai2 
PE=1 SV=5 - [GNAI2_MOUSE] 
Q8R422 CD109 antigen OS=Mus musculus GN=Cd109 PE=1 SV=1 - [CD109_MOUSE] 
Q9QZF2 Glypican-1 OS=Mus musculus GN=Gpc1 PE=1 SV=1 - [GPC1_MOUSE] 
Q3TRK3 
Putative uncharacterized protein OS=Mus musculus GN=Dbn1 PE=2 SV=1 - 
[Q3TRK3_MOUSE] 
A0A1D5RLD8 
Glyceraldehyde-3-phosphate dehydrogenase OS=Mus musculus GN=Gm10358 PE=1 
SV=1 - [A0A1D5RLD8_MOUSE] 
Q3TQW3 
Putative uncharacterized protein OS=Mus musculus GN=Ptbp1 PE=2 SV=1 - 
[Q3TQW3_MOUSE] 
P62137 
Serine/threonine-protein phosphatase PP1-alpha catalytic subunit OS=Mus musculus 
GN=Ppp1ca PE=1 SV=1 - [PP1A_MOUSE] 
Q8VCQ8 Caldesmon 1 OS=Mus musculus GN=Cald1 PE=1 SV=1 - [Q8VCQ8_MOUSE] 
K3W4L0 
Unconventional myosin-XVIIIa OS=Mus musculus GN=Myo18a PE=1 SV=1 - 
[K3W4L0_MOUSE] 
Q9JJ28 Protein flightless-1 homolog OS=Mus musculus GN=Flii PE=1 SV=1 - [FLII_MOUSE] 
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A0A0U1RNK7 
Dedicator of cytokinesis protein 7 OS=Mus musculus GN=Dock7 PE=1 SV=1 - 
[A0A0U1RNK7_MOUSE] 
B2CY77 
Laminin receptor (Fragment) OS=Mus musculus GN=Rpsa PE=2 SV=1 - 
[B2CY77_MOUSE] 
Q08509 
Epidermal growth factor receptor kinase substrate 8 OS=Mus musculus GN=Eps8 PE=1 
SV=2 - [EPS8_MOUSE] 
Q6R891 Neurabin-2 OS=Mus musculus GN=Ppp1r9b PE=1 SV=1 - [NEB2_MOUSE] 
Q3TZU7 Sorting nexin OS=Mus musculus GN=Snx9 PE=2 SV=1 - [Q3TZU7_MOUSE] 
P62141 
Serine/threonine-protein phosphatase PP1-beta catalytic subunit OS=Mus musculus 
GN=Ppp1cb PE=1 SV=3 - [PP1B_MOUSE] 
Q3TGE1 
Putative uncharacterized protein OS=Mus musculus GN=Actr3 PE=2 SV=1 - 
[Q3TGE1_MOUSE] 
Q03265 
ATP synthase subunit alpha, mitochondrial OS=Mus musculus GN=Atp5a1 PE=1 SV=1 - 
[ATPA_MOUSE] 
Q4VBF8 Sipa1l1 protein OS=Mus musculus GN=Sipa1l1 PE=2 SV=1 - [Q4VBF8_MOUSE] 
Q0KL02 
Triple functional domain protein OS=Mus musculus GN=Trio PE=1 SV=3 - 
[TRIO_MOUSE] 
P62880 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 OS=Mus musculus 
GN=Gnb2 PE=1 SV=3 - [GBB2_MOUSE] 
Q9Z0U1 Tight junction protein ZO-2 OS=Mus musculus GN=Tjp2 PE=1 SV=2 - [ZO2_MOUSE] 
E9QAH1 
Golgi autoantigen, golgin subfamily b, macrogolgin 1 OS=Mus musculus GN=Golgb1 
PE=1 SV=1 - [E9QAH1_MOUSE] 
Q3TFD0 
Serine hydroxymethyltransferase OS=Mus musculus GN=Shmt2 PE=2 SV=1 - 
[Q3TFD0_MOUSE] 
Q69ZN7 Myoferlin OS=Mus musculus GN=Myof PE=1 SV=2 - [MYOF_MOUSE] 
Q99L75 Heat shock protein 4 OS=Mus musculus GN=Hspa4 PE=2 SV=1 - [Q99L75_MOUSE] 
Q9DC51 
Guanine nucleotide-binding protein G(k) subunit alpha OS=Mus musculus GN=Gnai3 
PE=1 SV=3 - [GNAI3_MOUSE] 
P80314 
T-complex protein 1 subunit beta OS=Mus musculus GN=Cct2 PE=1 SV=4 - 
[TCPB_MOUSE] 
P35979 60S ribosomal protein L12 OS=Mus musculus GN=Rpl12 PE=1 SV=2 - [RL12_MOUSE] 
P56480 
ATP synthase subunit beta, mitochondrial OS=Mus musculus GN=Atp5b PE=1 SV=2 - 
[ATPB_MOUSE] 
E9Q452 
Tropomyosin alpha-1 chain OS=Mus musculus GN=Tpm1 PE=1 SV=1 - 
[E9Q452_MOUSE] 
Q8BK67 Protein RCC2 OS=Mus musculus GN=Rcc2 PE=1 SV=1 - [RCC2_MOUSE] 
Q6IRU2 Tropomyosin alpha-4 chain OS=Mus musculus GN=Tpm4 PE=1 SV=3 - [TPM4_MOUSE] 
P05064 
Fructose-bisphosphate aldolase A OS=Mus musculus GN=Aldoa PE=1 SV=2 - 
[ALDOA_MOUSE] 
P47754 
F-actin-capping protein subunit alpha-2 OS=Mus musculus GN=Capza2 PE=1 SV=3 - 
[CAZA2_MOUSE] 
P18872 
Guanine nucleotide-binding protein G(o) subunit alpha OS=Mus musculus GN=Gnao1 
PE=1 SV=3 - [GNAO_MOUSE] 
G3X9T8 Ceruloplasmin OS=Mus musculus GN=Cp PE=1 SV=1 - [G3X9T8_MOUSE] 
E9Q450 
Tropomyosin alpha-1 chain OS=Mus musculus GN=Tpm1 PE=1 SV=1 - 
[E9Q450_MOUSE] 
G3X9J0 
Signal-induced proliferation-associated 1-like protein 3 OS=Mus musculus GN=Sipa1l3 
PE=1 SV=1 - [SI1L3_MOUSE] 
P80313 
T-complex protein 1 subunit eta OS=Mus musculus GN=Cct7 PE=1 SV=1 - 
[TCPH_MOUSE] 
A0A1L1SUX8 
Thy-1 membrane glycoprotein (Fragment) OS=Mus musculus GN=Thy1 PE=1 SV=1 - 
[A0A1L1SUX8_MOUSE] 
Q8BH78 Reticulon OS=Mus musculus GN=Rtn4 PE=1 SV=1 - [Q8BH78_MOUSE] 
Q61344 Beta-tropomyosin OS=Mus musculus GN=Tpm2 PE=2 SV=1 - [Q61344_MOUSE] 
P28301 Protein-lysine 6-oxidase OS=Mus musculus GN=Lox PE=1 SV=1 - [LYOX_MOUSE] 
E9Q133 
T-complex protein 1 subunit gamma OS=Mus musculus GN=Cct3 PE=1 SV=1 - 
[E9Q133_MOUSE] 
Q3TCE7 
Putative uncharacterized protein OS=Mus musculus GN=Arpc1b PE=2 SV=1 - 
[Q3TCE7_MOUSE] 
Q3TFA9 
Putative uncharacterized protein OS=Mus musculus GN=Tmod3 PE=2 SV=1 - 
[Q3TFA9_MOUSE] 
Q5SF07 
Insulin-like growth factor 2 mRNA-binding protein 2 OS=Mus musculus GN=Igf2bp2 PE=1 
SV=1 - [IF2B2_MOUSE] 
Q61753 
D-3-phosphoglycerate dehydrogenase OS=Mus musculus GN=Phgdh PE=1 SV=3 - 
[SERA_MOUSE] 
F7DBB3 
AHNAK nucleoprotein 2 (Fragment) OS=Mus musculus GN=Ahnak2 PE=1 SV=1 - 
[F7DBB3_MOUSE] 
Q7TPV4 Myb-binding protein 1A OS=Mus musculus GN=Mybbp1a PE=1 SV=2 - [MBB1A_MOUSE] 
O54724 
Polymerase I and transcript release factor OS=Mus musculus GN=Ptrf PE=1 SV=1 - 
[PTRF_MOUSE] 
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P31001 Desmin OS=Mus musculus GN=Des PE=1 SV=3 - [DESM_MOUSE] 
Q8QZY1 
Eukaryotic translation initiation factor 3 subunit L OS=Mus musculus GN=Eif3l PE=1 SV=1 
- [EIF3L_MOUSE] 
Q3TEU8 Coronin OS=Mus musculus GN=Coro1c PE=2 SV=1 - [Q3TEU8_MOUSE] 
Q925B0 
PRKC apoptosis WT1 regulator protein OS=Mus musculus GN=Pawr PE=1 SV=2 - 
[PAWR_MOUSE] 
D0VYV7 
Erythrocyte protein band 4.1-like 3 isoform C OS=Mus musculus GN=Epb41l3 PE=2 SV=1 
- [D0VYV7_MOUSE] 
O89079 Coatomer subunit epsilon OS=Mus musculus GN=Cope PE=1 SV=3 - [COPE_MOUSE] 
P51410 60S ribosomal protein L9 OS=Mus musculus GN=Rpl9 PE=2 SV=2 - [RL9_MOUSE] 
Q9R0P3 S-formylglutathione hydrolase OS=Mus musculus GN=Esd PE=1 SV=1 - [ESTD_MOUSE] 
Q63844 
Mitogen-activated protein kinase 3 OS=Mus musculus GN=Mapk3 PE=1 SV=5 - 
[MK03_MOUSE] 
G5E8R0 
Tropomyosin 1, alpha, isoform CRA_i OS=Mus musculus GN=Tpm1 PE=1 SV=1 - 
[G5E8R0_MOUSE] 
P47753 
F-actin-capping protein subunit alpha-1 OS=Mus musculus GN=Capza1 PE=1 SV=4 - 
[CAZA1_MOUSE] 
Q8BG95 
Protein phosphatase 1 regulatory subunit 12B OS=Mus musculus GN=Ppp1r12b PE=1 
SV=2 - [MYPT2_MOUSE] 
P67778 Prohibitin OS=Mus musculus GN=Phb PE=1 SV=1 - [PHB_MOUSE] 
Q8BMA4 Putative uncharacterized protein OS=Mus musculus PE=2 SV=1 - [Q8BMA4_MOUSE] 
A2AL12 
Heterogeneous nuclear ribonucleoprotein A3 OS=Mus musculus GN=Hnrnpa3 PE=1 
SV=1 - [A2AL12_MOUSE] 
P31230 
Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 OS=Mus musculus 
GN=Aimp1 PE=1 SV=2 - [AIMP1_MOUSE] 
P42208 Septin-2 OS=Mus musculus GN=Sept2 PE=1 SV=2 - [SEPT2_MOUSE] 
P54823 
Probable ATP-dependent RNA helicase DDX6 OS=Mus musculus GN=Ddx6 PE=1 SV=1 - 
[DDX6_MOUSE] 
A2AMW0 
Capping protein (Actin filament) muscle Z-line, beta, isoform CRA_a OS=Mus musculus 
GN=Capzb PE=1 SV=1 - [A2AMW0_MOUSE] 
Q3TF41 
Nucleosome assembly protein 1-like 1, isoform CRA_d OS=Mus musculus GN=Nap1l1 
PE=2 SV=1 - [Q3TF41_MOUSE] 
Q4VA93 Protein kinase C OS=Mus musculus GN=Prkca PE=1 SV=1 - [Q4VA93_MOUSE] 
Q9CVB6 
Actin-related protein 2/3 complex subunit 2 OS=Mus musculus GN=Arpc2 PE=1 SV=3 - 
[ARPC2_MOUSE] 
Q60598 Src substrate cortactin OS=Mus musculus GN=Cttn PE=1 SV=2 - [SRC8_MOUSE] 
Q01721 
Growth arrest-specific protein 1 OS=Mus musculus GN=Gas1 PE=2 SV=2 - 
[GAS1_MOUSE] 
Q3TGL4 Fibulin 2, isoform CRA_b OS=Mus musculus GN=Fbln2 PE=2 SV=1 - [Q3TGL4_MOUSE] 
B0LAA8 
Nucleoside diphosphate kinase (Fragment) OS=Mus musculus GN=Nme2 PE=2 SV=1 - 
[B0LAA8_MOUSE] 
E9QN08 
Elongation factor 1-delta (Fragment) OS=Mus musculus GN=Eef1d PE=1 SV=1 - 
[E9QN08_MOUSE] 
Q5DTS3 
MKIAA4020 protein (Fragment) OS=Mus musculus GN=Sept7 PE=2 SV=1 - 
[Q5DTS3_MOUSE] 
Q60865 Caprin-1 OS=Mus musculus GN=Caprin1 PE=1 SV=2 - [CAPR1_MOUSE] 
Q9CQV8 14-3-3 protein beta/alpha OS=Mus musculus GN=Ywhab PE=1 SV=3 - [1433B_MOUSE] 
Q3TIP8 
Chloride intracellular channel protein OS=Mus musculus GN=Clic1 PE=2 SV=1 - 
[Q3TIP8_MOUSE] 
Q9CX86 
Heterogeneous nuclear ribonucleoprotein A0 OS=Mus musculus GN=Hnrnpa0 PE=1 
SV=1 - [ROA0_MOUSE] 
E9Q0U7 
Heat shock protein 105 kDa OS=Mus musculus GN=Hsph1 PE=1 SV=1 - 
[E9Q0U7_MOUSE] 
Q922R8 
Protein disulfide-isomerase A6 OS=Mus musculus GN=Pdia6 PE=1 SV=3 - 
[PDIA6_MOUSE] 
P54071 
Isocitrate dehydrogenase [NADP], mitochondrial OS=Mus musculus GN=Idh2 PE=1 SV=3 
- [IDHP_MOUSE] 
Q3TKR5 
Putative uncharacterized protein OS=Mus musculus GN=Rpl5 PE=2 SV=1 - 
[Q3TKR5_MOUSE] 
Q9DBJ1 
Phosphoglycerate mutase 1 OS=Mus musculus GN=Pgam1 PE=1 SV=3 - 
[PGAM1_MOUSE] 
P0DP27 Calmodulin-2 OS=Mus musculus GN=Calm2 PE=1 SV=1 - [CALM2_MOUSE] 
Q3TWN8 
Putative uncharacterized protein OS=Mus musculus GN=Aldh18a1 PE=2 SV=1 - 
[Q3TWN8_MOUSE] 
Q91XV3 
Brain acid soluble protein 1 OS=Mus musculus GN=Basp1 PE=1 SV=3 - 
[BASP1_MOUSE] 
Q8K173 
Col3a1 protein (Fragment) OS=Mus musculus GN=Col3a1 PE=2 SV=1 - 
[Q8K173_MOUSE] 
A0A0J9YUR2 Cytospin-B OS=Mus musculus GN=Specc1 PE=1 SV=1 - [A0A0J9YUR2_MOUSE] 
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Q5SQB0 Nucleophosmin OS=Mus musculus GN=Npm1 PE=1 SV=1 - [Q5SQB0_MOUSE] 
F8VPU2 
FERM, RhoGEF and pleckstrin domain-containing protein 1 OS=Mus musculus GN=Farp1 
PE=1 SV=1 - [FARP1_MOUSE] 
Q3UAG2 
6-phosphogluconate dehydrogenase, decarboxylating OS=Mus musculus GN=Pgd PE=2 
SV=1 - [Q3UAG2_MOUSE] 
A0A0R4J169 
Leucine-rich repeat flightless-interacting protein 2 OS=Mus musculus GN=Lrrfip2 PE=1 
SV=1 - [A0A0R4J169_MOUSE] 
Q3TQY2 
Putative uncharacterized protein OS=Mus musculus GN=Dctn4 PE=2 SV=1 - 
[Q3TQY2_MOUSE] 
A0A0J9YTU3 Cytospin-B OS=Mus musculus GN=Specc1 PE=1 SV=1 - [A0A0J9YTU3_MOUSE] 
Q3UPL0 
Protein transport protein Sec31A OS=Mus musculus GN=Sec31a PE=1 SV=2 - 
[SC31A_MOUSE] 
P05202 
Aspartate aminotransferase, mitochondrial OS=Mus musculus GN=Got2 PE=1 SV=1 - 
[AATM_MOUSE] 
E9Q035 
Uncharacterized protein OS=Mus musculus GN=Gm20425 PE=4 SV=1 - 
[E9Q035_MOUSE] 
P28352 
DNA-(apurinic or apyrimidinic site) lyase OS=Mus musculus GN=Apex1 PE=1 SV=2 - 
[APEX1_MOUSE] 
Q02013 Aquaporin-1 OS=Mus musculus GN=Aqp1 PE=1 SV=3 - [AQP1_MOUSE] 
Q3TJ01 
tRNA-splicing ligase RtcB homolog OS=Mus musculus GN=Rtcb PE=2 SV=1 - 
[Q3TJ01_MOUSE] 
A0A171KXD3 
Protein arginine N-methyltransferase 1 OS=Mus musculus GN=Prmt1 PE=1 SV=1 - 
[A0A171KXD3_MOUSE] 
Q6P5F9 Exportin-1 OS=Mus musculus GN=Xpo1 PE=1 SV=1 - [XPO1_MOUSE] 
P67984 60S ribosomal protein L22 OS=Mus musculus GN=Rpl22 PE=1 SV=2 - [RL22_MOUSE] 
A0A0J9YTY0 Septin-11 OS=Mus musculus GN=Sept11 PE=1 SV=1 - [A0A0J9YTY0_MOUSE] 
Q6ZQE7 
MKIAA0270 protein (Fragment) OS=Mus musculus GN=Palm PE=2 SV=1 - 
[Q6ZQE7_MOUSE] 
D3Z0S1 Annexin (Fragment) OS=Mus musculus GN=Anxa4 PE=1 SV=1 - [D3Z0S1_MOUSE] 
P32067 Lupus La protein homolog OS=Mus musculus GN=Ssb PE=1 SV=1 - [LA_MOUSE] 
Q8BL36 
Putative uncharacterized protein OS=Mus musculus GN=Fam98a PE=2 SV=1 - 
[Q8BL36_MOUSE] 
Q80UE5 Epb4.1l2 protein OS=Mus musculus GN=Epb41l2 PE=2 SV=1 - [Q80UE5_MOUSE] 
P60122 RuvB-like 1 OS=Mus musculus GN=Ruvbl1 PE=1 SV=1 - [RUVB1_MOUSE] 
Q3ULZ3 
Phosphoserine aminotransferase OS=Mus musculus GN=Psat1 PE=2 SV=1 - 
[Q3ULZ3_MOUSE] 
O08807 Peroxiredoxin-4 OS=Mus musculus GN=Prdx4 PE=1 SV=1 - [PRDX4_MOUSE] 
Q9Z1Z2 
Serine-threonine kinase receptor-associated protein OS=Mus musculus GN=Strap PE=1 
SV=2 - [STRAP_MOUSE] 
O35682 
Myeloid-associated differentiation marker OS=Mus musculus GN=Myadm PE=1 SV=2 - 
[MYADM_MOUSE] 
P63330 
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform OS=Mus 
musculus GN=Ppp2ca PE=1 SV=1 - [PP2AA_MOUSE] 
P63037 
DnaJ homolog subfamily A member 1 OS=Mus musculus GN=Dnaja1 PE=1 SV=1 - 
[DNJA1_MOUSE] 
Q3TDD8 
Putative uncharacterized protein OS=Mus musculus GN=Eif4b PE=2 SV=1 - 
[Q3TDD8_MOUSE] 
O35295 
Transcriptional activator protein Pur-beta OS=Mus musculus GN=Purb PE=1 SV=3 - 
[PURB_MOUSE] 
Q6ZQ58 La-related protein 1 OS=Mus musculus GN=Larp1 PE=1 SV=3 - [LARP1_MOUSE] 
A0A0R4J1Y7 
Thioredoxin domain-containing protein 5 OS=Mus musculus GN=Txndc5 PE=1 SV=1 - 
[A0A0R4J1Y7_MOUSE] 
Q8BG67 Protein EFR3 homolog A OS=Mus musculus GN=Efr3a PE=1 SV=1 - [EFR3A_MOUSE] 
Q3UGJ5 
Putative uncharacterized protein OS=Mus musculus GN=Rasa3 PE=2 SV=1 - 
[Q3UGJ5_MOUSE] 
Q3UDS4 
Putative uncharacterized protein OS=Mus musculus GN=Sqrdl PE=2 SV=1 - 
[Q3UDS4_MOUSE] 
Q8R010 
Aminoacyl tRNA synthase complex-interacting multifunctional protein 2 OS=Mus musculus 
GN=Aimp2 PE=1 SV=2 - [AIMP2_MOUSE] 
A2AW05 
FACT complex subunit SSRP1 (Fragment) OS=Mus musculus GN=Ssrp1 PE=1 SV=1 - 
[A2AW05_MOUSE] 
P26043 Radixin OS=Mus musculus GN=Rdx PE=1 SV=3 - [RADI_MOUSE] 
Q9DB77 
Cytochrome b-c1 complex subunit 2, mitochondrial OS=Mus musculus GN=Uqcrc2 PE=1 
SV=1 - [QCR2_MOUSE] 
F6QYF8 
Aminopeptidase (Fragment) OS=Mus musculus GN=Npepps PE=1 SV=1 - 
[F6QYF8_MOUSE] 
Q3TCL2 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Akr1b3 PE=2 SV=1 - 
[Q3TCL2_MOUSE] 
Q8BGH2 
Sorting and assembly machinery component 50 homolog OS=Mus musculus 
GN=Samm50 PE=1 SV=1 - [SAM50_MOUSE] 
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E9PWY9 
Phenylalanine--tRNA ligase alpha subunit OS=Mus musculus GN=Farsa PE=1 SV=1 - 
[E9PWY9_MOUSE] 
A0A0J9YUD8 
High mobility group protein B1 OS=Mus musculus GN=Hmgb1 PE=1 SV=1 - 
[A0A0J9YUD8_MOUSE] 
P26231 Catenin alpha-1 OS=Mus musculus GN=Ctnna1 PE=1 SV=1 - [CTNA1_MOUSE] 
Q921M3 Splicing factor 3B subunit 3 OS=Mus musculus GN=Sf3b3 PE=1 SV=1 - [SF3B3_MOUSE] 
P29758 
Ornithine aminotransferase, mitochondrial OS=Mus musculus GN=Oat PE=1 SV=1 - 
[OAT_MOUSE] 
P28658 Ataxin-10 OS=Mus musculus GN=Atxn10 PE=1 SV=2 - [ATX10_MOUSE] 
Q9D051 
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial OS=Mus musculus 
GN=Pdhb PE=1 SV=1 - [ODPB_MOUSE] 
Q3TTX0 
Putative uncharacterized protein OS=Mus musculus GN=Matr3 PE=2 SV=1 - 
[Q3TTX0_MOUSE] 
B7ZMP1 
Probable Xaa-Pro aminopeptidase 3 OS=Mus musculus GN=Xpnpep3 PE=1 SV=1 - 
[XPP3_MOUSE] 
Q80WJ7 Protein LYRIC OS=Mus musculus GN=Mtdh PE=1 SV=1 - [LYRIC_MOUSE] 
Q3TNN6 
Putative uncharacterized protein OS=Mus musculus GN=Capg PE=2 SV=1 - 
[Q3TNN6_MOUSE] 
A0A0J9YUN4 Dynamin-1 OS=Mus musculus GN=Dnm1 PE=1 SV=1 - [A0A0J9YUN4_MOUSE] 
Q3UK68 
Putative uncharacterized protein OS=Mus musculus GN=Naca PE=2 SV=1 - 
[Q3UK68_MOUSE] 
Q641N8 
Nedd4l protein (Fragment) OS=Mus musculus GN=Nedd4l PE=2 SV=1 - 
[Q641N8_MOUSE] 
A0A0H3XWX3 
Insulin-like growth factor 2 mRNA binding protein 1 dN CRDBP-2 OS=Mus musculus 
GN=Igf2bp1 PE=2 SV=1 - [A0A0H3XWX3_MOUSE] 
Q3TYZ4 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Arhgef2 PE=2 SV=1 - 
[Q3TYZ4_MOUSE] 
P26443 
Glutamate dehydrogenase 1, mitochondrial OS=Mus musculus GN=Glud1 PE=1 SV=1 - 
[DHE3_MOUSE] 
Z4YKV1 
Guanine nucleotide-binding protein G(s) subunit alpha isoforms short OS=Mus musculus 
GN=Gnas PE=1 SV=1 - [Z4YKV1_MOUSE] 
A0A0A0MQF1 Kalirin OS=Mus musculus GN=Kalrn PE=1 SV=1 - [A0A0A0MQF1_MOUSE] 
Q9QZD9 
Eukaryotic translation initiation factor 3 subunit I OS=Mus musculus GN=Eif3i PE=1 SV=1 
- [EIF3I_MOUSE] 
Q8BR76 Meckelin OS=Mus musculus GN=Tmem67 PE=1 SV=2 - [MKS3_MOUSE] 
Q3V2Z4 Annexin OS=Mus musculus PE=2 SV=1 - [Q3V2Z4_MOUSE] 
Q922Z3 Trap1 protein (Fragment) OS=Mus musculus GN=Trap1 PE=2 SV=1 - [Q922Z3_MOUSE] 
P49718 
DNA replication licensing factor MCM5 OS=Mus musculus GN=Mcm5 PE=1 SV=1 - 
[MCM5_MOUSE] 
H7BWZ3 
Actin-related protein 2/3 complex subunit 3 OS=Mus musculus GN=Arpc3 PE=1 SV=1 - 
[H7BWZ3_MOUSE] 
H7BX23 
Prolyl 4-hydroxylase subunit alpha-3 OS=Mus musculus GN=P4ha3 PE=1 SV=1 - 
[H7BX23_MOUSE] 
Q9QWJ3 Alpha-1-globin (Fragment) OS=Mus musculus PE=2 SV=1 - [Q9QWJ3_MOUSE] 
P60335 Poly(rC)-binding protein 1 OS=Mus musculus GN=Pcbp1 PE=1 SV=1 - [PCBP1_MOUSE] 
Q9DCW4 
Electron transfer flavoprotein subunit beta OS=Mus musculus GN=Etfb PE=1 SV=3 - 
[ETFB_MOUSE] 
O35326 
Serine/arginine-rich splicing factor 5 OS=Mus musculus GN=Srsf5 PE=1 SV=2 - 
[SRSF5_MOUSE] 
O89086 RNA-binding protein 3 OS=Mus musculus GN=Rbm3 PE=1 SV=1 - [RBM3_MOUSE] 
Q3TW74 
Putative uncharacterized protein OS=Mus musculus GN=Mthfd1 PE=2 SV=1 - 
[Q3TW74_MOUSE] 
Q7TMI0 
Psmd11 protein (Fragment) OS=Mus musculus GN=Psmd11 PE=2 SV=1 - 
[Q7TMI0_MOUSE] 
Q00612 
Glucose-6-phosphate 1-dehydrogenase X OS=Mus musculus GN=G6pdx PE=1 SV=3 - 
[G6PD1_MOUSE] 
Q3U026 
Putative uncharacterized protein OS=Mus musculus GN=Mogs PE=2 SV=1 - 
[Q3U026_MOUSE] 
O70251 Elongation factor 1-beta OS=Mus musculus GN=Eef1b PE=1 SV=5 - [EF1B_MOUSE] 
A0A0N4SVP8 
Predicted pseudogene 5580 OS=Mus musculus GN=Gm5580 PE=3 SV=1 - 
[A0A0N4SVP8_MOUSE] 
P46471 
26S protease regulatory subunit 7 OS=Mus musculus GN=Psmc2 PE=1 SV=5 - 
[PRS7_MOUSE] 
Q9WUM5 
Succinate--CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial OS=Mus 
musculus GN=Suclg1 PE=1 SV=4 - [SUCA_MOUSE] 
K9JA74 
Glutathione S-transferase pi 2 (Fragment) OS=Mus musculus GN=Gstp2 PE=2 SV=1 - 
[K9JA74_MOUSE] 
P51655 Glypican-4 OS=Mus musculus GN=Gpc4 PE=1 SV=2 - [GPC4_MOUSE] 
Q9CZU6 Citrate synthase, mitochondrial OS=Mus musculus GN=Cs PE=1 SV=1 - [CISY_MOUSE] 
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F6ZV59 
Heterogeneous nuclear ribonucleoprotein D0 (Fragment) OS=Mus musculus GN=Hnrnpd 
PE=1 SV=1 - [F6ZV59_MOUSE] 
A0A0A6YXZ1 
CLIP-associating protein 1 OS=Mus musculus GN=Clasp1 PE=1 SV=2 - 
[A0A0A6YXZ1_MOUSE] 
Q3UEB3 
Poly(U)-binding-splicing factor PUF60 OS=Mus musculus GN=Puf60 PE=1 SV=2 - 
[PUF60_MOUSE] 
Q3TXF9 
Sodium/potassium-transporting ATPase subunit alpha OS=Mus musculus GN=Atp1a1 
PE=2 SV=1 - [Q3TXF9_MOUSE] 
Q78ZA7 
Nucleosome assembly protein 1-like 4 OS=Mus musculus GN=Nap1l4 PE=1 SV=1 - 
[NP1L4_MOUSE] 
P35486 
Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial 
OS=Mus musculus GN=Pdha1 PE=1 SV=1 - [ODPA_MOUSE] 
Q8K335 
Glutamate-rich WD repeat containing 1 OS=Mus musculus GN=Grwd1 PE=2 SV=1 - 
[Q8K335_MOUSE] 
P50247 Adenosylhomocysteinase OS=Mus musculus GN=Ahcy PE=1 SV=3 - [SAHH_MOUSE] 
Q8BUM1 
Putative uncharacterized protein OS=Mus musculus GN=Tardbp PE=2 SV=1 - 
[Q8BUM1_MOUSE] 
P10605 Cathepsin B OS=Mus musculus GN=Ctsb PE=1 SV=2 - [CATB_MOUSE] 
Q7TN20 
Ythdf3 protein (Fragment) OS=Mus musculus GN=Ythdf3 PE=2 SV=1 - 
[Q7TN20_MOUSE] 
Q8R5L1 
Complement component 1 Q subcomponent-binding protein, mitochondrial OS=Mus 
musculus GN=C1qbp PE=1 SV=1 - [Q8R5L1_MOUSE] 
D3Z3E8 
Putative helicase MOV-10 OS=Mus musculus GN=Mov10 PE=1 SV=1 - 
[D3Z3E8_MOUSE] 
Q6ZPF4 Formin-like protein 3 OS=Mus musculus GN=Fmnl3 PE=1 SV=2 - [FMNL3_MOUSE] 
Q8R2X0 Ehd2 protein OS=Mus musculus GN=Ehd2 PE=2 SV=1 - [Q8R2X0_MOUSE] 
Q9CYL5 
Golgi-associated plant pathogenesis-related protein 1 OS=Mus musculus GN=Glipr2 PE=1 
SV=3 - [GAPR1_MOUSE] 
A0A0A6YY29 
Calcyclin-binding protein (Fragment) OS=Mus musculus GN=Cacybp PE=1 SV=1 - 
[A0A0A6YY29_MOUSE] 
Q1L6K5 
Apoptosis-inducing factor short isoform 2 OS=Mus musculus GN=Aifm1 PE=2 SV=1 - 
[Q1L6K5_MOUSE] 
Q99MR6 
Serrate RNA effector molecule homolog OS=Mus musculus GN=Srrt PE=1 SV=1 - 
[SRRT_MOUSE] 
Q9CPY7 Cytosol aminopeptidase OS=Mus musculus GN=Lap3 PE=1 SV=3 - [AMPL_MOUSE] 
P61027 
Ras-related protein Rab-10 OS=Mus musculus GN=Rab10 PE=1 SV=1 - 
[RAB10_MOUSE] 
E9QAT0 
Synaptic functional regulator FMR1 OS=Mus musculus GN=Fmr1 PE=1 SV=1 - 
[E9QAT0_MOUSE] 
Q9D4P2 
Putative uncharacterized protein OS=Mus musculus GN=Spag16 PE=2 SV=1 - 
[Q9D4P2_MOUSE] 
A0A067XG53 
Peripheral plasma membrane protein CASK (Fragment) OS=Mus musculus GN=Cask 
PE=1 SV=1 - [A0A067XG53_MOUSE] 
Q3UDN8 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Trim28 PE=2 SV=1 - 
[Q3UDN8_MOUSE] 
Q7TT37 Elongator complex protein 1 OS=Mus musculus GN=Ikbkap PE=1 SV=2 - [ELP1_MOUSE] 
Q9ERK4 Exportin-2 OS=Mus musculus GN=Cse1l PE=1 SV=1 - [XPO2_MOUSE] 
P51660 
Peroxisomal multifunctional enzyme type 2 OS=Mus musculus GN=Hsd17b4 PE=1 SV=3 - 
[DHB4_MOUSE] 
Q6IRT4 
Eukaryotic translation initiation factor 3 subunit F OS=Mus musculus GN=Eif3f PE=2 SV=1 
- [Q6IRT4_MOUSE] 
Q9WUM3 Coronin-1B OS=Mus musculus GN=Coro1b PE=1 SV=1 - [COR1B_MOUSE] 
F8VQB6 Unconventional myosin-X OS=Mus musculus GN=Myo10 PE=1 SV=1 - [MYO10_MOUSE] 
P24547 
Inosine-5'-monophosphate dehydrogenase 2 OS=Mus musculus GN=Impdh2 PE=1 SV=2 
- [IMDH2_MOUSE] 
Q9CRS5 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Ewsr1 PE=2 SV=1 - 
[Q9CRS5_MOUSE] 
G3UYU4 Flotillin-1 OS=Mus musculus GN=Flot1 PE=1 SV=1 - [G3UYU4_MOUSE] 
Q9CT37 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Hnrnpr PE=2 SV=3 - 
[Q9CT37_MOUSE] 
Q3THA0 
Eukaryotic translation initiation factor 3 subunit G OS=Mus musculus GN=Eif3g PE=2 
SV=1 - [Q3THA0_MOUSE] 
Q3TWV4 
AP-2 complex subunit mu OS=Mus musculus GN=Ap2m1 PE=1 SV=1 - 
[Q3TWV4_MOUSE] 
E9PYT3 Atlastin-3 OS=Mus musculus GN=Atl3 PE=1 SV=1 - [E9PYT3_MOUSE] 
Q8VHY0 
Chondroitin sulfate proteoglycan 4 OS=Mus musculus GN=Cspg4 PE=1 SV=3 - 
[CSPG4_MOUSE] 
Q3U890 
Putative uncharacterized protein OS=Mus musculus GN=Hars PE=2 SV=1 - 
[Q3U890_MOUSE] 
C6EQH3 
Succinate--CoA ligase [GDP-forming] subunit beta, mitochondrial OS=Mus musculus 
GN=Suclg2 PE=2 SV=1 - [C6EQH3_MOUSE] 
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P01027 Complement C3 OS=Mus musculus GN=C3 PE=1 SV=3 - [CO3_MOUSE] 
E9Q740 
Signal recognition particle 72 OS=Mus musculus GN=Srp72 PE=1 SV=1 - 
[E9Q740_MOUSE] 
A0A0G2JG59 Nexilin (Fragment) OS=Mus musculus GN=Nexn PE=1 SV=1 - [A0A0G2JG59_MOUSE] 
Q9D0F3 Protein ERGIC-53 OS=Mus musculus GN=Lman1 PE=1 SV=1 - [LMAN1_MOUSE] 
P49817 Caveolin-1 OS=Mus musculus GN=Cav1 PE=1 SV=1 - [CAV1_MOUSE] 
O35646 Calpain-6 OS=Mus musculus GN=Capn6 PE=1 SV=2 - [CAN6_MOUSE] 
Q3U1H7 Sorting nexin OS=Mus musculus GN=Snx18 PE=2 SV=1 - [Q3U1H7_MOUSE] 
Q3U8N2 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Gas7 PE=2 SV=1 - 
[Q3U8N2_MOUSE] 
E9QL13 
MCG8382, isoform CRA_c OS=Mus musculus GN=Rbm14 PE=1 SV=2 - 
[E9QL13_MOUSE] 
O08842 
GDNF family receptor alpha-2 OS=Mus musculus GN=Gfra2 PE=1 SV=2 - 
[GFRA2_MOUSE] 
B1ARU1 
Microtubule-actin cross-linking factor 1 OS=Mus musculus GN=Macf1 PE=1 SV=1 - 
[B1ARU1_MOUSE] 
Q3TD51 
Putative uncharacterized protein OS=Mus musculus GN=Picalm PE=2 SV=1 - 
[Q3TD51_MOUSE] 
S4R238 MICOS complex subunit OS=Mus musculus GN=Chchd3 PE=1 SV=1 - [S4R238_MOUSE] 
Q3UT02 
Putative uncharacterized protein OS=Mus musculus GN=Larp4 PE=2 SV=1 - 
[Q3UT02_MOUSE] 
Q99JY0 
Trifunctional enzyme subunit beta, mitochondrial OS=Mus musculus GN=Hadhb PE=1 
SV=1 - [ECHB_MOUSE] 
A0A0R4J083 
Long-chain-specific acyl-CoA dehydrogenase, mitochondrial OS=Mus musculus GN=Acadl 
PE=1 SV=1 - [A0A0R4J083_MOUSE] 
Q0VGU9 Rbm39 protein OS=Mus musculus GN=Rbm39 PE=2 SV=1 - [Q0VGU9_MOUSE] 
Q3TUI9 
Proteasome subunit alpha type OS=Mus musculus GN=Psma5 PE=2 SV=1 - 
[Q3TUI9_MOUSE] 
Q6PHN9 
Ras-related protein Rab-35 OS=Mus musculus GN=Rab35 PE=1 SV=1 - 
[RAB35_MOUSE] 
Q3TN31 
Proteasome subunit alpha type OS=Mus musculus GN=Psma7 PE=2 SV=1 - 
[Q3TN31_MOUSE] 
Q04736 Tyrosine-protein kinase Yes OS=Mus musculus GN=Yes1 PE=1 SV=3 - [YES_MOUSE] 
Q61599 
Rho GDP-dissociation inhibitor 2 OS=Mus musculus GN=Arhgdib PE=1 SV=3 - 
[GDIR2_MOUSE] 
Q5SX49 Profilin OS=Mus musculus GN=Pfn1 PE=1 SV=1 - [Q5SX49_MOUSE] 
Q62418 Drebrin-like protein OS=Mus musculus GN=Dbnl PE=1 SV=2 - [DBNL_MOUSE] 
E0CXA0 
Hepatoma-derived growth factor (Fragment) OS=Mus musculus GN=Hdgf PE=1 SV=1 - 
[E0CXA0_MOUSE] 
Q3V3R1 
Monofunctional C1-tetrahydrofolate synthase, mitochondrial OS=Mus musculus 
GN=Mthfd1l PE=1 SV=2 - [C1TM_MOUSE] 
Q3TYK3 Nuclear factor 1 OS=Mus musculus GN=Nfix PE=1 SV=1 - [Q3TYK3_MOUSE] 
Q8K258 Srp68 protein OS=Mus musculus GN=Srp68 PE=2 SV=1 - [Q8K258_MOUSE] 
Q571A1 
MKIAA0765 splice variant 1 (Fragment) OS=Mus musculus GN=Cpne1 PE=2 SV=1 - 
[Q571A1_MOUSE] 
Q9D2G2 
Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex, mitochondrial OS=Mus musculus GN=Dlst PE=1 SV=1 - 
[ODO2_MOUSE] 
P61164 Alpha-centractin OS=Mus musculus GN=Actr1a PE=1 SV=1 - [ACTZ_MOUSE] 
Q8BWT1 
3-ketoacyl-CoA thiolase, mitochondrial OS=Mus musculus GN=Acaa2 PE=1 SV=3 - 
[THIM_MOUSE] 
Q8R539 WD-repeat protein p122 OS=Mus musculus GN=Wdr6 PE=2 SV=1 - [Q8R539_MOUSE] 
Q3UNJ3 Peptidylprolyl isomerase OS=Mus musculus GN=Fkbp10 PE=2 SV=1 - [Q3UNJ3_MOUSE] 
Q6PGC1 
ATP-dependent RNA helicase DHX29 OS=Mus musculus GN=Dhx29 PE=1 SV=1 - 
[DHX29_MOUSE] 
L0HCN1 Ifi202b OS=Mus musculus PE=2 SV=1 - [L0HCN1_MOUSE] 
G3XA25 
Acetyl-CoA acetyltransferase, cytosolic OS=Mus musculus GN=Acat2 PE=1 SV=1 - 
[G3XA25_MOUSE] 
Q3TFC2 
Putative uncharacterized protein OS=Mus musculus GN=Nono PE=2 SV=1 - 
[Q3TFC2_MOUSE] 
Q3TLE8 
Putative uncharacterized protein OS=Mus musculus GN=Cyb5b PE=2 SV=1 - 
[Q3TLE8_MOUSE] 
P27641 
X-ray repair cross-complementing protein 5 OS=Mus musculus GN=Xrcc5 PE=1 SV=4 - 
[XRCC5_MOUSE] 
A0A068BFR3 
RAS oncogene family protein OS=Mus musculus GN=Rab11b PE=2 SV=1 - 
[A0A068BFR3_MOUSE] 
Q8BSI4 
Putative uncharacterized protein OS=Mus musculus GN=Gpc6 PE=2 SV=1 - 
[Q8BSI4_MOUSE] 
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B7ZWM8 
Leucine-rich repeat and calponin homology domain-containing protein 3 OS=Mus 
musculus GN=Lrch3 PE=1 SV=1 - [B7ZWM8_MOUSE] 
A0A0G2JDW7 
40S ribosomal protein S27 (Fragment) OS=Mus musculus GN=Rps27 PE=1 SV=1 - 
[A0A0G2JDW7_MOUSE] 
Q3ULG5 DNA helicase OS=Mus musculus GN=Mcm6 PE=1 SV=1 - [Q3ULG5_MOUSE] 
A0A0N4SW34 
V-type proton ATPase subunit E 1 (Fragment) OS=Mus musculus GN=Atp6v1e1 PE=1 
SV=1 - [A0A0N4SW34_MOUSE] 
E9Q715 
Putative RNA-binding protein Luc7-like 2 OS=Mus musculus GN=Luc7l2 PE=1 SV=1 - 
[E9Q715_MOUSE] 
B2RQQ7 
CDC42 binding protein kinase beta OS=Mus musculus GN=Cdc42bpb PE=2 SV=1 - 
[B2RQQ7_MOUSE] 
Q9CQE8 UPF0568 protein C14orf166 homolog OS=Mus musculus PE=1 SV=1 - [CN166_MOUSE] 
A2BE93 Protein SET (Fragment) OS=Mus musculus GN=Set PE=1 SV=1 - [A2BE93_MOUSE] 
E0CXB1 
Proteasome endopeptidase complex OS=Mus musculus GN=Psma6 PE=1 SV=1 - 
[E0CXB1_MOUSE] 
Q9D7S7 
60S ribosomal protein L22-like 1 OS=Mus musculus GN=Rpl22l1 PE=1 SV=1 - 
[RL22L_MOUSE] 
Q8CGI9 
Psmd1 protein (Fragment) OS=Mus musculus GN=Psmd1 PE=2 SV=1 - 
[Q8CGI9_MOUSE] 
O70194 
Eukaryotic translation initiation factor 3 subunit D OS=Mus musculus GN=Eif3d PE=1 
SV=2 - [EIF3D_MOUSE] 
G3X909 Slit homolog 2 protein OS=Mus musculus GN=Slit2 PE=1 SV=1 - [G3X909_MOUSE] 
A2AFI9 
Histone-binding protein RBBP7 OS=Mus musculus GN=Rbbp7 PE=1 SV=1 - 
[A2AFI9_MOUSE] 
B1AQR8 Galectin OS=Mus musculus GN=Lgals9 PE=1 SV=1 - [B1AQR8_MOUSE] 
G5E829 
Plasma membrane calcium-transporting ATPase 1 OS=Mus musculus GN=Atp2b1 PE=1 
SV=1 - [AT2B1_MOUSE] 
Q99JI4 
26S proteasome non-ATPase regulatory subunit 6 OS=Mus musculus GN=Psmd6 PE=1 
SV=1 - [PSMD6_MOUSE] 
E9QL12 Dysferlin OS=Mus musculus GN=Dysf PE=1 SV=1 - [E9QL12_MOUSE] 
S4R294 Protein PRRC2C OS=Mus musculus GN=Prrc2c PE=1 SV=1 - [S4R294_MOUSE] 
Q9CRL8 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Gm10817 PE=2 
SV=1 - [Q9CRL8_MOUSE] 
K7Q751 Focal ashension kinase 1 OS=Mus musculus GN=Ptk2 PE=2 SV=1 - [K7Q751_MOUSE] 
O08583 THO complex subunit 4 OS=Mus musculus GN=Alyref PE=1 SV=3 - [THOC4_MOUSE] 
B8JJM3 
Complement factor B (Fragment) OS=Mus musculus GN=Cfb PE=3 SV=1 - 
[B8JJM3_MOUSE] 
Q9WVJ2 
26S proteasome non-ATPase regulatory subunit 13 OS=Mus musculus GN=Psmd13 
PE=1 SV=1 - [PSD13_MOUSE] 
Q5SUW3 
Growth factor receptor-bound protein 10 OS=Mus musculus GN=Grb10 PE=1 SV=1 - 
[Q5SUW3_MOUSE] 
Q8BH80 
Putative uncharacterized protein OS=Mus musculus GN=Vapb PE=1 SV=1 - 
[Q8BH80_MOUSE] 
D3Z7K0 
Ubiquitin thioesterase OTUB1 (Fragment) OS=Mus musculus GN=Otub1 PE=1 SV=1 - 
[D3Z7K0_MOUSE] 
Q3US65 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Srpk1 PE=2 SV=1 - 
[Q3US65_MOUSE] 
P97807 
Fumarate hydratase, mitochondrial OS=Mus musculus GN=Fh PE=1 SV=3 - 
[FUMH_MOUSE] 
A0A0R4J119 
Cytoplasmic FMR1-interacting protein 1 OS=Mus musculus GN=Cyfip1 PE=1 SV=1 - 
[A0A0R4J119_MOUSE] 
Q64339 Ubiquitin-like protein ISG15 OS=Mus musculus GN=Isg15 PE=1 SV=4 - [ISG15_MOUSE] 
Q4VAA7 Sorting nexin-33 OS=Mus musculus GN=Snx33 PE=1 SV=1 - [SNX33_MOUSE] 
B1AU76 
Nuclear autoantigenic sperm protein OS=Mus musculus GN=Nasp PE=1 SV=1 - 
[B1AU76_MOUSE] 
B1AZ26 
Cordon-bleu protein-like 1 (Fragment) OS=Mus musculus GN=Cobll1 PE=1 SV=8 - 
[B1AZ26_MOUSE] 
P55012 
Solute carrier family 12 member 2 OS=Mus musculus GN=Slc12a2 PE=1 SV=2 - 
[S12A2_MOUSE] 
P62965 
Cellular retinoic acid-binding protein 1 OS=Mus musculus GN=Crabp1 PE=1 SV=2 - 
[RABP1_MOUSE] 
Q9D1R9 60S ribosomal protein L34 OS=Mus musculus GN=Rpl34 PE=1 SV=2 - [RL34_MOUSE] 
Q9R1P1 
Proteasome subunit beta type-3 OS=Mus musculus GN=Psmb3 PE=1 SV=1 - 
[PSB3_MOUSE] 
Q8C1L7 
40S ribosomal protein S21 OS=Mus musculus GN=mCG_6739 PE=2 SV=1 - 
[Q8C1L7_MOUSE] 
A0A0N4SVT3 
Guanine nucleotide-binding protein subunit gamma (Fragment) OS=Mus musculus 
GN=Gng12 PE=1 SV=1 - [A0A0N4SVT3_MOUSE] 
Q99KR1 
Psmc5 protein (Fragment) OS=Mus musculus GN=Psmc5 PE=2 SV=1 - 
[Q99KR1_MOUSE] 
 
160 
P09671 
Superoxide dismutase [Mn], mitochondrial OS=Mus musculus GN=Sod2 PE=1 SV=3 - 
[SODM_MOUSE] 
P42125 
Enoyl-CoA delta isomerase 1, mitochondrial OS=Mus musculus GN=Eci1 PE=1 SV=2 - 
[ECI1_MOUSE] 
P30412 
Peptidyl-prolyl cis-trans isomerase C OS=Mus musculus GN=Ppic PE=1 SV=1 - 
[PPIC_MOUSE] 
D3Z0E7 Rabenosyn-5 (Fragment) OS=Mus musculus GN=Rbsn PE=1 SV=1 - [D3Z0E7_MOUSE] 
Q3TJA9 
DnaJ (Hsp40) homolog, subfamily A, member 3, isoform CRA_b OS=Mus musculus 
GN=Dnaja3 PE=2 SV=1 - [Q3TJA9_MOUSE] 
F6U8X4 
Serine/threonine-protein kinase SIK3 (Fragment) OS=Mus musculus GN=Sik3 PE=1 SV=1 
- [F6U8X4_MOUSE] 
P32233 
Developmentally-regulated GTP-binding protein 1 OS=Mus musculus GN=Drg1 PE=1 
SV=1 - [DRG1_MOUSE] 
Q3U6K8 
Putative uncharacterized protein OS=Mus musculus GN=Vdac1 PE=2 SV=1 - 
[Q3U6K8_MOUSE] 
Q8BGU5 Cyclin-Y OS=Mus musculus GN=Ccny PE=1 SV=1 - [CCNY_MOUSE] 
Q3UJW1 
Putative uncharacterized protein OS=Mus musculus GN=Aldh2 PE=2 SV=1 - 
[Q3UJW1_MOUSE] 
Q5SX46 
Mitochondrial 2-oxoglutarate/malate carrier protein (Fragment) OS=Mus musculus 
GN=Slc25a11 PE=1 SV=1 - [Q5SX46_MOUSE] 
Q9CW59 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Aox3 PE=2 SV=1 - 
[Q9CW59_MOUSE] 
F6USD5 
Mesencephalic astrocyte-derived neurotrophic factor (Fragment) OS=Mus musculus 
GN=Manf PE=1 SV=1 - [F6USD5_MOUSE] 
Q6PB52 
Lrpap1 protein (Fragment) OS=Mus musculus GN=Lrpap1 PE=2 SV=1 - 
[Q6PB52_MOUSE] 
P54923 
[Protein ADP-ribosylarginine] hydrolase OS=Mus musculus GN=Adprh PE=1 SV=1 - 
[ADPRH_MOUSE] 
Q3UAZ7 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Hmgb2 PE=2 SV=1 - 
[Q3UAZ7_MOUSE] 
Q9D0M3 
Cytochrome c1, heme protein, mitochondrial OS=Mus musculus GN=Cyc1 PE=1 SV=1 - 
[CY1_MOUSE] 
Q3UXI9 
Putative uncharacterized protein OS=Mus musculus GN=Ilf2 PE=2 SV=1 - 
[Q3UXI9_MOUSE] 
Q8R2Q8 
Bone marrow stromal antigen 2 OS=Mus musculus GN=Bst2 PE=1 SV=1 - 
[BST2_MOUSE] 
O08614 Cytoskeletal protein OS=Mus musculus GN=Utrn PE=2 SV=1 - [O08614_MOUSE] 
P68181 
cAMP-dependent protein kinase catalytic subunit beta OS=Mus musculus GN=Prkacb 
PE=1 SV=2 - [KAPCB_MOUSE] 
F8WI90 Tyrosine-protein kinase OS=Mus musculus GN=Src PE=1 SV=1 - [F8WI90_MOUSE] 
P62315 
Small nuclear ribonucleoprotein Sm D1 OS=Mus musculus GN=Snrpd1 PE=1 SV=1 - 
[SMD1_MOUSE] 
A0A1B0GS13 
Apoptosis regulator BAX (Fragment) OS=Mus musculus GN=Bax PE=1 SV=1 - 
[A0A1B0GS13_MOUSE] 
P42669 
Transcriptional activator protein Pur-alpha OS=Mus musculus GN=Pura PE=1 SV=1 - 
[PURA_MOUSE] 
Q8HW98 IgLON family member 5 OS=Mus musculus GN=Iglon5 PE=2 SV=2 - [IGLO5_MOUSE] 
Q3KQQ1 
Nsfl1c protein (Fragment) OS=Mus musculus GN=Nsfl1c PE=2 SV=1 - 
[Q3KQQ1_MOUSE] 
Q05CM5 Eif5 protein (Fragment) OS=Mus musculus GN=Eif5 PE=2 SV=1 - [Q05CM5_MOUSE] 
Q3TCX4 
Putative uncharacterized protein OS=Mus musculus GN=Zfp622 PE=2 SV=1 - 
[Q3TCX4_MOUSE] 
E9PZJ8 
Activating signal cointegrator 1 complex subunit 3 OS=Mus musculus GN=Ascc3 PE=1 
SV=1 - [ASCC3_MOUSE] 
A0A1D5RLE4 
Casein kinase II subunit alpha' (Fragment) OS=Mus musculus GN=Csnk2a2 PE=1 SV=1 - 
[A0A1D5RLE4_MOUSE] 
Q3U3L3 
Putative uncharacterized protein OS=Mus musculus GN=Serpinb6a PE=2 SV=1 - 
[Q3U3L3_MOUSE] 
Q9Z2I0 
LETM1 and EF-hand domain-containing protein 1, mitochondrial OS=Mus musculus 
GN=Letm1 PE=1 SV=1 - [LETM1_MOUSE] 
Q5SS83 Flotillin 2, isoform CRA_a OS=Mus musculus GN=Flot2 PE=1 SV=1 - [Q5SS83_MOUSE] 
Q61081 
Hsp90 co-chaperone Cdc37 OS=Mus musculus GN=Cdc37 PE=1 SV=1 - 
[CDC37_MOUSE] 
Q3TPM3 Cullin-1 (Fragment) OS=Mus musculus GN=Cul1 PE=1 SV=1 - [Q3TPM3_MOUSE] 
Q5SWD9 
Pre-rRNA-processing protein TSR1 homolog OS=Mus musculus GN=Tsr1 PE=1 SV=1 - 
[TSR1_MOUSE] 
A0JLR3 Dhx36 protein (Fragment) OS=Mus musculus GN=Dhx36 PE=2 SV=1 - [A0JLR3_MOUSE] 
P28660 Nck-associated protein 1 OS=Mus musculus GN=Nckap1 PE=1 SV=2 - [NCKP1_MOUSE] 
A0A1D5RLW4 
Unconventional myosin-IXb (Fragment) OS=Mus musculus GN=Myo9b PE=1 SV=1 - 
[A0A1D5RLW4_MOUSE] 
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Q543N4 
Putative uncharacterized protein OS=Mus musculus GN=Bysl PE=2 SV=1 - 
[Q543N4_MOUSE] 
A2ARI4 
Leucine-rich repeat-containing G-protein coupled receptor 4 OS=Mus musculus GN=Lgr4 
PE=1 SV=1 - [LGR4_MOUSE] 
Q6P4T2 
U5 small nuclear ribonucleoprotein 200 kDa helicase OS=Mus musculus GN=Snrnp200 
PE=1 SV=1 - [U520_MOUSE] 
Q61425 
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial OS=Mus musculus GN=Hadh 
PE=1 SV=2 - [HCDH_MOUSE] 
P23949 
mRNA decay activator protein ZFP36L2 OS=Mus musculus GN=Zfp36l2 PE=1 SV=2 - 
[TISD_MOUSE] 
P51863 
V-type proton ATPase subunit d 1 OS=Mus musculus GN=Atp6v0d1 PE=1 SV=2 - 
[VA0D1_MOUSE] 
P21981 
Protein-glutamine gamma-glutamyltransferase 2 OS=Mus musculus GN=Tgm2 PE=1 
SV=4 - [TGM2_MOUSE] 
Q9DBS1 
Transmembrane protein 43 OS=Mus musculus GN=Tmem43 PE=1 SV=1 - 
[TMM43_MOUSE] 
Q8R2U0 Nucleoporin SEH1 OS=Mus musculus GN=Seh1l PE=2 SV=1 - [SEH1_MOUSE] 
Q3TLT9 
Putative uncharacterized protein OS=Mus musculus GN=Cd44 PE=2 SV=1 - 
[Q3TLT9_MOUSE] 
B1AQG7 
Zinc finger protein 207 (Fragment) OS=Mus musculus GN=Zfp207 PE=1 SV=1 - 
[B1AQG7_MOUSE] 
Q05BC6 Sucla2 protein OS=Mus musculus GN=Sucla2 PE=2 SV=1 - [Q05BC6_MOUSE] 
O08582 GTP-binding protein 1 OS=Mus musculus GN=Gtpbp1 PE=1 SV=2 - [GTPB1_MOUSE] 
Q6P5D8 
Structural maintenance of chromosomes flexible hinge domain-containing protein 1 
OS=Mus musculus GN=Smchd1 PE=1 SV=2 - [SMHD1_MOUSE] 
P50136 
2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial OS=Mus musculus 
GN=Bckdha PE=1 SV=1 - [ODBA_MOUSE] 
Q4G0C2 Prss3 protein (Fragment) OS=Mus musculus GN=Prss3 PE=2 SV=1 - [Q4G0C2_MOUSE] 
F7ALS6 
Aspartate aminotransferase, cytoplasmic (Fragment) OS=Mus musculus GN=Got1 PE=1 
SV=1 - [F7ALS6_MOUSE] 
Q3UZD8 
Putative uncharacterized protein OS=Mus musculus GN=Rangap1 PE=2 SV=1 - 
[Q3UZD8_MOUSE] 
B7ZNW0 Pgam5 protein OS=Mus musculus GN=Pgam5 PE=2 SV=1 - [B7ZNW0_MOUSE] 
E9Q7G6 
RNA-binding motif, single-stranded-interacting protein 2 OS=Mus musculus GN=Rbms2 
PE=1 SV=1 - [E9Q7G6_MOUSE] 
O35648 Centrin-3 OS=Mus musculus GN=Cetn3 PE=1 SV=1 - [CETN3_MOUSE] 
Q9DCL1 
Putative uncharacterized protein OS=Mus musculus GN=Dhrs4 PE=2 SV=1 - 
[Q9DCL1_MOUSE] 
Q9WTX2 
Interferon-inducible double-stranded RNA-dependent protein kinase activator A OS=Mus 
musculus GN=Prkra PE=1 SV=1 - [PRKRA_MOUSE] 
F7D909 
Paraspeckle component 1 (Fragment) OS=Mus musculus GN=Pspc1 PE=1 SV=1 - 
[F7D909_MOUSE] 
P04925 Major prion protein OS=Mus musculus GN=Prnp PE=1 SV=2 - [PRIO_MOUSE] 
Q9EPK2 Protein XRP2 OS=Mus musculus GN=Rp2 PE=1 SV=3 - [XRP2_MOUSE] 
Q80TP6 
MKIAA0890 protein (Fragment) OS=Mus musculus GN=mKIAA0890 PE=4 SV=3 - 
[Q80TP6_MOUSE] 
O08604 
Retinoic acid early-inducible protein 1-gamma OS=Mus musculus GN=Raet1c PE=1 SV=1 
- [RAE1C_MOUSE] 
Q9D832 
DnaJ homolog subfamily B member 4 OS=Mus musculus GN=Dnajb4 PE=1 SV=1 - 
[DNJB4_MOUSE] 
Q64669 
NAD(P)H dehydrogenase [quinone] 1 OS=Mus musculus GN=Nqo1 PE=1 SV=3 - 
[NQO1_MOUSE] 
D3Z3B8 Disks large homolog 1 OS=Mus musculus GN=Dlg1 PE=1 SV=1 - [D3Z3B8_MOUSE] 
B8JJI9 COUP transcription factor 1 OS=Mus musculus GN=Nr2f1 PE=1 SV=1 - [B8JJI9_MOUSE] 
Q8K354 
Carbonyl reductase [NADPH] 3 OS=Mus musculus GN=Cbr3 PE=1 SV=1 - 
[CBR3_MOUSE] 
A0A0A6YVU8 MCG119397 OS=Mus musculus GN=Gm9774 PE=4 SV=1 - [A0A0A6YVU8_MOUSE] 
Q9CY29 
Putative uncharacterized protein OS=Mus musculus GN=Psmd4 PE=2 SV=1 - 
[Q9CY29_MOUSE] 
G3UXY0 
Proteasome activator complex subunit 1 OS=Mus musculus GN=Psme1 PE=1 SV=1 - 
[G3UXY0_MOUSE] 
Q91VA7 
Isocitrate dehydrogenase [NAD] subunit, mitochondrial OS=Mus musculus GN=Idh3b 
PE=1 SV=1 - [Q91VA7_MOUSE] 
A0A0R4J0C8 
3'-5' exoribonuclease 1 OS=Mus musculus GN=Eri1 PE=1 SV=1 - 
[A0A0R4J0C8_MOUSE] 
Q8C3X8 Lipase maturation factor 2 OS=Mus musculus GN=Lmf2 PE=1 SV=1 - [LMF2_MOUSE] 
Q9CSF9 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Rsl1d1 PE=2 SV=1 - 
[Q9CSF9_MOUSE] 
D3Z1B9 
V-type proton ATPase catalytic subunit A (Fragment) OS=Mus musculus GN=Atp6v1a 
PE=1 SV=1 - [D3Z1B9_MOUSE] 
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P57784 
U2 small nuclear ribonucleoprotein A' OS=Mus musculus GN=Snrpa1 PE=1 SV=2 - 
[RU2A_MOUSE] 
E9Q9H2 
DnaJ homolog subfamily C member 2 OS=Mus musculus GN=Dnajc2 PE=1 SV=1 - 
[E9Q9H2_MOUSE] 
Q8R1H1 Nrd1 protein (Fragment) OS=Mus musculus GN=Nrd1 PE=2 SV=1 - [Q8R1H1_MOUSE] 
P16675 Lysosomal protective protein OS=Mus musculus GN=Ctsa PE=1 SV=1 - [PPGB_MOUSE] 
Q5NC05 
Transcription termination factor 2 OS=Mus musculus GN=Ttf2 PE=1 SV=2 - 
[TTF2_MOUSE] 
A0A0G2JDI9 
ATP-binding cassette sub-family D member 3 OS=Mus musculus GN=Abcd3 PE=1 SV=1 - 
[A0A0G2JDI9_MOUSE] 
Q80ZR5 Rtf1 protein (Fragment) OS=Mus musculus GN=Rtf1 PE=2 SV=1 - [Q80ZR5_MOUSE] 
Q9CTR1 Histone H2A (Fragment) OS=Mus musculus GN=H2afy2 PE=2 SV=1 - [Q9CTR1_MOUSE] 
Q3UNU2 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Smc3 PE=2 SV=1 - 
[Q3UNU2_MOUSE] 
Q7TQJ8 
Wilms tumor protein 1-interacting protein OS=Mus musculus GN=Wtip PE=1 SV=1 - 
[WTIP_MOUSE] 
Q6P1B9 Bin1 protein OS=Mus musculus GN=Bin1 PE=1 SV=1 - [Q6P1B9_MOUSE] 
Q9D8Z1 
Activating signal cointegrator 1 complex subunit 1 OS=Mus musculus GN=Ascc1 PE=1 
SV=1 - [ASCC1_MOUSE] 
P0C6F1 
Dynein heavy chain 2, axonemal OS=Mus musculus GN=Dnah2 PE=1 SV=1 - 
[DYH2_MOUSE] 
F7DFQ2 
WD repeat-containing protein 26 (Fragment) OS=Mus musculus GN=Wdr26 PE=1 SV=1 - 
[F7DFQ2_MOUSE] 
Q80UK4 MICAL-like 2 OS=Mus musculus GN=Micall2 PE=2 SV=1 - [Q80UK4_MOUSE] 
A0A087WQ23 TRMT1-like protein OS=Mus musculus GN=Trmt1l PE=1 SV=1 - [A0A087WQ23_MOUSE] 
Q7TNC9 
Inositol polyphosphate-5-phosphatase A OS=Mus musculus GN=Inpp5a PE=1 SV=1 - 
[Q7TNC9_MOUSE] 
A0A0A6YXK7 
Centrosomal protein of 170 kDa (Fragment) OS=Mus musculus GN=Cep170 PE=1 SV=1 - 
[A0A0A6YXK7_MOUSE] 
Q8BJY1 
26S proteasome non-ATPase regulatory subunit 5 OS=Mus musculus GN=Psmd5 PE=1 
SV=4 - [PSMD5_MOUSE] 
Q3UQ81 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=P4ha2 PE=2 SV=1 - 
[Q3UQ81_MOUSE] 
Q8CFZ0 
SUMO-conjugating enzyme UBC9 OS=Mus musculus GN=Ube2i PE=1 SV=1 - 
[Q8CFZ0_MOUSE] 
Q8BPA1 
Putative uncharacterized protein OS=Mus musculus GN=Stom PE=2 SV=1 - 
[Q8BPA1_MOUSE] 
Q2XSQ4 TIP47 protein isoform 2 OS=Mus musculus GN=Plin3 PE=2 SV=1 - [Q2XSQ4_MOUSE] 
P60670 
Nuclear protein localization protein 4 homolog OS=Mus musculus GN=Nploc4 PE=1 SV=3 
- [NPL4_MOUSE] 
Q91ZE0 
Trimethyllysine dioxygenase, mitochondrial OS=Mus musculus GN=Tmlhe PE=1 SV=2 - 
[TMLH_MOUSE] 
Q3TGI0 
Putative uncharacterized protein OS=Mus musculus GN=Xrcc1 PE=2 SV=1 - 
[Q3TGI0_MOUSE] 
Q8K274 Ketosamine-3-kinase OS=Mus musculus GN=Fn3krp PE=1 SV=2 - [KT3K_MOUSE] 
F6V4G5 Alpha-adducin (Fragment) OS=Mus musculus GN=Add1 PE=1 SV=1 - [F6V4G5_MOUSE] 
Q3UGL3 
Putative uncharacterized protein OS=Mus musculus GN=Clint1 PE=2 SV=1 - 
[Q3UGL3_MOUSE] 
F7B6X4 Ataxin-2 (Fragment) OS=Mus musculus GN=Atxn2 PE=1 SV=1 - [F7B6X4_MOUSE] 
Q07417 
Short-chain specific acyl-CoA dehydrogenase, mitochondrial OS=Mus musculus 
GN=Acads PE=1 SV=2 - [ACADS_MOUSE] 
Q9R0X4 
Acyl-coenzyme A thioesterase 9, mitochondrial OS=Mus musculus GN=Acot9 PE=1 SV=1 
- [ACOT9_MOUSE] 
Q4FJY5 Ltb4dh protein OS=Mus musculus GN=Ptgr1 PE=2 SV=1 - [Q4FJY5_MOUSE] 
G3X939 
Sodium/hydrogen exchanger 3 OS=Mus musculus GN=Slc9a3 PE=1 SV=1 - 
[SL9A3_MOUSE] 
P63321 Ras-related protein Ral-A OS=Mus musculus GN=Rala PE=1 SV=1 - [RALA_MOUSE] 
F8VQ42 
Kinesin-like protein (Fragment) OS=Mus musculus GN=Kif2a PE=1 SV=1 - 
[F8VQ42_MOUSE] 
F7ARZ1 
28S ribosomal protein S23, mitochondrial (Fragment) OS=Mus musculus GN=Mrps23 
PE=1 SV=1 - [F7ARZ1_MOUSE] 
Q9CSH0 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Hnrnpll PE=2 SV=1 - 
[Q9CSH0_MOUSE] 
A0A0A6YXS8 Antithrombin-III OS=Mus musculus GN=Serpinc1 PE=1 SV=1 - [A0A0A6YXS8_MOUSE] 
Q9QYB1 
Chloride intracellular channel protein 4 OS=Mus musculus GN=Clic4 PE=1 SV=3 - 
[CLIC4_MOUSE] 
A0A087WP98 Prothymosin alpha OS=Mus musculus GN=Ptma PE=1 SV=1 - [A0A087WP98_MOUSE] 
Q8CDZ6 
Putative uncharacterized protein OS=Mus musculus GN=Wls PE=2 SV=1 - 
[Q8CDZ6_MOUSE] 
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Q3UTB8 GrpE protein homolog OS=Mus musculus GN=Grpel1 PE=2 SV=1 - [Q3UTB8_MOUSE] 
E9Q6G0 
Microtubule-associated serine/threonine-protein kinase 4 (Fragment) OS=Mus musculus 
GN=Mast4 PE=1 SV=1 - [E9Q6G0_MOUSE] 
Q3TTY6 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Lin7c PE=2 SV=1 - 
[Q3TTY6_MOUSE] 
D3YTS3 
RIKEN cDNA D630045J12 gene OS=Mus musculus GN=D630045J12Rik PE=1 SV=2 - 
[D3YTS3_MOUSE] 
Q3TT24 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Ptprf PE=2 SV=1 - 
[Q3TT24_MOUSE] 
Q921E4 
Receptor expression-enhancing protein OS=Mus musculus GN=Reep5 PE=2 SV=1 - 
[Q921E4_MOUSE] 
Q8BU18 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Tpr PE=2 SV=1 - 
[Q8BU18_MOUSE] 
D3Z7P4 
Glutaminase kidney isoform, mitochondrial OS=Mus musculus GN=Gls PE=1 SV=1 - 
[D3Z7P4_MOUSE] 
B0R029 
Synaptosomal-associated protein 23 (Fragment) OS=Mus musculus GN=Snap23 PE=1 
SV=8 - [B0R029_MOUSE] 
Q3UHM4 
Putative uncharacterized protein OS=Mus musculus GN=Gm10723 PE=2 SV=1 - 
[Q3UHM4_MOUSE] 
S4R2U9 
Rho guanine nucleotide exchange factor 40 OS=Mus musculus GN=Arhgef40 PE=1 SV=1 
- [S4R2U9_MOUSE] 
A2A4W9 
RNA-binding protein fox-1 homolog 3 (Fragment) OS=Mus musculus GN=Rbfox3 PE=1 
SV=1 - [A2A4W9_MOUSE] 
Q922T9 
Lamp1 protein (Fragment) OS=Mus musculus GN=Lamp1 PE=2 SV=1 - 
[Q922T9_MOUSE] 
Q3UZV3 
Putative uncharacterized protein OS=Mus musculus GN=Pcsk2 PE=2 SV=1 - 
[Q3UZV3_MOUSE] 
O88653 
Ragulator complex protein LAMTOR3 OS=Mus musculus GN=Lamtor3 PE=1 SV=1 - 
[LTOR3_MOUSE] 
P23591 GDP-L-fucose synthase OS=Mus musculus GN=Tsta3 PE=1 SV=3 - [FCL_MOUSE] 
B7ZWC4 
Insulin-like growth factor 2 receptor OS=Mus musculus GN=Igf2r PE=2 SV=1 - 
[B7ZWC4_MOUSE] 
Q3UE11 Putative uncharacterized protein OS=Mus musculus PE=2 SV=1 - [Q3UE11_MOUSE] 
P32020 
Non-specific lipid-transfer protein OS=Mus musculus GN=Scp2 PE=1 SV=3 - 
[NLTP_MOUSE] 
P70199 ERF1 (Fragment) OS=Mus musculus GN=Etf1 PE=2 SV=1 - [P70199_MOUSE] 
D6RII3 
Echinoderm microtubule-associated protein-like 1 OS=Mus musculus GN=Eml1 PE=1 
SV=1 - [D6RII3_MOUSE] 
Q14B70 Highly divergent homeobox OS=Mus musculus GN=Hdx PE=2 SV=1 - [HDX_MOUSE] 
A0A0J9YVG0 
Protein phosphatase 1G OS=Mus musculus GN=Ppm1g PE=1 SV=1 - 
[A0A0J9YVG0_MOUSE] 
Q3U6X6 
Putative uncharacterized protein OS=Mus musculus GN=Pgm2 PE=2 SV=1 - 
[Q3U6X6_MOUSE] 
Q6A096 
MKIAA0264 protein (Fragment) OS=Mus musculus GN=Mrps27 PE=2 SV=1 - 
[Q6A096_MOUSE] 
F6XYA0 
SUN domain-containing protein 1 (Fragment) OS=Mus musculus GN=Sun1 PE=1 SV=8 - 
[F6XYA0_MOUSE] 
D3Z7B1 
Run domain Beclin-1-interacting and cysteine-rich domain-containing protein OS=Mus 
musculus GN=Rubcn PE=1 SV=1 - [D3Z7B1_MOUSE] 
P20918 Plasminogen OS=Mus musculus GN=Plg PE=1 SV=3 - [PLMN_MOUSE] 
Q58EV2 Apoa1 protein OS=Mus musculus GN=Apoa1 PE=2 SV=1 - [Q58EV2_MOUSE] 
Q8BRU6 
Synaptic vesicular amine transporter OS=Mus musculus GN=Slc18a2 PE=1 SV=1 - 
[VMAT2_MOUSE] 
Q9Z1Z5 
Succinate dehydrogenase Ip subunit (Fragment) OS=Mus musculus GN=Sdhb PE=2 
SV=1 - [Q9Z1Z5_MOUSE] 
Q8K2C9 
Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 3 OS=Mus musculus GN=Hacd3 
PE=1 SV=2 - [HACD3_MOUSE] 
Q679P5 
Histone-lysine N-methyltransferase, H3 lysine-79 specific OS=Mus musculus GN=Dot1l 
PE=2 SV=1 - [Q679P5_MOUSE] 
A2BDX3 
Adenylyltransferase and sulfurtransferase MOCS3 OS=Mus musculus GN=Mocs3 PE=1 
SV=1 - [MOCS3_MOUSE] 
P49182 Heparin cofactor 2 OS=Mus musculus GN=Serpind1 PE=1 SV=1 - [HEP2_MOUSE] 
E9Q5Q0 
Ataxin-2-like protein (Fragment) OS=Mus musculus GN=Atxn2l PE=1 SV=2 - 
[E9Q5Q0_MOUSE] 
O09164 
Extracellular superoxide dismutase [Cu-Zn] OS=Mus musculus GN=Sod3 PE=1 SV=1 - 
[SODE_MOUSE] 
Q9CTI8 
Putative uncharacterized protein (Fragment) OS=Mus musculus GN=Atp6v1d PE=2 SV=1 
- [Q9CTI8_MOUSE] 
Q3TUQ7 
Non-specific serine/threonine protein kinase OS=Mus musculus GN=Prkaa1 PE=2 SV=1 - 
[Q3TUQ7_MOUSE] 
B7FAT3 
CDNA sequence BC005537 (Fragment) OS=Mus musculus GN=BC005537 PE=4 SV=1 - 
[B7FAT3_MOUSE] 
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P39749 Flap endonuclease 1 OS=Mus musculus GN=Fen1 PE=1 SV=1 - [FEN1_MOUSE] 
D3YZE6 
UDP-glucuronosyltransferase (Fragment) OS=Mus musculus GN=Ugt1a6a PE=3 SV=1 - 
[D3YZE6_MOUSE] 
Q3TUN7 
Putative uncharacterized protein OS=Mus musculus GN=Hbb-bh1 PE=2 SV=1 - 
[Q3TUN7_MOUSE] 
D3Z7R6 Calponin OS=Mus musculus GN=Cnn2 PE=1 SV=1 - [D3Z7R6_MOUSE] 
Q99JZ9 
Signal recognition particle 54 kDa protein OS=Mus musculus GN=Srp54c PE=2 SV=1 - 
[Q99JZ9_MOUSE] 
G5E850 
Cytochrome b-5, isoform CRA_a OS=Mus musculus GN=Cyb5a PE=1 SV=1 - 
[G5E850_MOUSE] 
D3YUY3 
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha OS=Mus musculus GN=Pip5k1a 
PE=1 SV=1 - [D3YUY3_MOUSE] 
Q3U617 
Putative uncharacterized protein OS=Mus musculus GN=Psmd8 PE=2 SV=1 - 
[Q3U617_MOUSE] 
D3YXG0 Hemicentin-1 OS=Mus musculus GN=Hmcn1 PE=1 SV=1 - [HMCN1_MOUSE] 
E9Q8K5 Titin OS=Mus musculus GN=Ttn PE=1 SV=1 - [E9Q8K5_MOUSE] 
H3BKD4 
Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 OS=Mus 
musculus GN=Asap1 PE=1 SV=1 - [H3BKD4_MOUSE] 
B1AXI9 
5-azacytidine induced gene 1 OS=Mus musculus GN=Cep131 PE=1 SV=1 - 
[B1AXI9_MOUSE] 
Q8VCK2 Ctsd protein (Fragment) OS=Mus musculus GN=Ctsd PE=2 SV=1 - [Q8VCK2_MOUSE] 
Q8BJ75 
Putative uncharacterized protein OS=Mus musculus GN=Chd6 PE=2 SV=1 - 
[Q8BJ75_MOUSE] 
Q920A5 
Retinoid-inducible serine carboxypeptidase OS=Mus musculus GN=Scpep1 PE=1 SV=2 - 
[RISC_MOUSE] 
E9PUC2 
Long-chain-fatty-acid--CoA ligase 3 OS=Mus musculus GN=Acsl3 PE=1 SV=1 - 
[E9PUC2_MOUSE] 
A0A087WNV6 
5'-3' exoribonuclease 1 OS=Mus musculus GN=Xrn1 PE=1 SV=1 - 
[A0A087WNV6_MOUSE] 
 
 
 
Supplementary Table 4 Full data lists of proteins identified in GFP-Trap® of (a) GFP-only, 
(b) GFP-TMEM67 full length and (c) GFP-TMEM67 DECL before the filtering steps used to 
create the double positive lists. (Lists included as separate excel files.) 
 
 
 
 
